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Abstract. 
The ferlins are a protein family characterised by the presence of five to seven Ca2+-regulated, 
membrane-binding C2 domains. C2 domains regulate vesicle fusion in the synaptotagmin 
protein family, and animal models of ferlin deficiency display pathologies linked to defects in 
Ca2+-dependent vesicle fusion, likely mediated by the C2 domains. Of the six human ferlins, 
mutations in dysferlin and otoferlin cause disease. Dysferlin mutations cause limb-girdle 
muscular dystrophy (LGMD2B) due to defective Ca2+-dependent, vesicle-mediated membrane 
repair. Furthermore, our group has previously shown that the Ca2+-dependent proteases, 
calpains, cleave dysferlin following membrane injury, releasing the C-terminal mini-
dysferlinC72 fragment that we hypothesise mediates membrane repair. Otoferlin mutations 
cause non-syndromic deafness due to defective Ca2+-dependent auditory neurotransmission, 
while no mutations have been identified that cause pathologies in other ferlins. My project has 
sought to 1- characterise the subcellular localisation of the human ferlin family, and following 
the discovery of dysferlin cleavage by the calpains, 2- refine the calpain cleavage site in 
dysferlin and 3- determine if other members of the ferlin family are calpain substrates. 
My project provides the first super-resolution microscopy analysis of the subcellular 
localisation and endocytic trafficking of the human ferlins. Dysferlin and myoferlin, type-I 
ferlins, are present at the plasma membrane and on the endo-lysosomal pathway in the cell. In 
contrast, otoferlin and Fer1L6, type-II ferlins, are present at the plasma membrane and recycle 
to and from sub-compartments of the trans-Golgi network. Each ferlin has a unique subcellular 
localisation, indicating that each may regulate vesicle fusion events at specific subcellular 
compartments. 
My project has revealed that dysferlin is cleaved to mini-dysferlinC72 following injury in all 
cell types, indicating that dysferlin cleavage is a fundamental response to membrane injury. 
 6 
Dysferlin is cleaved to mini-dysferlinC72 by the ubiquitous calpains-1 and -2 in the amino acid 
sequence encoded for by the alternatively spliced exon 40a. Exon 40a-containing dysferlin 
recruits to sites of membrane injury in damaged myotubes, providing evidence for a role of 
exon 40a-dysferlin and mini-dysferlinC72 directly at sites of injury. 
Finally, I have shown that in addition to dysferlin, calpains cleave otoferlin and myoferlin. 
Unlike dysferlin, the calpain cleavage of otoferlin and myoferlin is not regulated by alternative 
splicing, indicating that the cellular situation in which each ferlin is cleaved differs. Cleavage 
of other members of the ferlin family indicates that ferlin cleavage is an evolutionarily 
conserved event, predating the split between type-I and type-II ferlins. I think calpain cleavage 
is central to ferlin function, allowing a specialised fragment of each ferlin to perform roles in 
the cell. 
In conclusion, my PhD has revealed for the first time the subcellular localisation of the ferlin 
family at super-resolution level, and shown that the ferlins are enzymatically modified by the 
calpains, releasing C-terminal mini-ferlins which, in the case of dysferlin, imparts a specific, 
fundamental response to plasma membrane injury.   
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Chapter 1: Introduction 
This project consists of two parts. The first is the subcellular characterisation of the ferlin 
protein family, and the second is the characterisation of the calpain cleavage of dysferlin 
following plasma membrane injury. 
The ferlin proteins are characterised by containing 5 to 7 C2 domains, anchored by a C-terminal 
transmembrane domain. As most C2 domain containing proteins contain only 1 or 2 C2 
domains, this abundance of C2 domains is a unique and defining feature of the ferlins. Some 
animal models of ferlin pathologies display defects in vesicle fusion. As vesicle fusion is 
hypothesised to be mediated by the C2 domain containing proteins synaptotagmins in 
neurotransmission, the ferlins are hypothesised to mediate vesicle fusion via their numerous 
C2 domains. 
To help us understand the role ferlins may play in vesicle fusion, this literature review will 
discuss the following subjects: 
 1.1 The importance of vesicle fusion in cellular trafficking and function. 
1.2 The role SNARES play in vesicle fusion, and the specific subcellular targeting they 
confer to the vesicle fusion within the cell. 
1.3 The structure and function of C2 domains, and how C2 domains mediate the 
calcium dependence of vesicle fusion, focussing on the synaptotagmin family as a case 
study. 
1.4-1.6 The known structure and function of the human ferlin family members. 
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1.1 SNAREs: the minimal protein set for vesicle fusion. 
Cellular trafficking is essential for the function and survival of a cell, and ultimately an 
organism as a whole. Trafficking within a cell is required for delivery of cargo (such as 
proteins, hormones and neurotransmitters) to organelles, the plasma membrane or extracellular 
space. Cargo is transported within membranous vesicles; these vesicles have a specific 
protein/chemical complement for their target membrane. Each vesicle and its target membrane 
contains the proteins required to ensure specificity of vesicle fusion to the target membrane 
and delivery of the correct cargo (Chen and Scheller, 2001). The protein complex responsible 
for this fusion is called the Soluble N-ethylmaleimide sensitive factor Attachment protein 
REceptor (SNARE) complex. Localisation of specific member SNARE complex members to 
discrete subcellular membranes helps provide specificity of membrane fusion in between 
vesicles, endosomes and subcellular compartments (Chen and Scheller, 2001). 
The SNARE complex consists of three proteins requisite for vesicle fusion: a vesicle(v)-
SNARE (vesicle associated membrane protein, VAMP), a target(t)-SNARE (syntaxin) and a 
cytosolic SNARE (synaptosomal-associated protein, SNAP) (Sutton et al., 1998). V- and t-
SNAREs are both membrane associated via a transmembrane domain, with the v-SNARE 
present on the vesicle (Figure 1.1: synaptic vesicle, v-SNARE, red) and the t-SNARE on the 
target membrane (Figure 1.1: presynaptic plasma membrane, t-SNARE, yellow). The SNAP is 
not associated with the membrane, but is present in the cytosol (Figure 1.1: green; (Pang and 
Sudhof, 2010) (Chen and Scheller, 2001) (Vogel et al., 2000)).  
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The SNARE complex forms a four-helix bundle, which is proposed to ‘zip’ together, providing 
the force to overcome the energetic barrier presented by fusing two negatively charged 
phospholipid membranes with one another (Figure 1.1: force, red arrows; (Jahn and Scheller, 
2006; Südhof, 2013; Südhof, 2014; Wickner and Schekman, 2008)). Each member of the 
SNARE complex provides helices to the four-helix bundle. The VAMP and syntaxin provides 
one helix each to bundle, while the SNAP provides the remaining two helices, with the bundle 
stabilised by charge:charge interactions (Sutton et al., 1998). Upon the four-helix bundle 
‘zipping’ together, an arginine from the VAMP and two glutamine residues from the SNAP 
and syntaxin each interact, forming a highly stable complex (Figure 1.1: SNARE complex four 
helix bundle; (Sutton et al., 1998)). 
Figure 1.1: Model of the synaptotagmin and SNARE complex in vesicle fusion at the 
synaptic cleft. In this model, synaptotagmin has calcium bound to the top loop region, but the 
top loops have not yet inserted into the plasma membrane. The vesicle-SNARE (VAMP, red), 
target-SNARE (syntaxin, yellow), and SNAP-25 (green), are zippered together, forming the 
four-helix bundle and exerting force (indicated with red arrows) on the synaptic vesicle and 
plasma membrane, pulling the two membranes together. A fifth helical proteincomplexin (in 
pink), is not discussed in the context of this review, and the syntaxin Habc-domain is excluded 
for clarity. This figure is adapted from Sudhof (2014) and (2013). 
Synaptotagmin Synaptotagmin 
Ca2+ Ca2+ 
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The zipping together of the four helix bundle is proposed to be a critical step for vesicle fusion. 
Initially, the SNAP and syntaxin proteins interact with each other, forming the acceptor 
complex (Teng et al., 2001). The v-SNARE interacts with the acceptor complex when within 
8 nm of each other (Yan et al., 2008), with the helices coming together like a zip, physically 
drawing the vesicle into close proximity (2 nm and less, (Sutton et al., 1998; Yan et al., 2008)) 
to the target membrane. Both the target and vesicle membranes are composed of negatively 
charged phospholipids, presenting a significant charge-repulsion barrier to overcome before 
hydrophobic interactions of the lipid tails become the driving force for vesicle fusion (Jahn and 
Scheller, 2006; Wickner and Schekman, 2008). The strength of the zipper interactions of 
multiple SNARE complexes (as opposed to a single SNARE complex) (indicated as ‘force’ in 
Figure 1. 1) is proposed to overcome repulsion of the target and vesicle membranes. A fusion 
pore can form following the assembly of the four helix bundle, allowing hydrophobic lipid 
interactions to drive fusion of the vesicle with the target membrane ((Han et al., 2004; Jahn and 
Scheller, 2006; McMahon et al., 2010; Wickner and Schekman, 2008)). Fusion finally results 
in delivery of the cargo to or across the target membrane. 
Localisation of specific SNARE complex members to discrete subcellular membranes helps 
provide specificity of membrane fusion in between vesicles, endosomes and subcellular 
compartments. Figure 1.2 illustrates how different syntaxins provide specificity for vesicle 
fusion to specific subcellular compartments (Chen and Scheller, 2001).  
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Figure 1.2: Schematic displaying the known SNAREs and their subcellular targets. A 
range of SNAREs target specific vesicles to specific targets in the cell: syntaxins 1-4 provide 
the target SNAREs for the plasma membrane; syntaxins 6, 10, 11 and 16 provide the target 
SNAREs for the trans-Golgi network; syntaxins 7 and 8 provide the target SNAREs for the 
endosomal/lysosomal pathway while syntaxins 5, 11, 17 and 18 provide target SNAREs for 
the Golgi complex. This figure highlights how the syntaxins, as target SNAREs, and the 
VAMPs, as vesicle SNAREs, provide targeting specificity of vesicle fusion throughout the 
cell. This figure is sourced from Chen and Scheller (2001). 
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Syntaxin-1, for example, is present at nerve synapses, (Bennett et al., 1992) providing a specific 
target for neurotransmitter containing vesicles. Syntaxin-6 is present on the trans-Golgi 
network, providing a specific target-SNARE for vesicle fusion throughout the trans-Golgi 
(Steegmaier et al., 1999).  
Other proteins such as Rab-GTPases facilitate the specific identity of the vesicle, controlling 
membrane protein complement, timing and delivery of vesicles to the target membrane 
(Jordens et al., 2005; Schimmöller et al., 1998). Rabs can facilitate assembly of the v-SNARE: 
t-SNARE complex which leads to vesicle fusion, however over-expression of either SNARE 
(v- or t-) can override the effect of genetic deletion of specific Rabs, that without SNARE over-
expression prevents vesicle fusion (Lupashin and Waters, 1997; Søgaard et al.).  
The SNAREs ultimately confer the specificity of vesicle fusion to the target membrane, a 
process that is facilitated by other requisite vesicle proteins such as the Rabs. The SNARE 
complex is ultimately responsible for specific cargo delivery and vesicle fusion to the target 
membrane. The SNARE complex does not, however, respond to internal or external signals 
such as calcium release: another protein family, the synaptotagmins, provides the calcium 
response to the vesicle fusion process. 
SNARE summary: 
 The SNAREs are required for vesicle fusion to a target membrane.  
 The specificity of vesicle fusion to target membranes can be determined by which 
SNAREs are present on the vesicular and target membranes. 
 The physical ‘zipping’ together of the four helix bundle created by the SNAREs 
overcomes the energetic barrier presented by the negative phospholipid headgroups of 
vesicle and target membranes. 
 SNAREs are proposed to be the minimal protein requirement for vesicle fusion.  
 17 
1.2 C2 domains: calcium sensing membrane-binding domains. 
Introduction to C2 domain structure and function. 
The SNAREs provide specificity of vesicle fusion to the target membrane, but do not respond 
to stimuli such as calcium. C2 domains are calcium mediated phospholipid binding domains, 
that, in the case of the synaptotagmin family (discussed below), provide the calcium 
dependence of vesicle fusion (Südhof, 2004; Walter et al., 2011). While synaptotagmin C2 
domains provide calcium dependence to vesicle fusion,  protein-kinase C (not discussed in 
detail in this review) C2 domains provide calcium-dependent tethering of the protein to the 
plasma membrane (Evans et al., 2006). 
C2 domains are a conserved structural domain of approximately 100 amino acids, which fold 
to form a common 8-stranded β-sheet structure, connected by surface loops ((Sutton et al., 
1995); Figure 1.3). The majority of C2 domain containing proteins contain only one or two C2 
domains. Few protein families contain 3 or more C2 domains, such as the mammalian 
uncoordinated proteins (Munc), multiple C2 domain proteins (MTC), extended synaptotagmins 
and the ferlin protein family (Lek et al., 2010). The ferlin family contains 5 to 7 C2 domains, 
the highest number of any protein family (Lek et al., 2010). 
C2 domains mediate calcium-dependant phospholipid membrane binding. Up to 5 aspartic acid 
residues are present in C2 domain surface loops, which can coordinate up to 3 calcium ions 
(Sutton et al., 1995; Xue et al., 2008). Upon calcium ion coordination, the C2 domain loops 
are able to penetrate phospholipid membranes, resulting in membrane binding (Fernandez et 
al., 2001; Sutton et al., 1995). The precise structure and amino acid composition of C2 domains 
can convey specific phospholipid- and calcium-binding properties to a protein (Cho and 
Stahelin, 2006; Stahelin et al., 2003; Xue et al., 2008). 
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Summary: C2 domains are calcium mediated phospholipid binding domains. 
 Calcium binds negatively charged residues in the top loops of C2 domains. 
 Calcium-bound C2 domains can bind phospholipids. 
 The majority of C2 domain containing protein families have only 1 or 2 C2 domains. 
 The ferlin protein family members contain between 5-7 C2 domains. 
Synaptotagmins: a case study of the role of C2 domains in vesicle fusion. 
For this review, synaptotagmins will be used as a case study to demonstrate how C2 domains 
confer calcium sensitivity to vesicle fusion, and how they lower the energy required for vesicle 
fusion to occur.  
Synaptotagmins are calcium sensitive regulators of vesicle fusion. Synaptotagmins confer the 
calcium-dependent kinetics of vesicle fusion and depending on the specific synaptotagmin, 
they can set either a linear or higher-order calcium-binding response for phospholipid binding 
(Johnson et al., 2010) (Shin et al., 2009). Synaptotagmin activity is regulated by the constituent 
C2 domains. 
Synaptotagmin-1 is the C2 domain containing protein responsible for conferring the calcium-
dependence of neurotransmitter containing vesicle fusion at the neural synapse (Fuson et al., 
2014). Hippocampal neurons cultured from synaptotagmin-1 knockout mice display an 
absence of rapid neurotransmitter release, indicating that synaptotagmin-1 is required for 
stimulation of vesicle fusion ex vivo (Geppert et al., 1994; Nishiki and Augustine, 2004). 
Synaptotagmin-1 is present on the neurotransmitter containing vesicle, positioning it for 
calcium-sensing at the pre-synaptic membrane (Figure 1.1: Synaptotagmin-1; Sudhof 2014; 
2013). C2B (that is, the second C2 domain, with C2A being the first) is the primary calcium 
sensor of synaptotagmin-1, conferring a linear relationship between calcium concentration and 
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membrane binding (Shin et al., 2009). The top loops of both synaptotagmin-1 C2 domains 
coordinate calcium ions ((Fernandez et al., 2001; Sutton et al., 1995; Xue et al., 2008); Figure 
1.3). Loop 2 of C2A also binds neuronal SNAREs, as does the C2B polybasic face, conferring 
direct interaction between the calcium-sensor and vesicle fusion machinery (Figure 1.3: C2B 
top loops and polybasic face; (Dai et al., 2007; Lynch et al., 2007). The bottom loop arginine 
residues constitutively bind vesicles and insert into the vesicle membrane (Figure 1.3: C2B Arg 
Figure 1.3: Structural model of synaptotagmin-1 C2A and C2B domains. The top loops 
of both synaptotagmin-1 C2 domains bind calcium ions, and insert into lipid membranes once 
calcium is bound. C2A binds 3 calcium ions (yellow circles), while C2B binds 2 calcium ions. 
The polybasic region of the synaptotagmin-1 C2B face coordinates SNARE complex binding, 
while arginine 398 and 399 impart lipid binding to the bottom loop of C2B. This figure is 
modified from Xue et al., (2008). 
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398 
398 and 399). Mutation of arginine 398 and 399 abolishes neurotransmitter release from 
hippocampal neurons (Figure 1.3; (Xue et al., 2008)).  
C2A of synaptotagmin-1 coordinates three calcium ions, and C2B two (Fernandez et al., 2001; 
Radhakrishnan et al., 2009; Xue et al., 2008). C2A calcium coordination results in increased 
membrane binding by increasing the calcium-binding affinity of C2B, which confers higher-
order lipid binding upon synaptotagmin-1 (Shin et al., 2009). Mutation of calcium coordinating 
residues in C2A results in a linear increase in synaptotagmin-1 binding to phospholipids with 
increasing calcium concentration. Mutation of C2B calcium coordinating residues abolishes 
membrane binding altogether (Desai et al., 2000; Mackler et al., 2002). These results indicate 
that C2B is predominantly required for calcium-dependent membrane binding in 
Figure 1.4: Model of calcium-bound synaptotagmin top loop insertion into a 
phospholipid bilayer. In this model, synaptotagmin has calcium bound to the top loop 
region, and the top loops have inserted into a phospholipid bilayer. Synaptotagmin loop 
insertion is proposed to disrupt the phospholipid bilayer, inducing membrane curvature and 
decreasing the local negative charge around the loop insertion region. This figure is adapted 
from Martens and McMahon (2008). 
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synaptotagmin-1, while C2A increases the ability of C2B to bind membranes in response to 
calcium. 
The binding of synaptotagmin-1 C2 domains with syntaxins is also regulated by calcium 
binding to the top loop regions. As mentioned above, syntaxin-1 is capable of binding both 
C2A and C2B. C2A is proposed to act as an ‘electrostatic switch’ for syntaxin interaction. 
Without calcium present, the C2A top loop region is negatively charged, which repulses 
syntaxin-1 binding via charge: charge repulsion with syntaxin-1 acidic residues. Calcium 
binding to the C2A top loops creates a positively charged region which can directly interact 
with acidic residues on syntaxin-1 (Shao et al., 2013). Mutation of a C2A calcium binding 
aspartic acid residue to a glutamic acid retains the top loop negative charge, but is incapable of 
binding calcium and reduces synaptic vesicle fusion by 80%, highlighting the importance of 
creating a positively charged region in the top loops of C2A (Striegel et al., 2012). In vivo, 
abolishing the ability of C2B to bind calcium also reduces synaptic vesicle fusion, as calcium-
dependent synaptotagmin-1 membrane interaction is almost absent, and assembly of the 
neuronal SNARE complex (the zipping together of syntaxin-1, SNAP25 and VAMP-1) is 
greatly diminished (Littleton et al., 2001).  
The above studies show that different C2 domains act to confer different responses to 
calcium upon a protein. In synaptotagmin-1, calcium binding to C2A enhances syntaxin: C2A 
binding and the affinity of C2B for calcium (Shao et al., 2013), but abolishing C2A calcium 
binding does not prevent synaptotagmin-1 binding to membranes (Shin et al., 2009). Calcium 
binding to C2B enhances the affinity for synaptotagmin-1 binding to membranes and SNARE 
assembly (Littleton et al., 2001). Crucially, in vivo both C2 domains of synaptotagmin-1 are 
required to bind calcium for vesicle fusion to occur at the neuronal synapse (Lee et al., 2013b) 
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showing that the different roles conferred upon the protein by individual C2 domains are 
required for proper protein function in vivo. 
In addition to synaptotagmins acting as the calcium-sensors for neurotransmitter-containing 
vesicle fusion, insertion of the C2 domain top loops into the phospholipid membrane is 
proposed to reduce the energetic barrier to vesicle fusion ((Martens and McMahon, 2008); 
Figure 1.4). Insertion of the calcium-bound loops into the opposing membrane lowers the 
overall negative charge of the local membrane due to insertion of positively-charged calcium 
ions. Top loop insertion also disrupts the curvature of the local membrane, which is proposed 
to reduce the energy required for fusion-pore formation ((Lynch et al., 2007; Martens and 
McMahon, 2008; Stein et al., 2007); Figure 1.4). C2 domains are not only the calcium-sensors 
for vesicle fusion, they also reduce the energy required for vesicle fusion to occur. 
Summary: Synaptotagmin C2 domains determine the calcium response of vesicle fusion. 
 C2 domains are the calcium-sensors for vesicle fusion. 
 C2 domains can bind the SNARE complex, directly interacting with vesicle fusion 
machinery. 
 The C2 domains of synaptotagmin-1 can cooperate, with C2A calcium binding 
increasing calcium and membrane binding of C2B. 
 C2A is an electrostatic switch, with calcium binding facilitating SNARE binding. 
 C2B is a membrane sensor, anchoring synaptotagmin-1 in the membrane and 
facilitating SNARE assembly. 
 Calcium binding to both synaptotagmin-1 C2 domains is required for synaptic vesicle 
fusion in vivo. 
 C2 domains can lower the energy required for vesicle fusion by decreasing the negative 
charge of the membrane and disrupting membrane curvature. 
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1.3 Ferlins: an ancient family of C2 domain containing proteins. 
The ferlin protein family is an unusual C2 domain containing family, as ferlins contain 5-7 C2 
domains, the largest number of any protein family (Lek et al., 2010). Ferlin proteins were first 
identified in the nematode Caenorhabditis elegans, where it was observed that fer-1 mutations 
resulted in defective sperm vesicle fusion and subsequent sterility (Achanzar and Ward, 1997). 
The Drosophila melanogaster ferlin, misfire, is involved in vesicle fusion in sperm and ovaries, 
with misfire mutations also resulting in sterility (Smith and Wakimoto, 2007). Mutations in 
dysferlin, the first identified human ferlin, result in a late onset muscular dystrophy (Bashir et 
al., 1998; Liu et al., 1998) hypothesised to be caused by the lack of vesicle-fusion mediated 
plasma membrane repair (Bansal et al., 2003). Mutations in otoferlin cause deafness in humans 
(Yasunaga et al., 2000; Yasunaga et al., 1999) due to defective neurotransmitter-containing 
vesicle fusion to the auditory nerve synapse from the inner hair cells of the cochlea (Roux et 
al., 2006). 
The unifying feature of all identified ferlin models from C. elegans to humans is a defect in 
calcium-dependent vesicle fusion. As ferlins contain an unusually high number of C2 domains, 
this begs the question: are the ferlins a family of vesicle fusion proteins, mediating calcium-
dependent vesicle fusion via their many C2 domains? 
Six putative mammalian ferlin genes have been identified, and ferlins have been identified in 
simple, single-celled eukaryotes, implying that the ferlins have ancient evolutionary origins 
(Lek et al., 2010). In humans, the ferlins are large proteins of around 2000 amino acids (Figure 
1.5). In addition to C2 domains, the ferlins also contain conserved domains specific to the ferlin 
family that no function has yet been attributed to: the FerI, FerA, FerB and DysF domains 
(Figure 1.5; (Lek et al., 2012; Lek et al., 2010)). 
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The six mammalian ferlins are split into two classes based upon presence or absence of the 
DysF domain. Dysferlin, myoferlin and Fer1L5 are type-I, or DysF domain containing ferlins 
while otoferlin, Fer1L4 and Fer1L6 are type-II ferlins, lacking DysF domains (Figure 1.5). All 
mammalian ferlins are anchored by a C-terminal (type-II) transmembrane domain, with a small 
extracellular or luminal domain. C2E and C2F are the most conserved ferlin C2 domains, while 
C2A is the most divergent (Helfmann et al., 2011) (Lek et al., 2010). 
Figure 1.5: Domain composition and layout of the ferlin protein family. The ferlin family 
of proteins contain 5-7 C2 domains, anchored by a C-terminal transmembrane domain. All 
human ferlins are predicted to contain FerI and FerB domains. The type-I ferlins, dysferlin, 
myoferlin and Fer1L5 also contain FerB and DysF domains, which the type-II ferlins 
(otoferlin, Fer1L4 and Fer1L6) do not contain. Otoferlin also contains a unique lysine and 
aspartic acid-rich region of unknown function. All domain predictions are sourced from 
SMART and UniPROT. 
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Characterisation of the ferlin family has focussed on dysferlin and otoferlin, both associated 
with human disease (Bashir et al., 1998; Liu et al., 1998; Yasunaga et al., 2000; Yasunaga et 
al., 1999). Dysferlin mutations cause limb-girdle type-2 muscular dystrophy (discussed in 
Chapter 1.4). Otoferlin mutations cause profound deafness in humans, including cases of 
temperature-sensitive deafness (discussed in Chapter 1.5). Myoferlin has been associated with 
growth-factor receptor trafficking and muscle development (Britton et al., 2000; Demonbreun 
et al., 2010). Since the commencement of this Ph.D. project, multiple publications have 
identified roles for myoferlin in cancer development (discussed in Chapter 1.6).  
Recent studies have identified Fer1L5 as an interaction partner of the endocytic recycling 
proteins EDH 1 and 2 (Posey et al., 2011). No pathologies have been identified for Fer1L4, 5 
or 6, although Fer1L4 mRNA has been reported to be downregulated in human stomach cancer 
samples (Glover et al., 2010; Sorimachi and Ono, 2012). 
The remainder of this review will focus on dysferlin, otoferlin and myoferlin. Chapter 1.4 
focusses in detail on dysferlin and the potential role it plays in vesicle fusion at sites of injury 
in damaged plasma membranes. Chapter 1.5 details what is known of the function otoferlin 
plays in vesicle fusion at the ribbon synapse in inner hair cells, while Chapter 1.6 focuses on 
myoferlin and the recent evidence for the function it plays in growth-factor receptor trafficking 
and cancer development. 
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1.4 Dysferlin. 
Dysferlin was the first identified human ferlin. In 1998, two groups concurrently published 
mutations in dysferlin identified to cause limb-girdle muscular dystrophy type 2B (Bashir et 
al., 1998; Liu et al., 1998). Dysferlinopathy is characterised by an initial presentation in the 
late teens of either limb-girdle or distal muscle weakness (Myoshi Myopathy). Patients have a 
slow-onset muscle weakness, with both proximal and distal muscle groups affected with the 
progression of dysferlinopathy (Bashir et al., 1998; Liu et al., 1998). Cardiomyopathy has been 
reported in dysferlinopathy patients (Wenzel et al., 2007), and has been characterised in 
dysferlin-deficient mouse models, with mice developing dilated cardiomyopathy with age (Han 
et al., 2007).  
Dysferlin alternative splicing, protein structure, expression and sub-cellular localisation. 
Dysferlin contains seven C2 domains, FerA, FerB and the DysF domains (Figure 1.6) and 
fourteen dysferlin isoforms have been identified (Figure 1.6, Table). An alternative exon 1 
(called V1) is transcribed from a separate promoter and contains a unique 5` UTR and exon 1. 
Three further exons, 5a, 17 and 40a, can be spliced in or out of dysferlin in any combination 
(apart from all three exons in the one transcript) with either exon 1 or V1 (Figure 1.6, Table). 
V1 is the only alternatively spliced exon in dysferlin that is directly in a functional domain- 
C2A. Exon 5a, 17 and 40a are all distal to C2 domains (Figure 1.6) and to date, no dystrophy-
causing mutations have been identified in the alternatively spliced exons of dysferlin (Krahn 
et al., 2010a). 
Promano et al. (2006; 2009) characterised the expression of the alternatively spliced exons of 
dysferlin in skeletal muscle and blood by quantitative PCR. 23% of skeletal muscle transcripts 
contain V1, compared to 12% of blood transcripts (Pramono et al., 2006). In 
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skeletal muscle, 4% of transcripts contain exon 5a, 99.8% of transcripts contain exon 17 and 
11% of transcripts contain exon 40a. In blood, 89.5% of transcripts contain exon 5a, 30% of 
Figure 1.6: Alternatively spliced isoforms of dysferlin. Dysferlin contains three alternatively 
spliced exons, and an alternatively spliced initiating exon 1. Exon V1 changes 29aa of dysferlin 
C2A, exon 5a occurs between C2A and C2B, exon 17 occurs immediately following C2C and 
exon 40a occurs between C2DE and C2E (1.6B, with dysferlin isoform 1 (UniPROT identifier 
O75923-1) as a comparison in 1.6A). Either exon 1, or exon V1 can combine with the 
alternatively spliced exons 5a, 17 and 40a in any combination, present or absent excepting 
containing all three together (that is, no identified dysferlin isoforms contain exon 5a, 17 and 
exon 40a in the one transcript, Table). 
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transcripts contain exon 17 and 48% of transcripts contain exon 40a (Pramono et al., 2009). 
The work of Promano et al. (2009) highlights the difference in dysferlin splicing between two 
tissues, however expression of these alternatively-spliced isoforms has not been investigated 
in other tissues to date. 
The dysferlin protein is ubiquitously expressed in rat tissues (Anderson et al., 1999), and is 
widely expressed in human tissues (the following have been identified in the Human Protein 
Atlas and/or indicated publications: skeletal muscle (Anderson et al., 1999), heart (Wenzel et 
al., 2007), kidney (Izzedine et al., 2006), smooth muscle, bone marrow, spleen, placenta 
(Vandré et al., 2007), testis, endothelia (Hochmeister et al., 2006; Sharma et al., 2010), brain 
(Galvin et al., 2006), and monocytes (de Morrée et al., 2013)). Despite ubiquitous expression, 
dysferlin mutations seem not cause disease outside of cardiac and skeletal muscle. As discussed 
below, dysferlin may play a role in other human pathologies, indicating deeper phenotyping of 
dysferlinopthy cases may reveal a more syndromic pathology. 
Dysferlin targets the plasma membrane in mouse embryonic fibroblasts (Hernández-Deviez et 
al., 2008) and C2C12 myoblasts (Evesson et al., 2010). In mouse and zebrafish muscle, 
dysferlin is present at the t-tubule system and sarcolemma (Kerr et al., 2014; McDade et al., 
2014; Roostalu and Strähle, 2012). Dysferlin traffics via the Golgi-apparatus to the plasma 
membrane, and is endocytosed via early endosomes to the lysosomes, where it is degraded 
(Evesson et al., 2010; Hernández-Deviez et al., 2008). Inhibition of the proteasomal system in 
control and patient primary human myoblasts results in increased dysferlin protein half-life 
(Azakir et al., 2014), indicating that dysferlin can be degraded in both lysosomes and the 
proteasome.  
Summary: There are many uncharacterised isoforms of dysferlin. 
 There are 14 possible isoforms of dysferlin. 
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 No functions have yet been identified for alternatively spliced exons in dysferlin. 
 Dysferlin isoform expression varies between skeletal muscle and blood cells. 
 Dysferlin is widely expressed throughout the human body. 
Dysferlin is required for muscle membrane repair. 
In 2003, the first dysferlin knockout mouse was published (Bansal et al., 2003). The dysferlin-
null mouse develops a slow-onset muscular dystrophy characterised by necrotic fibres, muscle 
regeneration, macrophage infiltration and lipid accumulation, progressing as mice age ((Bansal 
et al., 2003); Figure 1.7). This mouse model broadly models the human patient dystrophy, 
allowing study of dysferlin function in vivo for the first time.  
Damage of dysferlin-null mouse muscle fibres in the presence of FM143 revealed that dysferlin 
is required for membrane repair in skeletal muscle (Bansal et al., 2003). FM143 is a membrane 
impermeable fluorescent dye that can enter the cell through endocytosis, large-pore ion 
channels and if the membrane has been permeabilised, as happens following membrane injury. 
In wild type mouse muscle fibres, laser-injury in the presence of extracellular calcium induces 
limited FM143 uptake at the injury site (Figure 1.8 WT+Ca2+). Without extracellular calcium, 
wild-type muscle fibres do not exclude FM143 uptake following injury (Figure 1.8 WT-Ca2+). 
In dysferlin-null muscle fibres, FM143 dye uptake is also not excluded following injury despite 
the presence of calcium (Figure 1.8 DYSF-null +Ca2+). Dysferlin is required for effective 
muscle membrane repair. 
Bansal et al., (2003) also reported putative dysferlin recruitment to sites of membrane injury, 
indicating dysferlin plays a direct role at membrane lesions. Passing wild-type mouse muscle 
fibres through an 18 gauge needle to induce membrane injury revealed dysferlin recruitment 
to membrane patches, thought to be sites of injury, in damaged fibres. 
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Identification of a plasma membrane repair defect with dysferlin deficiency lead to the 
hypothesis that dysferlin, via the multiple C2 domains, mediates vesicle-fusion dependent 
membrane repair. The discovery that dysferlin was required for membrane repair provided a 
mechanism as to how dysferlin muscular dystrophy may progress: perhaps patients are 
incapable of repairing their muscles following membrane injury. Muscle damage may 
accumulate over their lifetimes, resulting in muscle fibre necrosis and weakness as patients 
age. 
Summary: Dysferlin is required for muscle plasma membrane repair. 
 Dysferlin knockout in mice causes a muscular dystrophy broadly similar to human 
dysferlinopathy patients. 
Figure 1.7: Dysferlin deficient muscle displays a progressive dystrophy in mice. In the 
dysferlin knockout mouse model used by Bansal et al., (2003) the mouse displayed a 
progressive muscular dystrophy. At two months, internalised nuclei are noted (black 
arrowheads), and fibrous infiltration is noted in-between the haematoxylin and eosin stained 
muscle. By eight months of age, adipocyte infiltration is noted (asterisk) into the muscle, and 
by ten months of age significant degeneration is evident. Sourced from Bansal et al., (2003). 
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 Mouse muscle fibres display calcium-dependent membrane repair. 
 Dysferlin knockout mice display a membrane repair defect. 
 Dysferlin may recruit to sites of membrane injury in mouse muscle fibres. 
 Dysferlin could be the C2 domain containing protein responsible for mediating vesicle 
fusion in membrane repair. 
 
Figure 1.8: Dysferlin knockout mouse muscle fibres display defective calcium-
dependent membrane repair. When wild type mouse muscle fibres are damaged by a laser 
in the presence of extracellular calcium (WT +Ca2+), FM143 dye entry into the fibre is 
minimal, and further dye entry is prevented over time, indicating the plasma membrane is 
repaired. Without extracellular calcium (WT -Ca2+), FM143 dye uptake into the damage 
muscle fibre increases over time, indicating calcium is required for mouse muscle fibre repair. 
In dysferlin knockout mouse muscle fibres, FM143 dye uptake increases over time following 
laser injury, despite the presence of extracellular calcium (DYSF-null +Ca2+) revealing a role 
for dysferlin in plasma membrane repair in muscle. This figure was sourced from Bansal et 
al., (2003). 
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The process of calcium-dependent membrane repair. 
Dysferlin deficiency causes a membrane repair defect. How does the process of membrane 
repair occur? Membrane repair is effected by calcium-dependent vesicle fusion at sites of 
membrane injury. Steinhardt et al., (1994) determined that membrane repair was calcium-
dependent, with ~200 μM of extracellular calcium required for effective repair after micro- 
injection damage of sea urchin embryos. In unfertilized urchin embryos, which contain many 
more intracellular vesicles than fertilized embryos, membrane lesions repaired more 
efficiently, implicating intracellular vesicles in membrane repair (Steinhardt et al., 1994).  
Bi et al., (1995) provided direct evidence for calcium-dependent vesicle fusion at sites of 
membrane injury, showing exocytic vesicles recruit to sites of injury in laser-damaged sea 
urchin embryos (Figure 1.9; (Bi et al., 1995)). Sea urchin embryos were damaged by laser in 
the presence of FM143, which does not enter undamaged cells (Figure 1.9A- arrow: damage 
site). Embryos were fixed 10-20 seconds post-injury and visualised by confocal microscopy. 
FM143-positive vesicles were visualised accumulating near the site of injury (Figure 1.9D). 
Incorporation of hydrophilic, extracellular rhodamine-dextran (that cannot cross lipid 
membranes, Figure 1.9B) into accumulating vesicles indicates vesicles are undergoing fusion 
with the plasma membrane (Figure 1.9E and F). Loading of the embryo with calcium-green 
dextran prior to injury highlights the cytoplasm, and reveals vesicles as dark circles (Figure 
1.9G). Injury of the embryo in the presence of cytoplasmic calcium-green dextran and 
extracellular rhodamine-dextran reveals that vesicles present in the embryo fuse with the 
plasma membrane following injury, incorporating extracellular rhodamine-dextran (Figure 
1.9H and I). 
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Figure 1.7 demonstrates exocytic vesicles recruiting to sites of injury in sea urchin embryos 
Figure 1.9 Intracellular vesicles recruit to sites of plasma membrane injury. Bi et al 
(1995) damaged sea urchin embryos in the presence of FM143 and fluorescent dextran. A-C 
show the embryo prior to damage, in the presence of FM143 (A), dextran (B) and the overlay 
(C). Following damage (D-F), FM143 and fluorescent dextran accumulate on (FM143) and in 
(dextran) the docking cortical vesicles around the site of laser injury (arrow). Loading the 
embryo with calcium-green dextran reveals the dextran impermeable vesicles (black) against 
the green cytoplasm (green, G). Damage of the embryo in the presence of rhodamine-dextran 
(red, H) reveals that vesicles present in the embryo are fusing with the plasma membrane 
following injury. This figure is sourced from Bi et al., 1995. 
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The above results established the model of vesicle-mediated plasma membrane repair: plasma 
membrane injury causes calcium influx into the cell, leading to recruitment and fusion of 
vesicles at the site of injury, resulting in cell survival (Figure 1.10, (McNeil and Kirchhausen, 
Figure 1.10: The current model for vesicle-mediated plasma membrane repair. A breach 
in the plasma membrane allows calcium to travel down a steep concentration gradient from 
the extracellular buffer to the cytoplasm (top). This calcium influx leads to calcium-dependent 
recruitment of vesicles to the area around the membrane breach (second from top). Vesicles 
then fuse, forming a vesicular patch (third from top). The vesicular patch fuses with the site 
of plasma membrane injury, restoring membrane integrity. This figure is sourced from 
McNeil and Kirchhausen (2005). 
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2005)). However, what vesicular population and what parts of the vesicle fusion machinery are 
responsible for membrane repair have not been identified. 
Summary: Membrane repair occurs via calcium-dependent vesicle fusion. 
 Plasma membrane repair requires vesicle exocytosis at the site of injury. 
 Vesicle exocytosis at sites of injury requires extracellular calcium influx. 
The calcium sensor for plasma membrane repair is unknown. 
Lysosomes have been proposed to be the vesicular population responsible for membrane repair 
(Reddy et al., 2001). LAMP1 externalisation occurs following scratch wound injury of 
fibroblasts, indicating that lysosomes are exocytosed following membrane injury. Increased 
extracellular fluorescent dextran uptake is observed only in fibroblasts where lysosome 
exocytosis has occurred, and addition of an inhibitory LAMP1 peptide to prevent lysosomal 
exocytosis inhibited membrane repair (Reddy et al., 2001).  
Synaptotagmin-7 is the predominant synaptotagmin on lysosomes, and mediates lysosomal 
exocytosis (Reddy et al., 2001). Synaptotagmin-7 represented an attractive candidate for the 
calcium sensor of vesicle fusion. Reddy et al., (2001) added the synaptotagmin-7 C2A domain 
to media of damaged cells to competitively inhibit endogenous synaptotagmin-7. 
Synaptotagmin-7 C2A inhibition prevented membrane repair following scratch wound injury, 
providing the first evidence of a C2 domain-containing protein playing a role in plasma 
membrane repair (Reddy et al., 2001). 
Other studies contradict the hypothesis that lysosomes represent the predominant vesicle pool 
utilised in plasma membrane repair. Using vacuolin-1 to inhibit lysosomal exocytosis, Cerny 
et al., (2004) demonstrated that lysosomes are dispensable in the acute membrane resealing 
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response. Vacuolin-1 induces fusion of endosomes and lysosomes, causing vacuolisation. 
These vacuoles are not exocytosed by increased intracellular calcium induced by ionomycin 
exposure or plasma membrane injury. Membrane repair is unaffected in vacuolin-1 treated 
cells, as determined by FM143 uptake following laser-induced membrane injury (Cerny et al., 
2004), arguing against an exclusive role for lysosomes as the vesicle pool and synaptotagmin-
7 as the calcium sensor in membrane repair.  
A conflicting report to Cerny et al., (2004) indicated that vacuolin-1 treatment does not inhibit 
lysosomal exocytosis following plasma membrane injury, as measured by release of the 
lysosomal enzyme β-hexosaminidase into the extracellular media (Huynh and Andrews, 2005). 
Cerny et al., (2004) did not observe significant β-hexosaminidase release into the extracellular 
media following membrane injury in vacuolin-1 treated cells. Both studies were undertaken 
using HeLa cells, therefore cell-type specific differences in lysosomal exocytosis that have 
been reported (Shaik et al., 2009) do not explain this discrepancy in β-hexosaminidase release. 
Huynh et al., (2005) provide data to suggest that the majority of β-hexosaminidase release 
following membrane injury is released within seconds of membrane injury. As Cerny et al., 
(2004) changed the extracellular media immediately following membrane injury, the majority 
of β-hexosaminidase released may have been lost in the media change. Vacuolin-1 treatment 
does not rule out a role for lysosomal exocytosis in plasma membrane repair. 
Recent results provide more convincing data that lysosomal exocytosis may be required for 
plasma membrane repair, and that dysferlin may be the calcium-sensor for lysosomal 
exocytosis in myoblasts. Mice lacking the endosomal and lysosomal calcium channel 
MCOLN1 (of which deficiency causes mucolipidosis IV in humans) display a plasma 
membrane repair as determined by FM143 dye uptake following laser injury in isolated muscle 
fibres (Cheng et al., 2014). Following plasma membrane injury, lysosomes fuse with the 
 37 
plasma membrane distal to the injury site, and this injury-dependent lysosomal fusion is 
reduced in dysferlin knockdown myoblasts indicating that dysferlin may be responsible for 
lysosomal fusion to the plasma membrane following injury (Defour et al., 2014).  No studies 
have yet identified direct recruitment of lysosomal marker to the site of membrane injury, 
despite directly investigating lysosomal recruitment (Lek et al., 2013; Roostalu and Strähle, 
2012). While lysosomal exocytosis appears to be required for successful membrane repair, 
cumulative evidence suggests that lysosomes are not the repair organelle forming the 
‘membrane patch’ at sites of injury. 
Summary: Membrane repair requires calcium-dependent vesicle fusion. 
 While lysosomes have been proposed to be the source of vesicles in membrane repair, 
this finding is controversial and the source of plasma membrane repair vesicles is still 
unconfirmed. 
 Lysosomal exocytosis distal to the injury site does appear to be required for plasma 
membrane repair, however no studies have identified lysosomal recruitment to sites of 
membrane injury. 
  No vesicle fusion machinery has been unequivocally identified to be involved in 
plasma membrane repair, leaving the exact mechanism of vesicle fusion at sites of 
injury unknown.’ 
Dysferlin recruits to sites of injury in zebrafish muscle and human myotubes. 
Could dysferlin be the calcium-sensor for vesicle fusion at sites of membrane injury? If 
dysferlin is mediating vesicle fusion at sites of injury, it would be expected that dysferlin is 
present at membrane lesions. Convincing images of dysferlin recruitment to sites of membrane 
injury were obtained in live zebrafish muscle by Roostalu and Strähle (2012). Using C-
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terminally fused dysferlin-mTFP (monomeric teal fluorescent protein), dysferlin recruitment 
to sites of injury was identified following laser injury of zebrafish muscle. Dysferlin 
recruitment was observed within 20 seconds following laser injury, with sites of injury 
completely filled with dysferlin by 3 minutes post-injury (Figure 1.11- Dysferlin-FL; (Roostalu 
and Strähle, 2012)). 
 
Figure 1.11: C-terminally fused dysferlin-mTFP and C-terminal truncated dysferlin-
mTFP proteins recruit to sites of injury in zebrafish muscle. Zebrafish muscle expressing 
dysferlin with mTFP fused to the C-terminus was damaged by laser injury. Full-length dysferlin 
(Dysferlin-FL), dysferlin consisting of C2D, E, F and G (C2D, DE, E and F using our 
nomenclature, Dysferlin-C) and the transmembrane domain of dysferlin (Dysferlin-TM) recruit 
to sites of injury within 20 seconds (white arrow). Only Dysferlin-FL and Dysferlin-C form a 
barrier over the site of injury by 3 minutes post-injury (inset). Dysferlin consisting of either 
C2A, B and C (Dysferlin-N), or the DysF domain (Dysferlin-DysF) did not recruit to sites of 
injury. This figure was adapted from Roostalu and Strähle, 2012. 
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injury completely filled with dysferlin by 3 minutes post-injury (Figure 1.11- Dysferlin-FL; 
(Roostalu and Strähle, 2012)). 
Figure 1.12: Only the C-terminus of dysferlin is detectable at sites of plasma membrane 
injury. A- MG53 (red) and dysferlin (green) recruit to sites of membrane injury induced by 
ballistics damage. B- Epitope positions of the four anti-dysferlin antibodies utilised by Angela 
Lek mapped onto the dysferlin protein. C- Dysferlin is only detectable with the C-terminal 
antibody Hamlet-1 in primary human myotubes damaged by ballistics injury and fixed 10 or 90 
seconds post-injury. Figure adapted from Lek et al (2013). 
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Full-length dysferlin (Dysferlin-FL, Figure 1.11), the four C-terminal C2 domains (Dysferlin-
C, Figure 1.11) and the transmembrane domain (Dysferlin-TM, Figure 1.11) recruit to sites of 
injury following zebrafish muscle damage (Roostalu and Strähle, 2012). The N-terminal C2 
domains (Dysferlin-N, Figure 1.11) and the DysF domains (Dysferlin-DysF) do not recruit to 
sites of injury alone. The dysferlin C-terminus appears to have a special role in recruiting to 
membrane lesions. While the transmembrane domain (DYSF-TM) can recruit to sites of injury, 
only full-length dysferlin (DYSF-FL) and the four C-terminal C2 domains (DYSF-C) fill the 
site of injury over time (Figure 1.11). 
To visualise dysferlin at sites of injury in primary human myotubes, Angela Lek, a previous 
Ph.D. student in our group, established a ballistics model for plasma membrane injury (Lek et 
al., 2013). In this assay, primary human myotubes are damaged with silica particles fired from 
a gene gun, which causes a repairable (in a calcium-dependent manner) plasma membrane 
insult. 
At bullet wounds, dysferlin and MG53, an E3 ubiquitin ligase required for muscle membrane 
repair (Cai et al., 2009a) recruit in a tight ring around the bullet wound (Fig 1.12A). Angela 
utilised a range of dysferlin antibodies to investigate dysferlin recruitment to sites of membrane 
injury: Romeo (epitope: 123-142), Hamlet-2 (epitope: 349-366), SAB2100636 (epitope: 1314-
1363) and Hamlet-1 (epitope: 1999-2016, antibodies depicted in figure 1.12B). Curiously, 
dysferlin could not be identified at sites of injury with Romeo, Hamlet-2 or SAB2100636 
(Figure 1.12C). Dysferlin could only be identified at sites of injury with the C-terminal Hamlet-
1 antibody (Figure 1.12C). 
To determine why dysferlin could only be observed at sites of injury with Hamlet-1, Angela 
used Western blot to investigate dysferlin from myotubes shot in the presence or absence of 
calcium. A ~72 kDa, Hamlet-1 reactive mini-dysferlin (that we call mini-dysferlinC72) was 
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identified enriched only in myotubes damaged in the presence of calcium (Figure 1.13A, Shot 
+Ca2+). When damaged myotube lysates were probed with the N-terminal dysferlin antibody, 
Romeo, a ~160 kDa band was observed in cells damaged in the presence of calcium (Figure 
1.13B, Damaged +Ca2+). The N-terminal dysferlin fragment (160 kDa) and mini-dysferlinC72 
(72 kDa) together correspond to full-length dysferlin (230 kDa), indicating that dysferlin is 
cleaved in two in a calcium dependent manner following injury (Lek et al., 2013). 
Dysferlin cleavage could explain why the N-terminus is unable to be detected at sites of 
membrane injury: it is simply not there. Dysferlin is separated into two following membrane 
injury, indicating proteolytic cleavage. Angela had found that this dysferlin cleavage was 
calcium-dependent, narrowing the search to the calcium-dependent proteases, calpains. 
Figure 1.13: A C-terminal mini-dysferlin is formed in a calcium- and damage-dependent 
manner in myotubes. A- Primary human myoblasts were damaged by ballistics injury in the 
presence (+Ca2+) or absence (-Ca2+) of calcium, or harvested by direct application of lysis 
buffer to the well (Un). Shot cells were harvested with lysis buffer 30 seconds following 
injury. Dysferlin was detected on the western blot with Hamlet-1. B- Cultured myotubes were 
damaged by scraping with a rubber scraper in the presence (+Ca2+) or absence (-Ca2+) of 
calcium. Cell pellets were collected 30 seconds post-injury and lysed. Dysferlin was detected 
on the western blot with Romeo. This figure is adapted from Lek et al. (2013). 
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Calpains are a family of calcium-dependent, neutral proteases (see next sub-section, (GOLL et 
al., 2003)). Calpains-1 and -2 had previously been demonstrated to be indispensable for plasma 
membrane repair in transected giant squid axons (Godell et al., 1997), mouse fibroblasts 
(Mellgren et al., 2007), myotubes (Mellgren et al., 2009) and cardiac muscle (Taneike et al., 
2011) making them attractive candidates for dysferlin cleavage following membrane injury.  
Angela used the cell permeable calpain inhibitor, calpeptin, to determine if calpains cleave 
dysferlin following membrane injury. Myotubes treated with calpeptin displayed a dose-
dependent inhibition of mini-dysferlinC72 formation in the presence of extracellular calcium 
(Figure 1.14). Calpains are responsible for dysferlin cleavage to mini-dysferlinC72 following 
membrane injury. Our group’s hypothesis is that calcium influx through the site of injury 
activates calpains, which cleave dysferlin to mini-dysferlinC72 which recruits to sites of 
membrane injury. We think that mini-dysferlinC72 is ultimately mediating vesicle fusion at sites 
of injury. 
Summary: Only the C-terminus of dysferlin is identifiable at sites of membrane injury. 
 C-terminal dysferlin constructs recruit to sites of injury in zebrafish skeletal muscle.  
 Only the C-terminus of endogenous dysferlin is detectable at sites of injury in primary 
human myotubes.  
 Dysferlin is cleaved following membrane injury, releasing the C-terminal 72kDa mini-
dysferlinC72.  
 Inhibition of the calcium-dependent proteases, calpains, prevents mini-dysferlinC72 
formation.  
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Calpains are required for membrane repair. 
Calpains were the first identified calcium-activated proteases, and was curious in that it did not 
have a readily identifiable consensus cleavage sequence (Guroff, 1964). The calpains are 
activated by calcium binding, which allows them to bind and cleave their substrates (reviewed 
in Goll et al., 2003). Of the 15 mammalian calpains identified, the following have been 
knocked-out in mice or identified in human disease: calpain-1 knockout causes platelet 
dysfunction in mice (Adam et al., 2012); calpain-2 knockout is embryonic lethal in mice (Dutt 
et al., 2006); deficiency of the muscle-specific calpain-3 causes limb-girdle muscular-
dystrophy type 2A in humans (Richard et al., 1995); calpain small subunit-1 (CAPNS1) 
knockout is embryonic lethal in mice (Arthur et al., 2000); calpain-5 mutations cause 
autosomal dominant neovascular inflammatory vitreoretinopathy (Mahajan et al., 2012); 
calpain-10 polymorphisms have been associated with type-2 diabetes in humans (reviewed in 
(Pandurangan et al., 2014)). 
Mellgren et al (2007) published the first report showing that the ubiquitously expressed 
calpains-1 and -2 are indispensable for rapid, calcium-dependent membrane repair using a 
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calpain knockout model. Calpain-1 and -2 share identical substrate specificity, and all current 
reports on calpain-1 and -2 in membrane repair do not separate their respective contributions 
to the repair process (Mellgren et al., 2009; Mellgren et al., 2007; Taneike et al., 2011; Xie and 
Barrett, 1991).  
Calpain-1 and -2 exist as heterodimers with the calpain small subunit-1 (Capns1) in vivo 
(Lenhart et al., 2014). Capns1 stabilises calpain-1 and -2, which are the catalytic subunits. 
Upon calcium binding, Capns1 dissociates from the catalytic subunit, and the calpain-1 or -2 
catalytic subunits are activated (GOLL et al., 2003; Lenhart et al., 2014). Capns1 -/- mouse 
embryonic fibroblasts harvested prior to embryonic lethality show complete absence of 
calpain-1 and -2 protein, providing an effective calpain-1 and -2 double knockout (Tan et al., 
2006).  
Figure 1.15: Calpain small-subunit-1 knockout cells display defective plasma membrane 
repair. A- Calpain small-subunit-1 deficient mouse embryonic fibroblasts (Capns1-/-) display 
increased FM143 dye uptake following plasma membrane injury with a laser (white arrows). 
Wild-type mouse embryonic fibroblasts (Capns1+/+) display little FM143 dye uptake following 
injury. B- Quantification of FM143 dye uptake following laser injury indicates that Capns1-/- 
fibroblasts (red) take up around four times more dye over 120 seconds compared to wild type 
(green) fibroblasts, highlighting their membrane repair defect. This figure is adapted from 
Mellgren et al., (2007). 
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Capns1 -/- fibroblasts survive scrape injury to a similar degree as wild-type cells without 
calcium following scrape injury, indicating calpains-1 and -2 are required for calcium 
dependent membrane repair. Addition of calpain-1 or calpain-2 into the media during scraping 
increases cell survival by 25%, comparable to Capns1 +/+ fibroblasts. Laser damage of 
Capns1 -/- fibroblasts revealed a membrane repair defect, with Capns1 -/- fibroblasts taking 
up four times more FM143 dye than Capns1 +/+ fibroblasts following injury (Figure 1.15B, 
visualised in A). Calpains-1 and -2 are required for plasma membrane repair. 
Taneike et al., (2011) established a conditional cardiac Capns1 knockout mouse model to 
examine the physiological role of calpains-1 and -2 in the heart in and ex vivo (Taneike et al., 
2011). Following a transverse aortic constriction injury, the authors found that Capns1 
knockout hearts have increased Evans Blue dye uptake (-/-: 6%, WT: 0%), indicating Capns1 
knockout hearts have greater membrane permeability following injury in vivo. Laser-induced 
membrane injury of both isolated Capns1 knockout cardiomyocytes and ex vivo hearts resulted 
in increased FM143 dye uptake compared to wild-type (Taneike et al., 2011). Calpains-1 and 
-2 are involved in plasma membrane repair in an intact organ ex vivo. 
Calpain-3 mutations cause limb-girdle muscular dystrophy type 2A (Richard et al., 1995), and 
it was unknown until 2009 if calpain-3 may mediate membrane repair in muscle. Mellgren et 
al., (2009) demonstrated that calpain-3 -/- muscle fibres have similar FM143 dye uptake 
compared to wild-type fibres following laser injury, excluding a role for calpain-3 in muscle 
membrane repair (Mellgren et al., 2009). Calpains-1 and -2 specifically are required for plasma 
membrane repair. 
For the remainder of this thesis, references to calpains will be specifically referring to calpain-
1 and -2, unless otherwise stated. 
Summary: Calpains-1 and -2 are required for membrane repair. 
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 The calpains are a family of calcium-dependent proteases. 
 Calpain-1 and -2 are ubiquitously expressed and share identical substrate specificity. 
 Knockout of calpain small-subunit-1 abolishes calpain-1 and-2 expression and results 
in defective membrane repair in fibroblasts. 
 Conditional knockout of calpain small-subunit-1 results in defective membrane repair 
in the heart in and ex vivo. 
 Calpain-3, mutations of which cause a muscular dystrophy, is not required for muscle 
membrane repair. 
Dysferlin links calpains and vesicle fusion in membrane repair. 
Godell et al., (1997) demonstrated that vesicle accumulation at the site of transection in giant 
squid axons leads to exclusion of extracellular dye, indicative of axon resealing (Godell et al., 
1997). Transection in the presence of calpain inhibitors prevented axon resealing. In axons 
treated with calpain inhibitors, vesicle accumulation and size was comparable to untreated 
transected axons, however vesicles did not fuse at the transection site. Calpains are required 
for the final step of vesicular resealing of the transected axon: fusion at the site of injury. This 
was the first evidence that calpains may be required for vesicle fusion during membrane repair 
(Godell et al., 1997). How calpains mediate vesicle fusion at sites of injury is unknown. 
 47 
Calpains-1 and -2 require an unusually high amount of calcium for activation. Calpain-1 
requires 10-50 μM calcium for half maximal activation while calpain-2 requires 200-400 μM 
calcium for half maximal activation (Goll et al., 1992). Intracellular calcium lies at 
approximately 106 nM (Williams et al., 1990), far below what is required for either calpain-1 
Figure 1.16: Dysferlin cleavage and complete recruitment requires 200 μM extracellular 
calcium. A- Cultured myotubes were damaged by scraping with a rubber scraper in increasing 
concentrations of extracellular calcium. Dysferlin and mini-dysferlinC72 are detected with 
Hamlet-1, and the N-terminal counter-fragment detected with Romeo-1. B- Primary human 
myotubes were shot in the presence of increasing extracellular calcium and fixed 10 seconds 
post-injury. MG53 (red) and dysferlin (green, detected with Hamlet-1) require 200 μM Ca2+ for 
complete recruitment. This figure is modified from Lek et al., (2013). 
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or -2 to be activated. Calcium influx from the extracellular environment (free serum calcium is 
maintained at 1-1.2 mM (Saliba et al., 2002; Waters et al., 1997)) during membrane injury 
would provide the calcium required to activate calpain-1 and -2 at the membrane lesion. 
Steinhardt et al., (1994) established that 200 μM of extracellular calcium is the concentration 
required for effective membrane repair. Damage of myotubes in increasing concentrations of 
extracellular calcium revealed that mini-dysferlinC72 formation occurs with 200 μM 
extracellular calcium (Figure 1.16A). Dysferlin recruitment to sites of injury is only complete 
with 200 μM calcium, prior to which dysferlin recruitment to damaged membranes is diffuse 
(Figure 1.16B) (Lek et al., 2013). 
200 μM calcium is a critical calcium concentration for plasma membrane repair. At 200 μM 
calcium, both calpains-1 and -2 would theoretically be active. Activated calpain-1 and -2 could 
cleave dysferlin, allowing mini-dysferlinC72 to recruit to sites of injury. We hypothesise that 
mini-dysferlinC72, via C2E and C2F, stimulates vesicle fusion at sites of injury, leading to 
plasma membrane repair. Release of the putative vesicle fusion module mini-dysferlinC72 by 
calpains would provide the link between calpains, vesicle fusion and membrane repair. 
Summary: Calpains-1 and -2 are calcium dependent proteases required for plasma membrane 
repair. 
 Calpain-1 and -2 are required for vesicle fusion at the transection site of squid and 
crayfish axons.  
 Calpain-1 and -2 have supra-physiological calcium requirements that would rarely be 
seen inside the cell.  
 A membrane lesion would lead to a calcium-influx sufficient to activate calpains-1 and 
-2.  
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 The calcium concentration required for calpain activation overlaps with the calcium 
requirement for effective membrane repair and dysferlin recruitment to sites of injury. 
 Calpain cleavage of dysferlin may allow mini-dysferlinC72 to mediate vesicle fusion at 
sites of injury, providing the link between calpains and vesicle fusion. 
Identified functions or pathologies for dysferlin in non-muscle tissues. 
Dysferlin deficiency causes a muscular dystrophy and muscle membrane repair defect, despite 
ubiquitous expression of dysferlin. While no dysferlin mutations have been identified to cause 
other human diseases, dysferlin has been identified in roles beyond acute membrane repair in 
muscle.  
In mouse endothelial cells dysferlin deficiency results in reduced cell adhesion, and reduced 
angiogenesis in mice in vivo (Sharma et al., 2010); monocyte cell adhesion is reduced with 
dysferlin deficiency in vitro (de Morrée et al., 2013); dysferlin aggregates in Alzheimer’s 
plaques in human brains (Galvin et al., 2006); dysferlin mis-localises on the red-blood cell 
plasma membrane (where it is not otherwise present) in Diamond-Blackfan anaemia patients 
(Pesciotta et al., 2014); dysferlin expression is induced in endothelia of leaky blood brain 
barriers, with dysferlin expression levels correlating with leakiness in multiple sclerosis cases 
(Hochmeister et al., 2006). These papers highlight potential roles for dysferlin beyond that of 
acute plasma membrane repair, and beyond that of muscle-specific function and pathology. 
While discussion of these papers is beyond the scope of this review, it is worth noting the array 
of functions dysferlin may play throughout the human body. 
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1.5 Otoferlin. 
Introduction. 
Otoferlin mutations were identified as a cause of non-syndromic recessive auditory neuropathy 
in humans in 1999 (Yasunaga et al., 2000; Yasunaga et al., 1999). Otoferlin deficiency causes 
profound deafness present from birth. In otoferlinopathy, auditory nerve development is 
normal, allowing for cochlear implants as a treatment for deafness (Rodríguez‐Ballesteros et 
al., 2003). Otoferlin deficiency causes defective neurotransmitter exocytosis in inner hair cells, 
resulting in no auditory nerve stimulation following sound reception (Roux et al., 2006). 
Otoferlin functions in calcium-dependent vesicle exocytosis (Roux et al., 2006) and vesicle 
replenishment (Pangrsic et al., 2010) at the ribbon synapse of inner hair cells and the vestibular 
organ (Dulon et al., 2009). Otoferlin is proposed to be the calcium-sensing C2 domain 
containing protein for vesicle fusion in the hearing process. 
Otoferlin protein structure and expression. 
Otoferlin is a protein of 1997 amino acids, encoded by 47 exons. Six C2 domains have been 
identified, as well as FerI and FerB domains (Figure 1.17). Five splice isoforms have been 
identified in humans; two full length (1997aa) and three short isoforms (1230 or 1307 aa) 
(Figure 1.17). The short isoforms are not present in mice (Yasunaga et al., 2000; Yasunaga et 
al., 1999). Deafness has been determined to be due to mutation in full length otoferlin; function 
for the short isoforms remains to be identified (Yasunaga et al., 2000). 
The two long isoforms of otoferlin are identical apart from alternative splicing of exon 47. If 
exon 47 is present, one predicted transmembrane domain is expressed; if exon 47 is absent, 
 51 
 
splicing to exon 48/3` UTR results in expression of an alternate transmembrane domain. 
Otoferlin short isoforms contain a unique 5’UTR/exon 1 which splices onto exon 19, resulting 
in a near identical protein product to full length, but lacking the N-terminal 747 amino acids 
containing the C2A, B, C and FerI domains. Either potential transmembrane domain can be 
present on the short isoforms. In humans, the predicted transmembrane domain encoded by 
Figure 1.17: Long, short and alternatively spliced isoforms of otoferlin. Five otoferlin 
isoforms have been identified in humans. Isoforms 1 (UniPROT: Q9HC10-1) and 5 
(Q9HC10-5) are the ‘long’ isoforms, and differ by the predicted transmembrane domains. 
Isoforms 2 (Q9HC10-2) and 4 (Q9HC10-4) are the shortest isoforms, missing the initial 746 
aa of the long isoforms and C2A, B and C domains, as well as 19aa encoded by exon 31. 
Isoforms 2 and 4 differ only by their predicted transmembrane domains. Isoform 3 
(Q9HC10-3) is another short isoform, encoded by the same initiating methionine as the other 
short isoforms, but including an additional exon following this, resulting in a different N-
terminus. 
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exon 47 is not expressed in inner hair cells, but is expressed in brain (Figure 1.18; (Choi et al., 
2009)). Both predicted transmembrane domains are expressed in human brain (Figure 1.18; 
(Choi et al., 2009)).  
Otoferlin is expressed in the inner, outer and vestibular hair cells, and nerves in mice (Schug 
et al., 2006) as well as the forebrain, kidney, retina, utricle and cerebellum in chickens 
(Goodyear et al., 2010). Anti-otoferlin immunoreactive products not corresponding to the full-
length otoferlin protein have also been identified in rat liver and skeletal muscle (Schug et al., 
2006). Otoferlin expression increases in outer hair cells until the onset of hearing, after which 
expression is lost from all but the apical outer hair cells (Roux et al., 2006; Schug et al., 2006). 
In contrast, otoferlin expression in inner hair cells increases until after the onset of hearing, 
following which expression is sustained (Roux et al., 2006). Expression is also noted in spiral 
ganglion neurons from P8 in mice (Schug et al., 2006) and mature vestibular hair cells (Dulon 
et al., 2009). 
Summary: Otoferlin is expressed in mature inner hair cells. 
Figure 1.18: The predicted transmembrane domain encoded by otoferlin exon 47 is 
expressed in brain, but not the cochlea. Choi et al., (2009) performed reverse-transcription 
PCR on mRNA isolated from human brain and cochlea, amplifying from exon 46 to exon 
48/3` UTR of otoferlin. No transcripts that utilise exon 47 are detectable in the cochlea, while 
exon 47 containing transcripts are utilised in the brain. Both brain and cochlea utilise exon 48 
containing transcripts that exclude exon 47. Figure sourced from Choi et al., (2009). 
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 Five isoforms of otoferlin are present in humans, two long and three short, while only 
two ‘full-length’ otoferlin isoforms have been identified in mice. 
 Alternate splicing can confer a different predicted transmembrane domain upon 
otoferlin. 
 Otoferlin is expressed in mature inner and vestibular hair cells, while expression is lost 
upon maturation of most outer hair cells. 
Mutations and human phenotype. 
Mutations causing profound deafness are present throughout otoferlin, in every otoferlin C2 
domain, multiple linker regions and exon 48 (Figure 1.10; (Choi et al., 2009; Mahdieh et al., 
2012; Marlin et al., 2010; Migliosi et al., 2002; Pangršič et al., 2012; Romanos et al., 2009; 
Varga et al., 2006; Varga et al., 2003; Wang et al., 2010; Yasunaga et al., 2000; Yasunaga et 
al., 1999). Deafness-causing mutations have not been identified in exon 47, which encodes the 
transmembrane domain expressed in brain but not inner hair cells ((Choi et al., 2009; Mahdieh 
et al., 2012); Figure 1.18). It remains to be determined if otoferlin expression in the brain is 
essential for hearing.  
Otoferlinopathy patients have an absent auditory brainstem response (as no response is elicited 
following click stimulus); normal oto-acoustic emissions (which can be lost over time), a 
measure of cochlear (outer hair cell) function; and normal cochlear microphonics, a measure 
of the alternating current generated by the outer hair cells during sound stimulus (Varga et al., 
2003). The above symptoms indicate that outer hair cell function is normal, but despite this no 
neural response is triggered by sound, indicating either inner hair cells or the auditory nerve is 
dysfunctional. Cochlear implantation can restore hearing in otoferlinopathy patients 
(Rodriguez-Ballesteros et al., 2003), indicating that the auditory nerve is still functional and 
the primary defect lies with inner hair cell function. 
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Specific otoferlin mutations have been identified to cause temperature-sensitive deafness 
(Figure 1.19, mutations identified in pink; (Marlin et al., 2010; Varga et al., 2006; Wang et al., 
2010). In temperature sensitive deafness, patients can hear normally until their body 
temperature elevates (although they may have difficulty with speech perception), often in the 
case of fever, following which they are rendered profoundly deaf. In all patients with 
temperature-sensitive deafness excepting one, deafness only occurs with fever (Marlin et al., 
2010; Varga et al., 2006). In one severe patient, deafness occurs with a body temperature above 
36.5°C. The patient can hear in the morning, but with rising body temperature throughout the 
day is profoundly deaf by afternoon (Wang et al., 2010). This represents an unusual and severe 
case of temperature-sensitive deafness. 
Summary: Otoferlin mutations cause human deafness. 
 Mutations in otoferlin cause recessive, non-syndromic deafness in humans. 
 Auditory nerve development is normal, with cochlear implants providing treatment. 
Figure 1.19: Identified otoferlin mutations causing recessive non-syndromic deafness in 
humans. Identified mutation in otoferlin that cause non-syndromic deafness cover the spread 
of the otoferlin protein. Mutations causing temperature-sensitive deafness are indicated in 
pink (I515T; G541S; R1607W and E1804del). CC denotes a predicted coil-coil domain. 
Figure sourced from Pangrsic et al., (2012). 
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 Specific otoferlin mutations cause temperature-sensitive deafness. 
Inner Hair Cells, Ribbon Synapses and Neurotransmitter Release 
Otoferlin is required for neurotransmitter (in this case, glutamate) release from the ribbon 
synapse in cochlea inner hair cells (Roux et al., 2006). Hair cells line the semi-circular canal 
of the inner ear (Figure 1.20A). Inner hair cells form one row along the organ of Corti, the 
auditory epithelium of the inner ear (Figure 1.20A). Otoferlin is expressed throughout inner 
hair cells, and localises to the basolateral region of outer hair cells (Figure 1.20B). The hairs, 
at the apical region of hair cells, extend into the scala media of the cochlea (Figure 1.20A and 
B, schematic). The basolateral region contains the ribbon synapse, and contacts the afferent 
nerve (Figure 1.20B and C, r- ribbon synapse, aff- afferent nerve, schematic; (Roux et al., 
2006)). 
The ribbon synapse is a specialised membranous organelle of retinal rod cells and cochlea and 
vestibular inner hair cells. Around the ribbon synapse, there are a number of tethered and free 
neurotransmitter-containing vesicles primed for rapid exocytosis to the presynaptic membrane 
upon stimulus (Figure 1.20C- SV; (Nouvian et al., 2006)). Upon stimulus reception (sound), 
synaptic vesicles are released from the ribbon synapse readily-releasable vesicle pool to the 
basolateral membrane (Figure 1.20C, PSD), releasing glutamate to the afferent (auditory) nerve 
(Figure 1.20C, aff). Rapid replenishment of the readily-releasable vesicle pool is required for 
the continued sensation of sound (Griesinger et al., 2005; Nouvian et al., 2006). 
The mechanosensory hairs extending into the scala media of the cochlea are exposed to the 
mechanical stimulus of sound. In cochlear hair cells, mechanical stimulation of the hairs 
activates mechanotransducer channels (Kennedy et al., 2003). CaV1.3 calcium channels are 
responsible for sound-induced calcium influx at the basolateral membrane/synaptic region in 
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inner hair cells (Brandt et al., 2003). Calcium influx induces exocytosis, measured by a change 
in membrane capacitance at the basolateral membrane which represents the increase in total 
membrane (which acts as a capacitor) caused by vesicle exocytosis (Beutner and Moser, 2001; 
Moser and Beutner, 2000). The membrane capacitance change is rapidly depressed due to 
exhaustion of the readily-releasable vesicle pool (Nouvian et al., 2006). Rapid intracellular 
vesicle replenishment repopulates the readily releasable vesicle pool to allow exocytosis to be 
sustained indefinitely (Griesinger et al., 2005).  
Synaptotagmins-1 and -2, associated with neurotransmitter release in nerves, are not present in 
inner hair cells at either the mRNA or protein level (Safieddine and Wenthold, 1999; Uthaiah 
and Hudspeth, 2010). Synaptotagmin-IV expression has been reported in mature inner hair 
Figure 1.20: Otoferlin expression in the organ of corti, hair cells and the structure of the 
ribbon synapse. The semi-circular canal in the organ of Corti is composed of inner- and 
outer-hair cells (A, green- myosin-VI). Otoferlin is expressed in both the inner and out hair 
cells at P6 (B, green), with expression in outer hair cells localised to the basolateral region of 
the cell, near the ribbon synapse, as opposed to the apical hair region. The ribbon synapse (r) 
is composed of an electron-dense core, and is surrounded by synaptic vesicles (SV) (C). The 
ribbon synapse closely abuts the synaptic cleft (C- PSD) and the afferent nerve (C-aff). Figure 
adapted from Roux et al., (2006; 2009) (A and B) and Psangric et al., (2011) (C). 
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cells (Johnson et al., 2010). In synaptotagmin-IV knockout mice, inner hair cell exocytosis 
resembles that of immature hair cells, not the mature counterparts. Synaptotagmin-IV knockout 
does not completely abolish mature inner-hair cell exocytosis (Johnson et al., 2010). However 
a more recent study was unable to detect synaptotagmin-IV mRNA in mature inner hair cells 
(Reisinger, 2011). No data has provided unambiguous identification of a synaptotagmin 
responsible for calcium-sensing and stimulation of vesicle fusion in inner hair cells. 
Evidence suggests otoferlin acts as the calcium-sensing protein for neurotransmitter-containing 
exocytosis in inner hair cells, acting as synaptotagmins-1 and -2 do for neurotransmitter release 
at neural synapses. Over-expression of otoferlin in synaptotagmin-1 knockout hippocampal 
neurons does not rescue the exocytosis defect caused by synaptotagmin-1 loss. Conversely 
synaptotagmin-1 over-expression in otoferlin knockout inner hair cells does not rescue the 
exocytosis defect caused by lack of otoferlin (Reisinger, 2011). The above results do not 
exclude a synaptotagmin-like role for otoferlin in the inner hair cell, but do show that neither 
protein is able to substitute for the specialised role of the other in the inner hair cell and neural 
synapse. 
Summary: Transduction of mechanical stimulus in inner hair cells causes neurotransmitter 
release to the auditory nerve. 
 Sound waves lead to depolarisation of the inner hair cell basolateral membrane. 
 Inner hair cell depolarisation leads to calcium influx and vesicle fusion at the 
basolateral membrane, releasing glutamate to the auditory nerve. 
 Neurotransmitter-containing vesicles are sourced from a readily releasable vesicle pool 
at the ribbon synapse. 
 Replenishment of the readily releasable vesicle pool is rapid, allowing sustained sound 
reception to occur. 
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 Synaptotagmins-1 and 2 are not present in mature inner hair cells- could otoferlin be 
the calcium-sensor for vesicle fusion in hearing? 
Phenotype of murine otoferlin models. 
There are two well characterised mouse models of otoferlin pathology. In the Otof-/- mouse, 
homologous recombination was used to remove exons 14 and 15 of the otoferlin gene, which 
results in no otoferlin being detectable by western blot and immunohistochemistry (Roux et 
al., 2006). Inner hair cell size, shape and number is similar to wild type mice in the Otof-/- 
mouse model, indicating otoferlin does not play a role in hair cell development (Roux et al., 
2006). The Pachanga mouse model was created by random chemical mutagenesis, introducing 
a mutation in the C2F domain of otoferlin (Schwander et al., 2007). In the Pachanga mouse, 
otoferlin is expressed at reduced levels compared to wild type mice, as determined by 
immunohistochemistry (Pangrsic et al., 2010). This is the only otoferlin mouse model in which 
otoferlin is detected in inner hair cells (Schwander et al., 2007). In the Pachanga mouse, inner 
hair cell size, shape and number is also normal (Pangrsic et al., 2010; Schwander et al., 2007). 
Both otoferlin mouse models are profoundly deaf. 
In the Otof-/- mouse model, exocytosis in mature inner hair cells is abolished, as determined by 
a lack of change in membrane capacitance at the basolateral membrane following 
depolarisation in patch-clamp recordings (Roux et al., 2006). No auditory brainstem response 
is noted in Otof-/- mice following auditory stimulation of the cochlea. Functional assessment of 
outer hair cell function by testing otoacoustic emissions revealed that outer hair cell function 
is normal, and direct electrical stimulation of the auditory nerve revealed that nerve conduction 
is normal in Otof-/- mice. This refined the cause of the hearing defect to the inner hair cells, and 
matches the human phenotype (Roux et al., 2006). The lack of exocytosis in the Otof-/- mouse 
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inner hair cells provides evidence for otoferlin as the calcium-sensor of the late steps of 
exocytosis at the ribbon synapse. 
Fusion of neurotransmitter containing vesicles from inner hair cells is relatively unperturbed 
in the Pachanga mouse model (Pangrsic et al., 2010). In the Pachanga mouse exocytosis (as 
measured by a change in membrane capacitance in patch-clamp assay of inner hair cells) 
rapidly diminishes upon inner hair cell stimulation, but exocytosis can be evoked again 
following a one second recovery period (Pangrsic et al., 2010). Otoferlin appears to be 
responsible for replenishment of the readily releasable vesicle pool in inner hair cells: 
stimulation exhaustions the readily releasable vesicle pool, which cannot be replenished 
quickly enough for hearing to continue. A rest period allows the readily releasable vesicle pool 
to be replenished by other, slower means, and the hair cell can again respond to stimulus. 
Stimulation again rapidly exhausts the vesicle supply, and as such the Pachanga mouse is 
unable to sustain hearing and is functionally deaf (Pangrsic et al., 2010).  
Summary: Otoferlin is required for vesicle exocytosis and replenishment in inner hair cells. 
 Exocytosis is abolished when inner hair cells completely lack otoferlin. 
 Exocytosis can occur when C2F mutant otoferlin is present, but the readily releasable 
vesicle pool is not replenished rapidly enough for sustained hearing to occur. 
 In both Otof-/- and Pachanga mouse models, otoferlin is not required for normal inner 
hair cell development. 
 Otoferlin is potentially required for inner hair cell exocytosis and readily releasable 
vesicle pool replenishment. 
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Otoferlin interacts with neuronal SNAREs in vitro, but not in inner hair cells. 
Otoferlin appears to be involved in calcium-dependent exocytosis in inner hair cells in vivo 
(Roux et al., 2006). In vitro characterisation of otoferlin C2 domain calcium-, phospholipid- 
and SNARE-complex binding provides further evidence for otoferlin as a calcium-sensor for 
vesicle fusion. All otoferlin C2 domains apart from C2A have been determined to bind calcium, 
phospholipids and aggregate liposomes in vitro (Johnson and Chapman, 2010; Padmanarayana 
et al., 2014). The C2C and C2F domains of otoferlin specifically interact with PIP2 in a calcium 
dependent manner in in vitro lipid binding assays (Padmanarayana et al., 2014). The entire 
otoferlin protein (without the transmembrane domain) is capable of inducing lipid ordering in 
vitro in liposomes, a putative precursor to stimulating vesicle fusion (Marty et al., 2013). The 
above results establish in vitro the ability of otoferlin C2 domains to bind calcium and lipids 
as well as aggregate and order liposomes in vitro, consistent with a role for otoferlin as a 
calcium-dependent vesicle-binding protein capable of lowering the energy required for vesicle 
fusion. 
All otoferlin C2 domains (excepting C2A) display calcium dependent binding to syntaxin-1 
and SNAP25 in in vitro pulldown assays incubating purified C2 domains with purified 
SNAREs (Johnson and Chapman, 2010). Otoferlin C2F displays the highest affinity for 
syntaxin-1 and SNAP25 in these assays. Extending the in vitro evidence for otoferlin:SNARE 
interaction, recent evidence has identified an otoferlin: syntaxin-1 interaction in rat brain 
lysates. Immunoprecipitation of otoferlin from rat brain lysate pulls down syntaxin-1, and vice 
versa (Ramakrishnan et al., 2014). However, in vivo studies dispute the relevance of otoferlin 
interaction with syntaxin-1 and SNAP-25 to neurotransmitter release from inner hair cells. 
Using a series of knockout mice for SNAP-25, and utilising botulinum toxin to cleave syntaxins 
1-3, Nouvian et al., (2011) demonstrated that neurotransmission from inner hair cells occurs 
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despite abolition of the entire neuronal SNARE complex. Hair cell exocytosis in the SNAP-25 
knockout and botulinum treated cells is inconsistent with the hypothesis that the neuronal 
SNAREs are responsible for vesicle fusion in inner hair cells. Furthermore, convincing 
immunohistochemical staining revealed that neuronal SNAREs are not detectable in inner hair 
cells from wild-type mice (Nouvian et al., 2011).  Inner hair cells do not appear to express 
neuronal SNAREs, therefore another unidentified SNARE complex may be responsible for 
inner hair cell synaptic vesicle release (Nouvian et al., 2011). While otoferlin can interact with 
neuronal SNAREs in vitro, interaction of otoferlin with these SNAREs in inner hair cells does 
not appear to occur, and is likely irrelevant for neurotransmitter release. It would be interesting 
to determine if otoferlin in the brain interacts with neuronal SNAREs in a biologically relevant 
manner. Otoferlin is still likely a calcium-sensor for vesicle fusion in hair cells, but does not 
interact with neuronal SNAREs to facilitate this fusion. The SNARE machinery required for 
inner hair cell exocytosis is yet to be identified. 
Summary: Neuronal SNAREs are not required for inner hair cell exocytosis. 
 Neuronal SNAREs were hypothesised to be responsible for exocytosis in inner hair 
cells. 
 Otoferlin interacts with neuronal SNAREs in vitro. 
 Otoferlin provides an attractive candidate as the calcium sensor to bring vesicles in 
proximity to the neuronal SNAREs for vesicle fusion in inner hair cells. 
 Inner hair cell exocytosis is not disrupted by abolition of the neuronal SNAREs. 
 The mechanism for exocytosis in inner hair cells remains to be identified. 
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Further cell biology implicating otoferlin in vesicle trafficking. 
Otoferlin interacts with the cellular motor myosin-VI (Roux et al., 2009), of which mutation 
also causes profound deafness in mice (Avraham et al., 1995). Myosin-VI deficient cells 
display immature exocytosis, which is not sufficient for hearing to occur (Roux et al., 2009). 
Otoferlin also interacts with Rab8b (Heidrych et al., 2008), a protein transport regulator 
proposed to have a role in vesicle transport from the trans-Golgi network to the basolateral 
membrane in polarised cells (Henry and Sheff, 2008). Otoferlin co-localises with the Golgi 
marker GM130 in inner hair cells (Schug et al., 2006). 
Otoferlin Summary. 
Otoferlin is required for exocytosis and vesicle recycling in inner hair cells. While otoferlin is 
hypothesised to be the calcium-sensor for vesicle fusion in inner hair cells, no direct evidence 
yet supports this. Otoferlin C2 domains are capable of binding calcium and phospholipids in 
vitro, consistent with a role in vesicle fusion in vivo. Otoferlin can also directly interact with 
SNARE vesicle fusion machinery, but this interaction does not occur in inner hair cells in vivo. 
A role for otoferlin mediating vesicle exocytosis remains to be demonstrated in vivo. 
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1.6 Myoferlin. 
Myoferlin was first described by Davis et al. (2000) and Britton et al., (2000). Myoferlin was 
not identified as a cause of human pathology, rather Davis et al., (2000) identified myoferlin 
following electronic database searches, discovering a gene highly similar to dysferlin which 
was subsequently cloned and characterised. Functional characterisation of myoferlin has been 
undertaken in myoblast fusion and receptor trafficking (Bernatchez et al., 2007; Bernatchez et 
al., 2009; Doherty et al., 2005b), with recent publications indicating overexpression correlates 
with cancer development and poor clinical outcomes. The role myoferlin plays in cancer 
development is still being elucidated. 
Protein structure and expression. 
Myoferlin displays a high level of homology to dysferlin, with 72% amino acid similarity and 
52% amino acid identity. Myoferlin contains seven C2 domains, FerA, FerB and the DysF 
domains (Figure 1.5). In contrast to dysferlin, myoferlin is expressed in a limited range of 
tissues. Northern blot analysis has identified myoferlin RNA expression in heart, placenta, 
lung, kidney and pancreas (Britton et al., 2000; Davis et al., 2000). A recent study of myoferlin 
expression by western blot in control human tissues identified myoferlin in skin, testis and 
liver, with no expression detected in skeletal muscle, bone, pericardium, kidney, pancreas, eye, 
brain, rectum, ilium or lung. (Turtoi et al., 2013). Due to the high level of homology between 
myoferlin and dysferlin, myoferlin was proposed to be functionally equivalent to dysferlin, and 
may be able to rescue dysferlin deficiency in dysferlinopathy patients (Davis et al., 2000). 
However, while myoferlin is expressed in cultured mouse myoblasts and myotubes 
(Demonbreun et al., 2010), no report has identified convincing expression of myoferlin in 
mature human or mouse skeletal muscle. 
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Summary: Myoferlin is similar to dysferlin, with expression limited in tissues. 
 Myoferlin is highly homologous to dysferlin. 
 Myoferlin expression is only noted in skin, testis and liver in control human tissues, in 
contrast to the ubiquitous expression of dysferlin. 
 Myoferlin is not expressed in mature skeletal muscle. 
Myoferlin in receptor trafficking and muscle development. 
Functional characterisation of a myoferlin knockout mouse model reveals that myoferlin 
deficiency leads to mice having smaller muscle fibres than wild-type counterparts (Doherty et 
al., 2005a). Myoferlin-null myoblasts undergo less fusion events compared to wild-type 
myoblasts, forming fewer myotubes that contain less nuclei than wild-type myotubes in culture. 
As myotube formation is required for mature muscle development, the smaller fibres noted in 
the myoferlin null mouse may be due to reduced efficiency of myoblast fusion in vivo (Doherty 
et al., 2005a). 
Myoferlin has been identified to interact with the endocytic recycling protein EHD2 (Doherty 
et al., 2008). In myoferlin-null mice, EHD2 expression is reduced, and overexpression of a 
dominant-negative EHD2 mutant results in decreased myoblast fusion in this model, indicating 
myoferlin is involved in endocytosis in myoblasts (Doherty et al., 2008). Myoferlin is also 
required for endocytosis in endothelial cells (Bernatchez et al., 2009) with myoferlin siRNA 
knockdown resulting in decreased clathrin and caveolae dependent endocytosis. Decreased 
endocytosis in myoferlin knockdown cells results in reduced vascular endothelial growth factor 
receptor-2 cell surface expression, implicating myoferlin in growth-factor receptor trafficking 
(Bernatchez et al., 2007; Bernatchez et al., 2009). The myoferlin-null mouse is also 
unresponsive to insulin-like growth factor-1, due to reduced insulin-like growth factor-1 
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receptor internalisation following ligand binding, further extending the receptor-trafficking 
roles of myoferlin (Demonbreun et al., 2010).  
Summary: Myoferlin is involved in muscle development and growth factor receptor trafficking. 
 Myoferlin knockout in mice leads to decreased myotube formation and decreased 
muscle size. 
 Myoferlin knock-down decreases clathrin and caveolae-dependent endocytosis and 
vascular endothelial growth-factor 2 receptor trafficking to the cell surface. 
Myoferlin and cancer development. 
Growth factor receptor trafficking appears to be central to the involvement of myoferlin in 
cancer development. Eisenberg et al., (2012) first investigated a role for myoferlin in cancer 
development due to the increased myoferlin expression noted in many histological cancer 
samples in the Human Protein Atlas. It was also noted that microarray data from breast cancer 
biopsies revealed myoferlin upregulation in cancer samples (Amatschek et al., 2004) and 
myoferlin expression was increased in the plasma membrane proteome of human cancer cell 
lines (Adam et al., 2002). Eisenberg et al., (2011) utilised a cell culture chamber invasion 
model, in which cells can ‘invade’, or grow into a matrigel filled chamber from their original 
growth chamber above. Knockdown of myoferlin reduced cell invasion into the chamber 
below, indicating that myoferlin may be required for cell migration, a crucial step in cancer 
development (Eisenberg et al., 2011). 
Following the report by Eisenberg et al., multiple studies have identified myoferlin 
upregulation in a range of tumours. Myoferlin upregulation is noted in human and mouse lung 
carcinoma (Leung et al., 2013); breast cancer tumour cells (Li et al., 2012); pancreatic 
adenocarcinoma (Wang et al., 2013); and breast ductal adenocarcinoma (Turtoi et al., 2013). 
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Notably, in each study, myoferlin expression is not observed in breast tissue, pancreas or lung 
from human control samples. 
In an effort to explore the role myoferlin plays in cancer development, myoferlin knockdown 
has been utilised in multiple cancer cell lines. Knock-down of myoferlin in patient pancreatic 
adenocarcinoma cell lines decreases cell proliferation and migration velocity, and decreases 
tumour weight in a murine tumour xenograft model (Wang et al., 2013). Using a breast cancer 
cell line (MDA 231), Volakis et al., (2014) demonstrated that myoferlin knockdown also 
reduces cell migration and cell adhesion. Furthermore, a xenograft model using myoferlin 
knock-down MDA 231 cells resulted in smaller tumour size compared to MDA 231 cells with 
unaltered myoferlin expression (Volakis et al., 2014). 
The mechanism as to how myoferlin exerts a role in cell proliferation and migration in tumours 
is yet to be elucidated, but roles in plasma membrane repair and growth factor receptor 
trafficking are promising early leads (Leung et al., 2013; Turtoi et al., 2013). Leung et al., 
(2013) damaged LLC cells (a mouse epithelial cancer cell line) with a laser in the presence of 
the membrane-impermeable dye, FM143. LLC cells with myoferlin knocked-down displayed 
an 8 times greater increase in FM143 dye uptake following laser injury compared to control 
siRNA treated LLC cells. Myoferlin upregulation in cancer cells may render cells more 
resistant to plasma membrane injury, increasing cell survival and subsequent tumour burden 
(Leung et al., 2013). 
Myoferlin knockdown in patient breast cancer adenocarcinoma cell lines reduces the epidermal 
growth-factor receptor expression, and subsequently causes a decrease in cell migration 
induced by addition of epidermal growth factor (Turtoi et al., 2013). Myoferlin knockdown 
disrupts caveolae assembly, and disrupted assembly reduces cell surface epidermal growth 
factor-receptor expression (Turtoi et al., 2013). 
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Summary: Myoferlin expression is increased in cancer cells, influencing cell growth, migration 
and tumour burden. 
 Myoferlin expression is increased in lung, breast and pancreatic tumours- tissues with 
no myoferlin expression in healthy controls. 
 Myoferlin knockdown reduces cell migration velocity, cell growth rate and cell 
adhesion in cancer cell lines. 
 Myoferlin knockdown reduces tumour growth in murine xenograft models. 
 Myoferlin may be involved in plasma membrane repair, increasing cancer cell survival 
following membrane injury. 
 Epidermal growth-factor receptor expression and epidermal growth factor response is 
decreased with myoferlin knockdown, implicating myoferlin expression with growth 
factor response in cancer cells. 
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1.7 Summary and aims for my project. 
The ferlin family is a protein family containing an unusually high number of calcium-
dependent phospholipid binding C2 domains. All identified ferlin pathologies present defects 
in vesicle fusion, indicating that the ferlins are involved in vesicle fusion. Given the established 
role of C2 domains in vesicle fusion in synaptotagmins, it is plausible that the ferlins could 
regulate vesicle fusion via their many C2 domains. 
In membrane repair and inner hair cell exocytosis, there is no identified calcium-sensor for 
vesicle fusion. Dysferlin and otoferlin are proposed to be the calcium-sensors for vesicle fusion 
in these processes. No vesicle fusion event has been identified for myoferlin, Fer1L4, Fer1L5 
or Fer1L6 to act as the calcium-sensing C2 domain containing protein to date. We currently 
know little about the expression and subcellular localisation of the human ferlins. Determining 
where the ferlins are expressed and where they are in the cell will help us form hypotheses as 
to the vesicle fusion events they may help regulate. To recap, dysferlin is ubiquitously 
expressed, and is present at the plasma membrane in cells and sarcolemma in muscle. Otoferlin 
has been identified in brain and hair cells in the cochlea and vestibular organ, and localises to 
vesicles in the Golgi apparatus, pre-synaptic zone and interacts with vesicle trafficking 
machinery in inner hair cells. Myoferlin traffics growth-factor receptors and is expressed only 
in skin, testis and liver in humans, although expression is upregulated in tumours originating 
from tissues in which myoferlin is not otherwise expressed.  
The aim of my Ph.D. project is to characterise where the ferlin family proteins are expressed 
in the body and where they go in the cell. Following on from Angela Lek’s discovery that 
dysferlin is cleaved by calpains in response to membrane injury, my project extended to 
identifying the calpain cleavage site of dysferlin, and which other human ferlins are calpain 
substrates. My project can be broken down into the following sub-aims: 
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Chapter 3: 
 Determine in which tissues each ferlin is expressed at the transcript level. 
 Determine which ferlins target to the plasma membrane in cells. 
 Determine where each ferlin targets within the cell at steady state (intracellular). 
 Determine the endocytic trafficking of each ferlin. 
Chapter 4: 
 Identify the cell types dysferlin is cleaved in following membrane injury. 
 Confirm that calpains are responsible for dysferlin cleavage in all cell types. 
Chapter 5: 
 Identify the calpain cleavage site within dysferlin. 
 Identify if mini-dysferlinC72 is present at sites of membrane injury. 
 Determine which other human ferlins are calpain cleavage substrates. 
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Chapter 2: Materials and Methods. 
2.1. Cell damage assays. 
Ballistics assay. 
Angela Lek, a previous Ph.D. student, developed our ballistics assay utilising a Bio-Rad Helios 
Gene Gun. 4 μM silica particles (Sigma Aldrich, substituted for gold particles) were prepared 
as per the manufacturer’s instructions. Briefly, silica particles were adhered to the inside of 
plastic tubing (Bio-Rad) using 5 μL of 5 mg.mL-1 poly-vinyl-pyrrolidone (Sigma Aldrich) 
dissolved in 3.5 mL 100% ethanol. Following drying, silica-lined tubing was cut to size to fit 
in the Gene Gun (Bio-Rad) cartridge.  
Differentiated primary human myotubes cultured on Thermanox coverslips (Nunc/Thermo-
Fischer Scientific) were transferred into a 24 well plate (BD Falcon) containing 200 μL 
Dulbecco’s Phosphate Buffered Saline (DPBS, Life Technologies) with calcium and 
magnesium. Cells were shot at 300 PSI, using helium as the propellant. Immediately following 
injury, 200 μL of DPBS was added to the well to replenish liquid lost due to the helium blast. 
At the desired timepoint, coverslips were removed from the 24 well plate and inverted onto a 
75 μL droplet of 3% ice-cold PFA (Sigma Aldrich) and fixed for 10 minutes at 10°C before 
proceeding with immunocytochemistry (ICC) staining (Chapter 2.5). 
Cell scrape assay. 
For our scrape-damage assay sub-confluent (80-90% confluence) cells cultured in a 6 well plate 
were damaged with a rubber scraper (BD Falcon). 
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Plus calcium scraping: For scrape-damage in plus calcium conditions, cells were washed 
twice with 1 mL room temperature DPBS + Ca2+, + Mg2+. Following washing, cells were 
scraped in room temperature 500 μL DPBS + Ca2+, + Mg2+ for 30 seconds. After scraping, 
cells were harvested into a 1.5 mL tube on ice, containing 50 μL 0.5 M EDTA (Sigma Aldrich) 
with 1:500 protease inhibitor cocktail (Sigma Aldrich). Scraped cells were pelleted at 300g for 
3 minutes at 4 °C, following which the supernatant was removed and cells lysed in RIPA buffer 
(Table 2.4) and prepared for western blot (Chapter 2.4). 
Minus calcium scraping: For scrape-damage without calcium, cells were washed once with 1 
mL DPBS -Ca2+, -Mg2+. Cells were then incubated in DPBS -Ca2+, -Mg2+ + 10 mM EDTA at 
room temperature for 30 seconds. DPBS -Ca2+, -Mg2+ + 10 mM EDTA was aspirated and cells 
washed twice with 1 mL room temperature DPBS -Ca2+, +Mg2+, following which cells were 
scraped for 30 seconds in 500 μL DPBS -Ca2+, +Mg2+. After scraping, cells were harvested as 
per plus calcium conditions into EDTA-containing tubes on ice. 
Calcium titration scraping: For scrape-damage experiments in varying levels of calcium-
containing DPBS, cells for all conditions were washed with 1 mL DPBS -Ca2+, -Mg2+, followed 
by incubation in DPBS -Ca2+, -Mg2+ + 10 mM EDTA at room temperature for 30 seconds. 
DPBS -Ca2+, -Mg2+ + 10 mM EDTA was aspirated off cells, and cells washed twice with 1 mL 
DPBS +Mg2+ + the desired concentration of calcium. Cells were then scraped for 30 seconds 
in 500 μL DPBS +Mg2+ + the desired concentration of calcium. Following scraping, cells were 
harvested as per plus calcium conditions into EDTA-containing tubes on ice. 
Undamaged minus calcium cell harvesting: Cells were washed in 1 mL room temperature 
DPBS -Ca2+, -Mg2+, following which cells were incubated in DPBS -Ca2+, -Mg2+ + 10 mM 
EDTA at room temperature for 30 seconds. 250 μL RIPA containing 1:500 protease inhibitor 
cocktail was then added per well, and cells lysed with gentle agitation on ice for 30 minutes. 
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Supernatants were then harvested and centrifuged for 15 minutes at 15000g at 4°C. Lysates 
were then treated with SDS-lysis buffer and DTT (Sigma Aldrich) as described in Chapter 2.4. 
Undamaged plus calcium cell harvesting: Cells were washed in 1 mL room temperature 
DPBS +Ca2+, +Mg2+. 250 μL RIPA lysis buffer lacking EDTA and protease inhibitors, with 
900 μM Ca2+, was added per well. Cells were lysed with gentle agitation for 2 minutes at room 
temperature. 50 μL of 0.5 M EDTA containing 1:500 protease inhibitor cocktail was then added 
to quench protease activity, and lysis continued for 30 minutes on ice. Supernatants were then 
harvested and centrifuged for 15 minutes at 15000g at 4°C. Lysates were then treated with 
SDS-lysis buffer and DTT as described in Chapter 2.4. 
Calpeptin-treated scraping: Three hours prior to scraping, cells were treated with the indicated 
concentration of calpeptin (5- 100 µM, Tocris Bioscience). 30 minutes prior to scraping, half 
of the media was replaced with media containing fresh calpeptin. Cells were then damaged as 
in plus calcium scrape conditions above, with the addition of the indicated concentration of 
calpeptin at every wash step, and in the scrape buffer. Scraped cell pellets were harvested and 
lysed as in plus calcium scraping. 
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2.2. Immunoprecipitation and in vitro calpain cleavage. 
Immunoprecipitation. 
Ferlin expression constructs encoding the ferlin with a C-terminal epitope tag (Table 2.11) 
were transfected into 10 cm plates HEK293 cells using CaPO4 transfection (Table 2.3). 24 
hours post transfection plates were lysed on ice for 30 minutes with 4 mL RIPA lysis buffer 
(Table 2.4) with 1:500 protease inhibitor cocktail. Cell lysates were transferred into a 15 mL 
tube and pre-cleared with 50 μL of Protein-G-Sepharose beads (GE Healthcare, prepared in 
RIPA buffer) with constant inversion at 4°C for 2 hours. Sepharose beads and insoluble 
material was pelleted at 15000g for 15 minutes at 4°C, following which the supernatant was 
transferred into a new tube. 1 μg of primary antibody (Hamlet-1 or Romeo for dysferlin or 
rabbit-α-myc for other ferlins) was added to the tube and incubated overnight at 4°C with 
constant inversion. Following overnight incubation, 150 μL of Protein-G-Sepharose beads 
(prepared in RIPA buffer) was added per tube, and incubated for a further 2 hours at 4°C with 
constant inversion. Protein-G beads were then pelleted at 4500g for 30 seconds and washed 
three times in 5 mL calcium-free HEPES cleavage buffer (20 mM HEPES; 50 mM NaCl; 2 
mM CaCl2; 1 mM MgCl2; Sigma Aldrich; pH 7.5). Beads were then used for the calpain 
cleavage assay. 
In vitro calpain cleavage. 
Ferlin-bound Protein-G beads were transferred into calcium-containing HEPES cleavage 
buffer (50 μL for each experimental condition) and split evenly into one tube for each condition 
used. Purified calpain-1 or calpain-2 (Merck Millipore) was diluted to the desired number of 
active units per μL-1 (AU.μL-1) in calcium-containing HEPES cleavage buffer on ice. Diluted 
calpain was then added to the tube containing the ferlin-bound Protein-G beads and the tubes 
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incubated for the indicated time OR indicated calcium concentration at 30°C to allow calpain 
cleavage to occur. To quench cleavage at the desired timepoint and remove bound protein from 
the beads, 40 μL of 4x SDS-lysis buffer (Table 2.4) and 10 μL of 2M DTT was added and tubes 
heated to 94 °C for 3 minutes. The cleavage reaction was then stored at -80°C for subsequent 
western blot (Chapter 2.4). 
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2.3 Cell culture and transfection. 
Culturing and plating conditions. 
Cell lines were cultured as detailed in Table 2.1. Primary human myoblasts were isolated by 
Angela Lek from control human muscle biopsies (Lek et al., 2013). Primary human myoblasts 
were differentiated for at least 4, but typically 7 days prior to scrape or ballistics injury. 
Mouse embryonic fibroblasts were isolated from wild-type, CAPNS1 -/- and CAPNS1 -/- 
lentiviral rescue embryos generated in, and provided to us by, the lab of Professor Peter Greer 
(Tan et al., 2006). 
Primary mouse astrocytes and microglia were isolated from C57BL/6 mice according to the 
protocol of Mecha et al., (2011). Briefly, two-day-old pups were decapitated and heads washed 
in 70% ethanol. The skull was cut open and brain removed from the cavity and placed into a 
dish containing chilled DMEM (Life Technologies). Holding the brain by the frontal lobes, the 
meninges were gently removed. Following removal of the meninges, the frontal lobes and any 
remaining brainstem was removed. The remaining brain was transferred into a fresh plate of 
chilled DMEM and chopped into approximately 2 mm2 pieces. The brain squares were then 
placed into a 15 mL falcon with DMEM and triturated into a single cell suspension with serum-
coated glass pipettes. The single cell suspension was centrifuged for 10 minutes at 170g, then 
re-suspended in DMEM containing 10% FBS and 10% HS (Life Technologies) and placed in 
a poly-D-lysine (Sigma Aldrich) coated T75 flask (BD Falcon) (one brain per T75).   
 76 
Table 2.1: Cell lines and growth media conditions. 
Cell line Growth Media Serum/ 
Supplements 
Antibiotic 
HEK293 DMEM 10% FBS (Fetal 
bovine serum) 
50 μg.mL-1 
Gentamycin 
C2C12 myoblast 1:1 DMEM:F12 15% FBS 50 μg.mL-1 
Gentamycin 
Human umbilical 
vein endothelia cell 
(HUVEC) 
M200 Low Serum Growth 
Supplement + 18% 
FBS 
50 μg.mL-1 
Gentamycin 
Mouse embryonic 
fibroblast (MEF) 
DMEM 10% FBS 50 μg.mL-1 
Gentamycin 
1° mouse astrocyte DMEM 10% FBS + 10% 
HS (Horse serum) 
2% 
Penicillin/Streptomycin 
(P/S) 
1° mouse microglia DMEM 10% FBS + 10% 
HS 
2% P/S 
1° mouse 
cardiomyocyte 
1:1 DMEM:F12 20% FBS + 5% HS 
+ 5% Amniomax + 
2 mM L-glutamine 
+ 1% non-essential 
amino acids + 3 
mM sodium 
pyruvate 
50 μg.mL-1 
Gentamycin + 1% P/S 
1° human myoblast 1:1 DMEM:F12 20% FBS + 10% 
Amniomax 
50 μg.mL-1 
Gentamycin 
1° human myotube 
(differentiation) 
1:1 DMEM:F12 3% HS + 1:100 
insulin-selenium-
transferase 
50 μg.mL-1 
Gentamycin 
MO3.13 DMEM 10% FBS 50 μg.mL-1 
Gentamycin 
MO3.13 
(differentiation) 
DMEM Serum-free + 100 
nM phorbol-12-
myristate-13-
acetate 
50 μg.mL-1 
Gentamycin 
All cell culture reagents were sourced from Life Technologies 
 
Flasks were sealed and cells grown for 10 days at 37°C without disruption. Following growth, 
flasks were shaken at 260 RPM for 16 hours at 37°C. The media was removed and centrifuged 
at 170g for 10 minutes, yielding a pellet of microglia. Microglia were then cultured in DMEM 
containing 10% FBS and 10% HS with 2% penicillin/streptomycin (Life Technologies) on 
poly-D-lysine coated 6 well plates (BD Falcon). The remaining cells in the  
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Table 2.2: Cell line plating conditions. 
Cell line Plating condition 
HEK293 Poly-D-lysine coated glass or plastic 
Primary human myotube 1:50 type-1 collagen (60 mg.mL-1) coated plastic 
(Thermanox) only 
HUVEC Matrigel (1:100) in serum free M200 media treated glass 
or plastic 
1° Mouse cardiomyocyte Uncoated plastic only 
1° Mouse astrocyte Poly-D-lysine coated glass or plastic 
1° Mouse microglia Poly-D-lysine coated glass or plastic 
MO3.13 Poly-D-lysine coated glass or plastic 
MEF Uncoated plastic or glass 
C2C12 1:50 type-1 collagen (60 mg.mL-1) coated glass or plastic 
 
flask were trypsinised and replated into a fresh T75 flask in DMEM containing 10% FBS and 
10% HS with 2% P/S. The cells that adhered in the fresh flask were microglia.  
Cardiomyocytes were isolated by Dr. Frances Lemckert using a Worthington neonatal 
cardiomyocyte isolation kit. Cardiomyocytes were de-differentiated for 5 days prior to scrape-
injury. 
MO3.13 cells were grown to 70% confluence, then transferred into serum-free media 
containing 100 nM PMA (Sigma Aldrich) and differentiated for 7 days prior to damage. 
Cell lines were plated for damage assays or ICC as in Table 2.2.  
Transfections. 
HEK293 cells were transfected with either polyethylenimine (PEI, Polysciences, for ICC) or 
calcium phosphate (Sigma Aldrich, for western blot) as in Table 2.3. For both reagents, 
HEK293 cells were seeded in a 6 well plate at 35% confluence, to be at 70% confluence for 
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transfection 24 hours later. Cells were re-plated onto coverslips 8 hour after transfection with 
CaPO4 to limit toxicity. Re-plating onto coverslips occurred 16 hours post transfection for PEI 
transfected cells. 
Table 2.3: Transfection conditions for a 6 well plate (per well/ 10 cm2). 
Reagent Reagent Volumes DNA Method 
CaPO4 100 μL 0.25 M CaCl2, 100 
μL BES 
4 μg Add DNA to tube. Add CaCl2, mix 
gently. Add BES dropwise and mix 
by gentle pipetting. Incubate for 15 
minutes. Add dropwise to cells. 
PEI 8.3 μL PEI, 100 μL 0.9% 
NaCl 
3 μg Add PEI and NaCl to tube, vortex. 
Add DNA and mix by gentle 
pipetting. Incubate for 15 minutes. 
Add dropwise to cells. 
GeneJuice 4.5 μL GeneJuice, 200 μL 
Optimem 
1.5 μg Add GeneJuice and Optimem to 
tube, vortex. Incubate for 5 minutes. 
Add DNA and mix by gentle 
pipetting. Incubate for 10 minutes. 
Add dropwise to cells. 
Note: all reagents and DNA at room temperature prior to use, and all incubations carried out 
at room temperature. 
 
C2C12s were seeded directly on coverslips in a 24 well plate at 30% confluence, to be 50-60% 
confluence for transfection 24 hours later. C2C12s were transfected with GeneJuice (Table 2.3) 
for at least 24 hours prior to cell use. 
MEFs were transfected using an AMAXA Nucleofector MEF1 transfection kit. MEFs were 
cultured in 10 cm dishes, split every 24 hours for 2 days prior to transfection. 2 million cells 
were transfected per vial of the MEF1 kit. Following transfection, MEFs were plated into fresh 
10 cm dishes and allowed 24 hours recovery prior to use. 
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2.4 Western blotting. 
All antibodies for western blot are detailed in Chapter 2.7. 
Cell lysis for western blot. 
All cells were harvested for western blot in RIPA lysis buffer. Following pelleting of scraped 
cells (above), 150 μL of RIPA lysis buffer (Table 2.4) containing 1:500 protease inhibitor 
cocktail (Sigma Aldrich) was added per well of a 6 well plate to the pellet. Cells were 
homogenized in RIPA buffer by pipetting, and incubated with constant inversion at 4°C for 30 
minutes. Cell lysates were then centrifuged for 15 minutes at 15000g at 4°C. Following 
centrifugation, the supernatant was removed, with a sample retained for a protein assay. 
Supernatants were then diluted in 4x SDS-lysis buffer (Table 2.4) and 50 mM DTT (final 
concentration). Lysates were heated at 94°C for 3 minutes and then stored at -80°C for later 
use. 
SDS-PAGE and transfer. 
All lysates were run on 4-12% Bis-Tris 10 well gels either 1 mm or 1.5 mm thick (Life 
Technologies). Gels were run in MOPS buffer (Table 2.4) at 170 volts for 1 hour 20 minutes, 
or until the 15 kDa protein marker was at the bottom of the gel. Protein was transferred onto 
PVDF membrane (Merck Millipore) in chilled transfer buffer (Table 2.4). Gels were 
sandwiched between a sponge and two sheets of filter paper on either side of the gel. Transfer 
was carried out at 100 volts for 1 hour (1 mm gel) or 1 hour 15 minutes (1.5 mm gel). 
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Table 2.4: Cell lysis and western blotting buffers. 
Buffer Recipe pH 
RIPA 50 mM Tris; 150 mM NaCl2; 10 mM EDTA; 0.5% 
deoxycholate; 0.1% SDS, 1.0% NP40 
7.8 
SDS-lysis 8% SDS; 40% Glycerol; 50 mM Tris; 40 mM EDTA; 
bromophenol blue 
7.5 
MOPS 50 mM 3-(N-Morpholino)propanesulfonic acid 4-
morpholinepropanesulfonic acid (MOPS); 50 mM Tris; 
0.1% SDS; 1 mM EDTA 
7.7 
Transfer (Astral 
Scientific) 
025 mM Tris; 192 mM glycerol; 0.025% SDS; 15% 
methanol added fresh before use 
As Supplied 
All reagents for RIPA, SDS-lysis and MOPS buffer sourced from Sigma Aldrich. 
Antibody incubation and developing. 
Following transfer, membranes were marked to indicate the protein transfer side. Membranes 
were blocked in PBST (Astral Scientific) containing 5% skim milk powder for 30 minutes 
(unless otherwise indicated, Chapter 2.7). Membranes were incubated in primary antibody (2 
mL per 8 cm by 6cm membrane) at 4°C overnight. Following primary incubation, blots were 
washed 5 times for 5 minutes in PBST prior to secondary antibody incubation. Membranes 
were incubated in horseradish peroxidase conjugated secondary antibody (Thermo-Fischer 
Scientific) for 2 hours at room temperature. Following a further 5 times 5 minute washes in 
PBST, excess liquid was removed and membranes incubated in ECL reagent (GE Healthcare) 
for 1 minute and developed on film (GE Healthcare). Membranes were regularly reprobed with 
GAPDH to demonstrate equal loading. 
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2.5 Immunocytochemistry protocols. 
All antibodies used for ICC are detailed in Chapter 2.7. Imaging was undertaken on a Leica 
SP5 confocal microscope, with selected coverslips imaged on a DeltaVision OMX 3D-SIM 
microscope (under the direction of Dr. Lynne Turbull). 
Live cell surface staining. 
Glass coverslips (No. 1 thickness, TAAB Laboratory Equipment LTD) containing HEK293 
cells transfected with ferlin expression constructs (ferlinMYC-FLAG pCMV6, Table 2.11) were 
washed by submersion three times into a well of ice cold Hanks Balanced Salt Solution (HBSS, 
Life Technologies). Washed coverslips were then inverted onto a 100 μL droplet of primary 
antibody (anti-epitope tag antibody) diluted in HBSS with 1% FBS and incubated at 10°C for 
1.5 hours. Coverslips were washed again by submersion three times into a well of ice cold 
HBSS and blocked by inversion onto a 100 μL droplet of 10°C HBSS with 1% FBS for 15 
minutes. Excess liquid was removed from blocked coverslips and coverslips were inverted onto 
a 100 μL droplet of secondary antibody diluted in HBSS with 1% FBS for 1 hour at 10°C in 
light protected conditions.  
Following secondary incubation, coverslips were washed by submersion three times into a well 
of ice cold HBSS and then fixed by inversion onto a 100μL droplet of 3% PFA for 15 minutes 
at 10°C. Post-fixation, coverslips were incubated for 10 minutes in 1:5000 (20 ng.mL-1) 4',6-
diamidino-2-phenylindole (DAPI, Life Technologies) if required. Fixed coverslips were then 
mounted onto a glass slide using Prolong Gold and nail polish to prevent mounting reagent 
drying. 
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Live cell endocytosis staining. 
To determine protein endocytosis, half of the media on coverslips containing HEK293 cells 
transfected with ferlin expression constructs (ferlinMYC-FLAG pCMV6, Table 2.11) was removed 
and replaced with fresh media containing an anti-epitope tag antibody and coverslips returned 
to the 37°C incubator. Coverslips were incubated in the antibody containing media for 30 
minutes. Following antibody incubation, coverslips were washed 3x in wells containing pH 2.2 
0.5 M glycine (Sigma Aldrich). Glycine was removed by washing 3x in wells containing 
HBSS, following which coverslips were inverted onto a 75 μL droplet of 3% PFA at 10°C for 
15 minutes. After fixation, coverslips were permeabilised by inversion onto a 75 μL droplet of 
0.1% saponin (Sigma Aldrich) in PBS for 10 minutes, and then washed 3x in wells containing 
DPBS and transferred onto a 75 μL droplet of DPBS with 2% BSA (Sigma Aldrich) for 15 
minutes.  
Coverslips were incubated on a 75 μL droplet of primary antibody (for an organelle marker) 
diluted in DPBS with 2% BSA for 1.5 hours. Coverslips were then washed 3x in wells 
containing DPBS and blocked for 15 minutes on a 75 μL droplet of DPBS with 2% BSA. 
Coverslips were incubated in secondary antibody for 1 hour in light protected conditions, and 
DAPI added at 1:5000 (final concentration) to the secondary antibody droplet 10 minutes 
before mounting the coverslip. Coverslips were washed and mounted onto a glass slide using 
Prolong Gold and nail polish. 
Total cell staining. 
For total staining, coverslips were washed 3x in wells containing DPBS and immediately fixed 
in a 75 μL droplet of 3% PFA for 15 minutes. Following fixation, coverslips were washed 3x 
in wells containing DPBS and permeabilised in 75 μL 0.15% Triton X-100 for 10 minutes 
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(excepting LAMP1 staining, in which case 0.2% saponin was used for 10 minutes and Rab7, 
in which case 0.3% triton was used for 15 minutes) or 100 μL 1:1 methanol:acetone for 4 
minutes (Hamlet-1 staining only) and washed 3x in wells containing DPBS. Coverslips were 
blocked in 75 μL of DPBS with 2% BSA for 15 minutes. Coverslips were incubated in 75 μL 
primary antibody diluted in DPBS with 2% BSA for 1.5 hours at room temperature OR 
overnight at 4°C (ballistics damage assay staining only).  
Following primary incubation coverslips were washed 3x in wells containing DPBS and 
blocked in 75 μL of DPBS with 2% BSA for 15 minutes. Coverslips were then incubated in 75 
μL secondary antibody for 1 hour at room temperature diluted in DPBS with 2% BSA in light 
protected conditions. If required, DAPI was added at 1:5000 (final concentration) to the 
secondary antibody droplet 10 minutes before mounting the coverslip. Coverslips were washed 
and mounted onto a glass slide using Prolong Gold and nail polish OR Flurosave (for ballistics 
assay staining only). 
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2.6 Flow associated cell sorting. 
Flow associated cell sorting (FACS) was undertaken to quantify the surface expression of the 
ferlin proteins. HEK293 cells were transfected with ferlin expression constructs expressing 
ferlins with C-terminal epitope tags and cytosolic EGFP (ferlinMYC-FLAG pIRES2-EGFP, Table 
2.11) were trypsinised, quenched with an equal volume of growth media and spun for 3 minutes 
at 300g. The media was removed and cell pellet resuspended in fresh growth media. Cells were 
replated for 2 hours at 37°C to allow export of surface proteins. 
Following 2 hours replating, cells were lifted off the plate with versene (Life Technologies). 
The versene was quenched with HBSS containing 5% FBS and cell suspension transferred to 
a new tube and cells pelleted at 300g for 3 minutes at 10°C. Cells were resuspended in 150μL 
of primary antibody (anti-epitope tag antibody) diluted in HBSS with 5% FBS and incubated 
in a rack on ice to maintain temperature at 10°C for 1.5 hours.  
Primary antibody was diluted in 5 mL HBSS with 5% FBS, and cells pelleted at 300g for 3 
minutes at 10°C and supernatant removed. Cells were then resuspended in 200 μL of secondary 
antibody diluted in HBSS with 5% FBS. Secondary antibody incubation occurred for 1 hour at 
10°C in light protected conditions. Secondary antibody was diluted by addition of 5 mL HBSS 
with 5% FBS, and cells pelleted at 300g for 3 minutes at 10°C and supernatant removed. The 
cell pellet was then resuspended in HBSS with 1% FBS and 1:200 propidium iodide (Life 
Technologies), to exclude permeabilised cells from FACS analysis. Samples were then 
analysed on a BD FACS DIVA cell sorter. 
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2.7 Antibodies and fluorescent reagents. 
Table 2.5: Dysferlin antibodies used in this study. 
Antibody 
(stock 
concentration) 
Western 
Blot 
ICC Epitope Company  Product 
Number 
Romeo 
(1 mg.mL-1) 
1:1000 1:500 TPLPGAV 
PLFPPPTPLE 
Abcam Ab124684 
Hamlet-1 
(0.36 mg.mL-1) 
1:500 1:100 RPAGQGR 
DEPNMNPKLE 
Leica HAMLET
-CE 
Anti-exon 40a 
(serum) 
1:500 1:50 ADGLSSL 
APTNTASPPSSPH 
Eurogentec 
(custom antibody) 
N/A 
 
Table 2.6: Anti-epitope tag antibodies used in this study. 
Antibody 
(stock concentration) 
Western 
Blot 
ICC Company  Product  
Number 
Mouse anti-Myc 
9E10 
(0.2 mg.mL-1) 
N/A Uptake: 1:100 
Total: 1:1000 
Santa Cruz SC-40 
Rabbit anti-Myc 
(1 mg.mL-1) 
1:5000 Surface: 1:500 
Uptake: 1:500 
Total: 1:5000 
Abcam Ab9106 
Rabbit anti-Flag 
(1 mg.mL-1) 
N/A Surface: 1:2500 
Uptake: 1:2500 
Total: 1:10000 
Abcam Ab1163 
 
Table 2.7: Organelle marker antibodies used in this study. 
Antibody 
(stock concentration) 
ICC Species Reactivity Company  Product 
Number  
LAMP1 1D4B 
(supernatant) 
1:100, 
(0.2% Saponin 
only) 
Rat Mouse 
only 
Iowa 
Hybridoma 
Bank 
1D4B 
LAMP1 H4A3 
(supernatant) 
1:100,  
(0.2% Saponin 
only) 
Mouse Human 
only 
Iowa 
Hybridoma 
Bank 
H4A3 
TGOLN2/TGN38 
(0.4 mg.mL-1) 
1:4000 Rabbit Human 
only 
Sigma 
Aldrich 
HPA0127
23 
Calreticulin 
(1 mg.mL-1) 
1:200 Mouse Human, 
mouse 
Novus 
Biological 
NPB1-
47518 
Calreticulin 
(0.6 mg.mL-1) 
1:200 Rabbit Human Chemicon 
International 
Ab3825 
GM130 
(0.25 mg.mL-1) 
1:250 Mouse Human, 
mouse 
BD 
Bioscience 
610822 
Pex14 
(0.4 mg.mL-1) 
1:1000 Rabbit Human, 
mouse 
Sigma 
Aldrich 
HPA0492
31 
Rab7 
(Not provided) 
1:25, (0.3% 
Triton only) 
Rabbit Human, 
mouse 
Cell 
Signalling 
Technologies 
D95F2 
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Table 2.8: Other antibodies used in this study. 
Antibody 
(stock concentration) 
Application Species Company  Product 
Number 
Mouse MG53 
(supernatant) 
ICC: 1:500 
 
Mouse J. Ma (Cai et al., 
2009b) 
N/A 
Rabbit MG53 
(supernatant) 
Western Blot: 1:5000 Rabbit J. Ma (Cai et al., 
2009b) 
N/A 
Myoferlin 7D2 
(1 mg.mL-1) 
Western Blot: 1:1000 Mouse Abcam Ab76746 
Otoferlin C12 
(0.2 mg.mL-1) 
Western Blot: 1:100, 
immunoprecipitated 
otoferlin only 
Mouse Santa Cruz Sc-271092 
GAPDH 6C5 
(1 mg.mL-1) 
Western Blot: 1:5000 Mouse Merck Millipore MAB374 
Smooth muscle 
actin 
(Not provided) 
Western Blot: 1:250 Mouse Novocastra 
Laboratories 
 
SMA-CE 
Sarcomeric Actin 
(Not provided) 
Western Blot: 1:2000 Mouse Sigma Aldrich A2172 
Glial fibrillary 
acidic protein 6F2 
(0.08 mg.mL-1) 
Western Blot: 1:1000 Mouse DAKO MO76101-
2 
Calpain-2 
(Not provided) 
ICC: 1:25- 0.01% 
Triton only 
Western Blot: 1:1000- 
BSA block only 
Rabbit Cell Signalling 
Systems 
2539 
 
Table 2.9: Florescent reagents used in this study. 
Reagent 
(Stock concentration) 
Wavelength 
(nm) 
ICC Company  Product 
Number 
 Wheat germ 
agglutinin 
488 1:500 Life Technologies W11261 
DAPI 
(1 mg.mL-1) 
405 1:5000 (10 
minutes only) 
Life Technologies D1306 
Anti-mouse 488 
(2 mg.mL-1) 
488 1:200 Life Technologies A21202 
Anti-mouse 555 
(2 mg.mL-1) 
555 1:200 Life Technologies A21424 
Anti-rabbit 488 
(2 mg.mL-1) 
488 1:200 Life Technologies A21260 
Anti-rabbit 555 
(2 mg.mL-1) 
555 1:200 Life Technologies A21428 
Anti-rabbit 594 
(2 mg.mL-1) 
594 1:200 Life Technologies A11037 
Anti-rabbit 647 
(2 mg.mL-1) 
647 1:200 Life Technologies A21245 
Anti-rat 488 
(2 mg.mL-1) 
488 1:200 Life Technologies A11006 
All isotype controls for fluorescent seconday antibodies are included in Appendix 1. 
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2.8 Polymerase chain reaction and cloning. 
Polymerase chain reaction. 
PCR was carried out for 30, 35 and 40 cycles with 92°C dissociation, 58°C annealing and 72°C, 
40 second extension (70 second for GAPDH) on a Applied Bioscience Thermocycler using 
Taq DNA polymerase (Life Technologies) and MasterAmp PCR Premix (Gene Target 
Solutions). cDNA was sourced from Clontech (Human  MTC Panel 1, Immune Panel and Gut 
Panel).  
Primers were designed to the 3` of each ferlin using Primer 3.0. Primers were purchased from 
Sigma Aldrich. GAPDH primers were supplied with the Clontech cDNA panels. All PCR 
products were excised, purified (QiaexII Gel Purification Kit, Qiagen) and sequenced. 
Expression constructs and cloning. 
All expression constructs used are listed in Table 2.11. DysferlinMycHis (DYSF-pcDNA3.1, 
National Center for Biotechnology Information [NCBI] reference sequence NP_003485.1) was 
a generous gift from Kate Bushby (Institute of Human Genetics, International Centre for Life, 
Newcastle upon Tyne, UK). Exon 40a was amplified from human skeletal muscle and inserted 
into dysferlin by Natalie Woolger, using ClaI (New England Biosciences). Myoferlin 
(NM_013451.3), OtoferlinNeuronal (NM_194248.2), Fer1L5 (NM_001293083.1) and Fer1L6 
(NM_001039112.2) were purchased in the pCMV6 MycDDDK vector from Origene.  
OtoferlinUbiquitous (NM_001287489.1) was amplified from human brain cDNA from prior to 
the endogenous SacII restriction site with primers replacing the exon 48 stop codon with an 
MluI restriction site (Table 2.10, otoferlin exon 48 cloning). Otoferlin exon 47 was replaced 
Table: 2.10: Primers used in this study. 
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Table 2.10: Primers used in this study. 
Gene Forward Reverse 
Dysferlin CAAGCTGGAAATGACCTTGG GCCTAGGAGGTCTGGAGGAG 
Otoferlin AGGCAGAGAAGAACCCAGTG AAGCCACTGAAAGGAAATGC 
Myoferlin CATGAACCCCAAGCTGGAC TGCAAACGTTGCTTGTTGG 
Fer1L4 AAAGCAGAGGAGGAGGAAGG GGGTGAGTGTCCAAGGTCAG 
Fer1L5 CTGGAGATTCTGTCAGAGAAGG GTTGGTAGCAGGAGGAAAGC 
Fer1L6 CTGTTGGAAAAGCCCGAAAG CCAAGAAGGGTTGATCTGTCC 
Otoferlin exon 
48 cloning 
CACGTGGAGACGAGGCCGCTGC CCCAGTTTTTCGAGGAA 
CCCCGTTGCGCAT 
 
in our OtoferlinNeuronal expression construct using a SacII and MluI digest (New England 
Bioscience),  followed  by  ligation  of  the  exon  48  fragment  with  T4  DNA  ligase  (Life 
Technologies). All ferlin constructs were sub-cloned into pIRES2 EGFP for plasma membrane 
detection studies. 
Plasmid mini-preps were prepared for cloning and sequencing using a Virogene MiniPrep kit. 
Plasmid maxi-preps for transfection were prepared using a Qiagen HI SPEED Maxi Kit. 
2.11: Expression constructs used in this study. 
Protein Vector Epitope Tags Fluorescent 
Protein 
Antibiotic 
Resistance 
Dysferlin pcDNA4 Myc, 6x His N/A Ampicillin 
OtoferlinNeuronal pCMV6 Myc, Flag N/A Kanamycin 
OtoferlinUbiquitous pCMV6 Myc, Flag N/A Kanamycin 
Myoferlin pCMV6 Myc, Flag N/A Kanamycin 
Fer1L5 pCMV6 Myc, Flag N/A Kanamycin 
Fer1L6 pCMV6 Myc, Flag N/A Kanamycin 
Dysferlin pIRES2 Myc, 6x His EGFP Kanamycin 
Dysferlin-40a pIRES2 Myc, 6x His EGFP Kanamycin 
OtoferlinNeuronal pIRES2 Myc, Flag EGFP Kanamycin 
OtoferlinUbiquitous pIRES2 Myc, Flag EGFP Kanamycin 
Myoferlin pIRES2 Myc, Flag EGFP Kanamycin 
Fer1L5 pIRES2 Myc, Flag EGFP Kanamycin 
Fer1L6 pIRES2 Myc, Flag EGFP Kanamycin 
Rab5-GFP pEGFP-C1 - EGFP Kanamycin 
Rab11a-GFP pEGFP-C1 - EGFP Kanamycin 
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Chapter 3: Subcellular localisation and endocytic trafficking of the ferlin protein 
family. 
Chapter 3 of my thesis is presented as a manuscript that has been accepted for publication in 
the journal Traffic. Author statements detailing my contribution to this manuscript are 
present in Appendix 2. The aims of this chapter were to: 
Determine in which tissues each ferlin is expressed at the transcript level. 
Determine which ferlins target to the plasma membrane in cells. 
Characterise where each ferlin targets within the cell at steady state (intracellular). 
Characterise the endocytic trafficking of each ferlin. 
Videos presented in the manuscript as Supplementary Videos 1 and 2 are included in Appendix 
4 of my thesis. 
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3.1 Paper: Ferlins show tissue-specific expression and segregate as plasma membrane/late 
endosomal or trans-Golgi/recycling ferlins. 
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Figure S1: Ubiquitous otoferlin is present at low levels at the plasma membrane (A) and neuronal otoferlin 
localises to a trans-Golgi compartment (B). A- HEK293 cells transfected with myoferlinMycFlag, otoferlin-UbMycFlag 
or Fer1L5MycFlag pIRES expression constructs were dissociated from plates with Versene and incubated with 
increasing concentrations (as indicated) of anti-FlagAlexa647 at 8°C for 90 minutes. Live cells were gated by 
exclusion of propidium iodide. Dot-plots represent the total live cell population, with EGFP fluorescence (indicating 
cell transfection) plotted on the y-axis and surface-bound anti-FlagAlexa647 on the x-axis. B- HEK293 cells were 
transfected with our neuronal otoferlin expression construct (lacking EGFP) then re-plated onto coverslips 
overnight. Neuronal otoferlin was detected with anti-Myc (Alexa594 OR Alexa488 false coloured red) and co-
labeled with markers for the endoplasmic reticulum (calreticulin), cis-Golgi (GM130) trans-Golgi (TGOLN2) or 
lysosomes (LAMP1) (Alexa488 OR Alexa594 false coloured green). Nuclei were labeled with DAPI (blue). Images 
were captured on a Leica SP5 confocal (single z-sections presented). Scale bars: 10 μM. 
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Figure S2: Dysferlin (A) and myoferlin (B) consistently co-localise with Rab5-GFP, endogenous Rab7 and 
Rab7-GFP in HEK293 cells and sparingly with LAMP1 in HEK293, C2C12 and Cos-7 cells. HEK293, C2C12 
or Cos-7 cells were transfected with dysferlin and myoferlin expression constructs (lacking EGFP) then re-plated 
onto coverslips overnight. Cells were fixed, permeabilised and labeled with anti-Myc (Alexa594 OR Alexa488 false 
coloured red) and either anti-GFP, anti-Rab7 or LAMP1 as indicated. Scale bars represent 10 µM. 
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Figure S3: Fer1L6 consistently labels a GM130 negative, LAMP1 negative, TGOLN2 positive recycling 
endosomal compartment. HEK293 cells were transfected with a Fer1L6 expression construct (lacking EGFP) 
then re-plated onto coverslips overnight. Cells were fixed, permeabilised and labeled with anti-Myc (Alexa594 OR 
Alexa488 false coloured red) and GM130, TGOLN2 or LAMP1. Scale bars represent 10 µM. 
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3.2 Supporting Results and Discussion for “Ferlins show tissue-specific expression and 
segregate as plasma membrane/late endosomal or trans-Golgi/recycling ferlins”. 
In Chapter 3.1 of my thesis, I established that type-I and type-II ferlins segregate into plasma 
membrane and late endosomal pathways (dysferlin and myoferlin), trans-Golgi and recycling 
pathways (otoferlin and Fer1L6) or a reticular subcellular compartment of an unidentified 
origin (Fer1L5). 
As commercially available reliable antibodies are not available for otoferlin, Fer1L5 and 
Fer1L6, I utilised an over-expression system in HEK293 cells. The advantages of this system 
are that it can be assured that each ferlin will be expressed at detectable levels, and the addition 
of the MycDDDK tag to the C-terminus of the ferlin from the pCMV6 vector allows ferlin 
detection independently of the availability of an antibody to each specific ferlin. The 
disadvantages of this system is that over-expression may cause aberrant protein localisation, 
and HEK293 cells may not express the ferlin endogenously and therefore may not possess the 
protein complement required for correct ferlin trafficking. 
To address the above caveats I present a range of images for each ferlin taken from multiple 
experiments to demonstrate consistency of ferlin localisation in HEK293 cells. I also present 
the localisation of each ferlin using the over-expression system in C2C12 myoblasts. C2C12 
myoblasts provide a good complement to HEK293 cells as they have been published to express 
endogenous dysferlin (Hernández-Deviez et al., 2006), myoferlin and Fer1L5 (Posey et al., 
2011) and could therefore be expected to possess the protein machinery require for trafficking 
of these ferlins. Finally, as HEK293 cells and C2C12s are of very different cellular origins 
(kidney epithelia compared to myoblast), consistent subcellular localisation between these cell 
types would provide evidence for the validity of ferlin localisation in our over-expression 
system. 
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lines this will give confidence that the subcellular localisation observed for the ferlins in
Figure 3.1: Dysferlin localises to endosomal pathways. DysferlinMycHis was transfected into 
HEK293 cells and detected following fixation and permeabilisation with anti-Myc. 
Organelles were detected with the indicated antibodies (or by co-transfection with Rab5-
GFP), and the nucleus with DAPI. For each marker (excepting LAMP1) images are taken 
from at least two experiments undertaken on different days. Scale bar= 10 µM. 
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HEK293 cells is the actual localisation each ferlin displays observed for the ferlins in HEK293
Figure 3.2: Myoferlin localises to endosomal pathways. MyoferlinMycFlag was transfected 
into HEK293 cells and detected following fixation and permeabilisation with anti-Myc. 
Organelles were detected with the indicated antibodies (or by co-transfection with Rab5-
GFP), and the nucleus with DAPI. For each marker (excepting LAMP1) images are taken 
from at least two experiments undertaken on different days. Scale bar= 10 µM. 
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Dysferlin (Figure 3.1) and myoferlin (Figure 3.2) display consistent localisation across 
multiple experiments. Both ferlins display robust plasma membrane and cytoplasmic organelle 
labelling. Occasional co-localisation with the cis-Golgi marker GM130 is consistent with 
dysferlin (Figure 3.1, GM130) and myoferlin (Figure 3.2, GM130) transiting the secretory 
pathway. Dysferlin and myoferlin show pronounced, consistent co-localisation with Rab5 and 
Rab7, indicating that the dysferlin and myoferlin-labelled cytoplasmic organelles are of 
endosomal origin (Figures 3.1 and 3.2, Rab5-GFP and Rab7). Sparse/rare co-localisation of 
both ferlins with LAMP1 is observed (Figure 3.1 and 3.2, LAMP1), showing that each ferlin 
primarily populates the endosomal pathway and not the lysosomes. 
Fer1L6 is consistently observed to intensely label a peri-nuclear structure in both HEK293 and 
C2C12 cells (Figure 3.3). This peri-nuclear accumulation resembles two characterised cellular 
organelles: the recycling endosomal compartment, a Rab11-labelled organelle responsible for 
recycling of plasma membrane proteins (Grant and Donaldson, 2009); and the aggresome, a 
highly regulated accumulation of ubquitinated, mis-folded protein targeted for degradation 
(Saliba et al., 2002).  
Figure 3.3: Fer1L6 localises to a distinct perinuclear compartment in HEK293 and 
C2C12 cells (previous page). Fer1L6MycFlag was transfected into HEK293 or C2C12 cells as 
indicated and detected following fixation and permeabilisation with anti-Myc. Organelles were 
detected with the indicated antibodies, and the nucleus with DAPI. Antibody endocytosis was 
also undertaken where indicated by addition of anti-Myc into the culture media for 30 minutes. 
Surface-bound anti-Myc was washed off with pH 2.2 glycine, following which cells were 
permeabilised, co-stained for GM130 and anti-Myc detected. For each marker (excepting 
LAMP1 in HEK293s) images are taken from at least two experiments undertaken on different 
days. Scale bar= 10 µM. 
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My results indicate that Fer1L6 is targeted to the recycling endosomal compartment as opposed 
to the aggresome. Fer1L6 shows robust plasma membrane labelling (Chapter 3.1, Figure 2) 
and endocytoses back to the perinuclear compartment in HEK293 and C2C12 cells (Chapter 
3.1, Figure 8 and Chapter 3.2, Figure 3.3 uptake). The robust plasma membrane labelling and 
endocytosis of Fer1L6 indicates that Fer1L6 is present in the secretory pathway, not being 
retained in an intracellular compartment. Furthermore, recent work by Reece Sophocleous, our 
Research Assistant, shows that Fer1L6 co-endocytoses with transferrin (Chapter 3.1, Figure 
9C, Redpath et al., 2014, Traffic accepted for publication), a well-established marker of 
recycling endocytic pathways (Kobayashi and Fukuda, 2013). Together, these data strongly 
suggests Fer1L6 is specifically targeted to the recycling endosomal compartment. 
Otoferlin consistently targets the trans-Golgi network, as shown by co-localisation with the 
trans-Golgi marker TGOLN2 by confocal imaging (Figure 3.4, TGOLN2). Otoferlin shows 
occasional co-localisation with the cis-Golgi (Figure 3.3, GM130), and little-or-no co-
localisation with the endoplasmic reticulum or lysosomes (Figure 3.3 calreticulin and LAMP1, 
respectively). 
I was not able to refine the sub-cellular localisation of Fer1L5. Fer1L5 appears reticular, 
however does not precisely co-localise with the endoplasmic reticulum marker calreticulin 
(Figure 3.5, upper panel), and does not enter the Golgi-apparatus (Figure 3.5, GM130, lower 
panel). To refine Fer1L5 localisation by 3D-SIM, cells expressing lower levels of Fer1L5 were 
specifically chosen for analysis (Figure 3.5, white arrows). 3D-SIM clearly shows Fer1L5 does 
not co-localise with calreticulin or GM130 (Figure 3.5, 3D-SIM), confirming confocal imaging 
results. The subcellular localisation of Fer1L5 remains to be identified. 
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Figure 3.4: Otoferlin localises to the trans-Golgi network. OtoferlinMycFlag was transfected 
into HEK293 cells and detected following fixation and permeabilisation with anti-Myc. 
Organelles were detected with the indicated antibodies, and the nucleus with DAPI. For each 
marker (excepting LAMP1) images are taken from at least two experiments undertaken on 
different days. Scale bar= 10 µM. 
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Figure 3.5: Fer1L5 does not co-localise with endoplasmic reticulum or Golgi markers. 
Fer1L5MycFlag was transfected into HEK293 cells and detected following fixation and 
permeabilisation with anti-Myc. Organelles were detected with the indicated antibodies, and 
the nucleus with DAPI. In confocal images, the white arrow indicates the level of expression 
of cells chosen for subsequent 3D-SIM imaging. Scale bar= 10 µM. 
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To confirm ferlin localisation in a second cell type, I used C2C12 myoblasts. Using the closest 
sub-cellular marker that cross-reacts with mouse antigens (C2C12 cells are of mouse origin), I 
confirmed that each ferlin targets similar sub-cellular compartments in a second cell type. 
Dysferlin and myoferlin are present at the plasma membrane and in cytoplasmic organelles that 
occasionally co-localise with LAMP1 (Figure 3.6, DYSF and MYOF). Fer1L6 is present in the 
distinct peri-nuclear compartment which near, but does not co-localise with GM130 (Figure 
3.6, Fer1L6). Otoferlin is present intertwined with, but not co-localised with, the cis-Golgi 
(Figure 3.6, OTOF) and Fer1L5 is present in a reticular-looking compartment that localises 
poorly with calreticulin (Figure 3.6, Fer1L5). Ferlin localisation is therefore similar between 
cell types, indicating that my results from HEK293 over-expression reliably reveal the true 
sub-cellular localisation of each human ferlin. 
Figure 3.6: Ferlin subcellular localisation is consistent in C2C12 myoblasts. Ferlin 
expression constructs were transfected into C2C12 myoblasts and detected following fixation 
and permeabilisation with anti-Myc. Organelles were detected with the indicated antibodies, 
and the nucleus with DAPI. Scale bar= 10 µM. 
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Little characterization has been undertaken as to the function of the DysF domain to date. The 
only functional study on DysF domains has determined that the DysF domain of the yeast 
peroxisomal proteins Pex30p and Pex31p regulates peroxisome size and number (Yan 2009). 
I investigated the potential peroxisome localisation of the DysF-domain containing human 
ferlins (dysferlin, myoferlin and Fer1L5), in addition to otoferlin as a DysF-negative control. 
No human ferlins exhibit observable co-localisation with the peroxisomal marker Pex-14 
(Figure 3.7). Co-localisation appears to occur between Fer1L5 and Pex14 in highly over-
expressing cells, however examination of cells expressing lower levels of Fer1L5 reveals a 
complete absence of Pex14 co-localisation (Figure 3.7, Fer1L5). The Pex14 co-localisation 
observed with Fer1L5 over-expression is due to the high Fer1L5 signal as opposed to Fer1L5 
residing on peroxisomes. If Fer1L5 truly localised to peroxisomes, Fer1L5:Pex14 co-
localisation would be observed in lesser-expressing cells. 
Figure 3.7: Ferlins do not co-localise with the peroxisomal marker Pex-14. Ferlin 
expression constructs were transfected into HEK293 cells and detected following fixation and 
permeabilisation with anti-Myc. Peroxisomes were detected with anti-Pex14, and the nucleus 
with DAPI. Scale bar= 10 µM. 
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Chapter 4: Calpain cleavage of dysferlin is a fundamental response to membrane repair 
4.1 Background 
Chapters 4 and 5 of my thesis detail and expand upon my contribution to my paper: “Calpain 
cleavage within dysferlin exon 40a releases a synaptotagmin-like module for membrane 
repair” (Redpath et al., 2014), which follows. Author statements detailing my contribution to 
this paper are presented in Appendix 3. This project directly follows on from that of the 
previous Ph.D. student, Angela Lek. Angela’s work identified that mini-dysferlinC72 was 
produced in primary human myotubes following membrane injury in a calcium-dependent 
manner by the calpain proteases (Chapter 1.2.1). 
The aims of this chapter were to: 
 Determine if dysferlin cleavage occurs in non-myogenic cell lineages following 
membrane injury. 
 Characterise the calcium-dependence of dysferlin cleavage in non-myogenic cell 
lineages. 
 Determine if dysferlin cleavage in non-myogenic cell lineages mediated by the 
calpains.  
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Paper: Calpain cleavage within dysferlin exon 40a releases a synaptotagmin-like module 
for membrane repair  
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4.2 Mini-dysferlinC72 formation in non-muscle cell types 
Dysferlinopathy primarily affects skeletal muscle, despite ubiquitous expression in the human 
body (see Chapter 1.4). While this is not unique in human disease, it is nonetheless puzzling: 
why does deficiency of a ubiquitously expressed protein lead to pathology primarily in one 
tissue? Following Angela Lek’s discovery of dysferlin cleavage following plasma membrane 
injury, we formulated the hypothesis that calpain cleavage of dysferlin to mini-dysferlinC72 is 
a muscle specific adaptation, conferring dysferlin-dependent membrane repair only in muscle. 
This could explain the predominant muscle pathology of dysferlinopathy. 
To test our hypothesis, I initially investigated two immortalised human cell lines: MO3.13 (a 
secondary oligodendrocyte cell line) and HEK293 (a secondary human embryonic kidney cell 
line). HEK293s express very little dysferlin (Figure 4.1), and as such no dysferlin cleavage was 
detected (Figure 4.1, left panel). Mini-dysferlinC72 is formed in MO3.13s scrape-damaged in 
the presence of extracellular calcium, confirming the calcium-dependence of dysferlin 
cleavage in a non-myogenic cell lineage (Figure 4.1, middle panel, mini-dysferlinC72: filled 
arrow). In undamaged MO3.13s, or MO3.13s damaged by scraping in the absence of 
extracellular calcium, no mini-dysferlinC72 is observed (Figure 4.5, middle panel, Un and –
Ca2+).  
MO3.13s were immortalized by fusion of primary human oligodendrocytes with a 
rhabdomyosarcoma, a cancer of skeletal muscle origin (McLaurin et al., 1995), meaning I could 
not exclude the possibility that MO3.13s are muscle-like. I could not conclude that mini-
dysferlinC72 formation is not muscle specific based upon my results in MO3.13s. 
I investigated multiple primary human and mouse cell lines to determine if mini-dysferlinC72 
formation occurs in non-muscle cell lines. Human umbilical vein endothelial cells (HUVEC) 
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were purchased from Life Technologies, and primary astrocytes and cardiomyocytes were 
isolated from P2 mice A/JARC wild-type and A/J dysferlin-null mice. These cells were 
subjected to scrape damage in the presence or absence of extracellular calcium, or harvested 
undamaged by directly adding RIPA lysis buffer containing EDTA. With each cell type (Figure 
4.2: HUVEC- left panel, astrocyte- mid panel, cardiomyocyte- right panel), mini-dysferlinC72 
formation is observed only in cells damaged in the presence of calcium (mini-dysferlinC72: 
filled arrow, primary human myotubes are included as a positive reference). Dysferlin cleavage 
to mini-dysferlinC72 is not specific to muscle. Furthermore the lack of mini-dysferlinC72 
Figure 4.1: Calcium-dependent formation of mini-dysferlinC72 is observed in secondary 
human oligodendrocytes following cell damage. Cells were cultured to confluence and 
damaged by scraping (+Ca2+) with or without calcium (-Ca2+), or harvested without damage 
by addition of lysis buffer (Un). Scraped cell pellets were lysed and dysferlin was detected by 
western blot using the Hamlet-1 antibody. Reprobing membranes with β-tubulin indicates 
equal protein loading. Mini-dysferlinC72 is observed following damage in the presence of 
calcium in MO3.13 cells. Primary human myotubes damaged in the same experiment are 
included as a control. 
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formation in dysferlin-null cardiomyocytes highlights that mini-dysferlinC72 is a product 
specific to the dysferlin protein (right panel). 
To confirm cell line identity, I probed cell lysates with smooth muscle actin, sarcomeric actin, 
GFAP and CD11c. Confirming that dysferlin is cleaved to mini-dysferlinC72 in non-muscle cell 
lines, HUVECs and astrocyte primary cell lines express no sarcomeric actin, a marker of cells 
of a myogenic lineage (Figure 4.3B). HUVECs also expressed smooth muscle actin (Figure 
4.3A), while astrocytes expressed GFAP (Figure 4.3C), common markers of the respective cell 
types (Brenner et al., 1994; Galustian et al., 1995). Primary mouse microglia (used in following 
experiments) expressed CD11c, consistent with their cell lineage (Remington et al., 2007) 
Figure 4.2: MinidysferlinC72 is produced in response to membrane injury in multiple 
primary cell lines. Human umbilical vein endothelial cells and primary human myotubes, 
primary mouse astrocytes, and primary mouse cardiomyocytes were damaged by scraping in 
PBS with (+Ca2+) or without calcium (-Ca2+), or harvested without damage by addition of lysis 
buffer to the plate (Un). Cell pellets were investigated by western blot. Dysferlin was detected 
using the Hamlet-1 antibody. Reprobing membranes with GAPDH or MG53 indicates equal 
protein loading. Mini-dysferlinC72 (indicated by black arrow) is observed following damage in 
the presence of calcium in all cell types.  
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(Figure 4.3D). All  the primary cell lines isolated by Angela Lek (primary human myoblasts), 
Frances Lemckert (primary mouse cardiomyocytes) and myself (astrocytes and microglia) 
Figure 4.3: Primary human and mouse cell lines express protein markers consistent with 
the cell lineage. Primary human myotubes (PHM), primary mouse astrocytes (Astro), human 
umbilical vein endothelial cells (HUVEC) secondary human oligodendrocytes (MO313) and 
primary mouse cardiomyocytes (CM) were probed for smooth muscle actin (A), sarcomeric 
actin (B) and glial fibrillary acidic protein (GFAP)(C) Microglia were identified by morphology 
and expression of CD11c (D). MO3.13, primary myotubes, HUVECs and astrocytes were also 
identified by morphology (E, F). A multinuclear myotube is indicated with a white arrow in 
(E), identifying differentiated myotubes. Microglia were harvested from an astrocyte feeder 
layer, indicated by a white arrow in (F). 
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appeared morphologically consistent with images in previous publications (Lek et al., 2013; 
Souza et al., 2013) (Mecha et al., 2011) (Figure 4.3E, F).  
As astrocytes, HUVECs and microglia were determined to be free from possible contamination 
of myogenic cells, I could conclude that dysferlin cleavage to mini-dysferlinC72 occurs in non-
muscle cell types. This was a very interesting result: dysferlin is cleaved to mini-dysferlinC72 
following membrane injury in all cell types following membrane injury. I next focused on 
determining if the calpains were responsible for dysferlin cleavage in our range of cell lines. 
Summary: Dysferlin is cleaved to mini-dysferlinC72 in non-muscle cell lines. 
 Dysferlin is cleaved following membrane injury in both muscle and non-muscle cell 
lines. 
 Dysferlin cleavage is damage- and calcium-dependent in all cell lines. 
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4.3 Calpain-cleavage of dysferlin in non-muscle cell lines. 
Angela Lek determined that the calpain proteases were responsible for dysferlin cleavage 
following membrane injury in primary human myotubes ((Lek et al., 2013); Figure 1.14) and I 
have determined that dysferlin cleavage is calcium-dependent in a wide range of cell types. I 
hypothesised that calpains would mediate dysferlin cleavage in our cell lines. If calpains cleave 
dysferlin following membrane injury in all cell types, this would indicate that calpain activation 
and dysferlin cleavage is a fundamental cellular response following membrane injury. If the 
null-hypothesis is true and calpains do not cleave dysferlin in all cell types, this result would 
indicate that dysferlin cleavage is regulated by specific proteases in specific cell types. 
I utilised the cell-permeable calpain inhibitor, calpeptin, to pharmacologically determine the 
requirement for active calpains for dysferlin cleavage following membrane injury. To ensure 
the calpains were effectively inhibited, cultured cells were treated with calpeptin 3 hours prior 
to injury and fresh calpeptin added in replacement media 30 minutes prior to injury. In all 
washing and scraping buffers, the indicated concentration of calpeptin was included. 
Dysferlin cleavage to mini-dysferlinC72 was inhibited in a dose-dependent manner with 
calpeptin treatment in primary human myotubes (Figure 4.4A) and primary mouse astrocytes 
(Figure 4.4B), despite the presence of extracellular calcium. Treatment with 30µM calpeptin 
in HUVECs (Figure 4.4C), microglia (Figure 4.4D) and MO3.13s (Figure 4.4E) was sufficient 
to inhibit dysferlin cleavage to mini-dysferlinC72 following scrape injury in the presence of 
extracellular calcium. Calpains are most likely responsible for dysferlin cleavage to mini-
dysferlinC72 in all cell types. Calpain activation and subsequent cleavage of dysferlin to mini-
dysferlinC72 is therefore a fundamental cellular response to plasma membrane injury. 
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Summary: Calpains cleave dysferlin in response to membrane injury. 
 Calpain inhibition with calpeptin prevents dysferlin cleavage following membrane 
injury, even in the presence of calcium. 
 Calpain cleavage of dysferlin represents a fundamental cellular response to plasma 
membrane injury. 
  
Figure 4.4: Calpeptin inhibits dysferlin cleavage following scrape injury. A-E: Cell lines 
were treated with the indicated concentration of calpeptin and damaged by scraping in the 
presence of calcium (+Ca2+) (excluding minus calcium controls (-Ca2+)). 10μg of protein from 
each cell line was separated by SDS-PAGE and transferred onto PVDF membrane. Dysferlin 
was detected using the Hamlet-1 antibody and reprobed with GAPDH to indicate equal 
protein loading. Mini-dysferlinC72 (indicated by black arrow) formation is blocked by 
treatment of cells with calpeptin, even in the presence of calcium.  
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4.4 Skeletal muscle, cardiac and astrocyte cell lines display similar activating 
concentrations of calcium for dysferlin cleavage. 
Angela Lek established in primary human myotubes that 200 µM extracellular calcium was 
required for mini-dysferlinC72 formation, the same extracellular calcium concentration required 
for sea urchin embryo survival following membrane injury (Steinhardt et al., 1994). 200 µM 
calcium is sufficient to maximally activate calpain-1, and at least partially activate calpain-2, 
which together are indispensable for membrane repair (Goll et al., 1992; Mellgren et al., 2007).  
Does mini-dysferlinC72 formation require 200 µM calcium in a range of cell types, or do 
different cell lineages display different calcium sensitivities for dysferlin cleavage following 
injury? I hypothesised that 200 µM extracellular calcium would represent a ‘universal’ calcium 
requirement for activation of the membrane repair cascade involving the cleavage of dysferlin.  
To determine how much calcium is required in the extracellular buffer for dysferlin cleavage 
following injury, cells were washed with EDTA-containing PBS to ensure that all wells were 
starting from the same baseline conditions. Cells were then washed in the indicated calcium-
containing buffer, ensuring replacement of the extracellular calcium and then damaged by 
scrape injury.  
In all cell types (primary human myotubes: Figure 4.5A, primary mouse astrocytes: Figure 
4.5B and primary mouse cardiomyocytes Figure 4.5C), mini-dysferlinC72 formation increased 
progressively with addition of increasing extracellular calcium in the scraping buffer (Figure 
4.5, mini-dysferlinC72 denoted with filled arrow). Little or no mini-dysferlin formation is 
observed without extracellular calcium present following injury (0 Ca2+), with mini-
dysferlinC72 formation rising steadily following damage in 50 μM to 900 μM extracellular 
calcium (Figure 4.5). Robust mini-dysferlinC72 formation is observed from 100 µM   
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extracellular calcium in myotubes and cardiomyocytes (Figure 4.5A, C), and from 200 µM 
extracellular calcium in astrocytes (Figure 4.5B), consistent with 200 µM calcium being a 
universal activating calcium concentration for plasma membrane repair. 
Summary: Dysferlin is cleaved in a dose-dependent manner following injury with increasing 
concentrations of extracellular calcium. 
 Dysferlin cleavage requires extracellular calcium. 
 The 100-200 µM calcium required for dysferlin cleavage in myotubes, astrocytes and 
cardiomyocytes is consistent with the 200 µM calcium required for membrane repair. 
  
Figure 4.5: MinidysferlinC72 formation increases progressively following membrane 
injury with increasing concentration of extracellular calcium. Primary human myotubes 
(A), primary mouse astrocytes (B) and primary mouse cardiomyocytes (C) were damaged by 
scraping in the presence of increasing concentrations of extracellular calcium, and lysed cell 
pellets separated by SDS-PAGE and investigated by western blot. Dysferlin was detected using 
the Hamlet-1 antibody. Reprobing membranes with GAPDH shows equal protein loading. 
Mini-dysferlinC72 (closed arrow) increases with increasing extracellular calcium in all cell types 
investigated. 
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4.5: MG53 is not required for dysferlin cleavage following membrane injury. 
MG53 is an established interaction partner of dysferlin, and has been reported to be required 
for the assembly of the membrane repair complex including dysferlin at sites of membrane 
injury (Cai et al., 2009a). Additionally, Angela Lek identified that MG53 is recruited to sites 
of injury temporally preceding dysferlin (Lek et al., 2013). I therefore queried if MG53 
expression is required for dysferlin cleavage to mini-dysferlinC72 following scrape injury. 
MG53 expression is reportedly limited to skeletal and cardiac muscle and lung (Cai et al., 
2009b; Hernández-Deviez et al., 2006), therefore cell lines such as astrocytes and HUVECs 
should not express MG53.  
I scrape-damaged five of the cell lines available in the presence of calcium and investigated 
mini-dysferlinC72 formation and MG53 expression. While primary mouse cardiomyocytes, 
MO3.13s and primary human myotubes express MG53, HUVECs and primary mouse 
astrocytes do not (Figure 4.6, MG53). Mini-dysferlinC72 is formed in both HUVECs and 
primary mouse astrocytes following injury, indicating that dysferlin cleavage is independent of 
MG53 expression in these cell lines (Figure 4.6, mini-dysferlinC72 black arrow). The N-terminal 
counter-fragment is also observed in all of the cell types I investigated, consistent with a single 
calpain cleavage site releasing the N- and C-terminal fragments of dysferlin following 
membrane injury (Figure 4.6, Romeo, grey arrow). 
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Summary: MG53 is not required for dysferlin cleavage. 
 Astrocytes and HUVECs do not express MG53. 
 Mini-dysferlinC72 is formed in astrocytes and HUVECs following scrape damage, 
confirming that MG53 is not required for dysferlin cleavage. 
  
Figure 4.6 Dysferlin undergoes injury-activated cleavage in cell types that do not express 
MG53, indicating mini-dysferlinC72 formation is MG53-independent. Lysates from cells 
injured in the presence of calcium were separated on duplicate SDS-PAGE gels.  One PVDF 
membrane was probed with Hamlet-1 that detects the dysferlin C-terminus and mini-
dysferlinC72 (black arrow). The duplicate PVDF membrane was probed with Romeo, detecting 
the dysferlin N-terminus and corresponding cleaved N-terminal fragment (grey arrow). 
Membranes were reprobed with anti-MG53 or anti-GAPDH. Mouse astrocytes and human 
umbilical vein endothelial cells do not express MG53, thus, formation of mini-dysferlinC72 
occurs independently of MG53. This figure is sourced from Redpath et al., 2014. 
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Chapter 5: The role of calpain in dysferlin cleavage 
5.1 Chapter Background 
In the previous chapter, I established that dysferlin is cleaved to mini-dysferlinC72 in cell lines 
from multiple lineages. Furthermore, in every cell line tested, dysferlin cleavage was inhibited 
by the calpain inhibitor, calpeptin, and dysferlin cleavage was activated by ~200 μM calcium. 
These results indicated that calpains are responsible for dysferlin cleavage to mini-dysferlinC72 
following plasma membrane injury. I next sought to define the calpain-cleavage site within 
dysferlin. 
The aims of this chapter were to: 
 Define the calpain cleavage site in dysferlin that gives rise to mini-dysferlinC72. 
 Determine which calpain is responsible for dysferlin cleavage following membrane 
injury. 
 Determine if calpains recruit to sites of membrane injury in a timeframe consistent with 
dysferlin cleavage and recruitment. 
 Provide direct evidence of mini-dysferlinC72 recruitment to sites of membrane injury. 
 Determine if calpain cleavage is a conserved modification of all ferlin family members, 
or a specific modification of dysferlin. 
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5.2 Identifying the calpain cleavage site within dysferlin. 
As I had determined that dysferlin cleavage to mini-dysferlinC72 was most likely undertaken by 
the calpain family of proteases, our group sought to define the exact calpain cleavage site in 
dysferlin that gives rise to mini-dysferlinC72. The experiments in Chapter 5.2 were undertaken 
by another Ph.D student, Natalie Woolger, as part of her project and are included here for 
clarity for the following sections of my own work. 
The first step in identifying where calpains cleave dysferlin was an in silico calpain cleavage 
prediction. Unlike many other proteases, calpains do not recognize a specific amino acid 
sequence. Calpains recognise specific secondary and tertiary structures of a substrate protein, 
making prediction of calpain cleavage less straightforward than for proteases with specific 
amino acid recognition motifs (Tompa et al., 2004). We utilised the GPS-CCD 1.0 (Liu et al., 
2011) calpain-cleavage predictor for this study. 
My supervisor, Sandra Cooper, performed the initial in silico search for potential calpain 
cleavage sites that could match the calculated size of mini-dysferlinC72. Initially searching in 
dysferlin isoform 1 yielded no cleavage sites consistent with mini-dysferlinC72 formation. One 
predicted site at amino acid 1375 would yield a C-terminal fragment of 81.75 kDa, while the 
next closest predicted site would give a C-terminal fragment of 59.3 kDa, inconsistent with the 
size of mini-dysferlinC72 (Table 5.1). However, an alternatively spliced exon, exon 40a, can be 
present between these two sites. Within exon 40a, calpains are predicted to cut dysferlin at six 
of seven amino acids, with two sites (amino acid 1483 and 1484) displaying a cleavage 
prediction score over 1, a high prediction score (Table 5.1, red box). Calpain cleavage within 
exon 40a would result in a C-terminal product of 71.8 kDa. 
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When all of the dysferlin alternate splicing events are included in the calpain cleavage When 
Table 5.1: Prediction of calpain cleavage sites in dysferlin. GPS-CCD 1.0 (Liu et al., 
2011) was used to predict the potential calpain cleavage sites within dysferlin isoform 1 
(UniPROT ID: O75923-1) and the alternatively spliced exons. For cleavage prediction, the 
highest possible score cutoff threshold was used (0.654). The left-hand table represents the 
predicted calpain cleavage sites in dysferlin isoform 1, while the right hand table represents 
how alternate splicing modifies the predicted calpain cleavage sites. 
    Dysferlin Isoform 1                     Alternately Spliced Isoforms 
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When all of the dysferlin alternative splicing events are included in the calpain cleavage 
prediction, each alternatively spliced exon (v1, 5a, 17 and 40a) confers additional predicted 
calpain cleavage sites upon dysferlin (Table 5.1). Exon 40a is the only alternatively spliced 
exon with cleavage sites predicted with a score over 1, and contains the highest score of any 
site in dysferlin (Table 5.1, red box AA 1484). 
As part of her Ph.D. project, Natalie Woolger, another student in our group, amplified dysferlin 
exon 40a from human skeletal muscle and sub-cloned it into our dysferlin isoform 1 expression 
construct (lacking exon 5a, including exon 17, lacking exon 40a). Natalie transfected HEK293 
cells with our dysferlin isoform 1 expression construct and our dysferlin with exon 40a 
Figure 5.1: Exon 40a contains the mini-dysferlinC72 calpain cleavage site in dysferlin. A-
HEK293 cells transfected with dysferlin without exon 40a (DYSF), dysferlin containing exon 
40a (+40a) or untransfected cells were damaged by scraping in the presence (+) or absence (-) 
of calcium. Dysferlin was detected by western blot with Hamlet-1, and β-tubulin and GAPDH 
indicate even loading. B- WT MEFs (WT), CAPNS1 knockout MEFs (-/-) and CAPNS1 -/- 
rescue MEFs (-/-R) were transfected with dysferlin without exon 40a (DYSF -40a), dysferlin 
with exon 40a (DYSF +40a) or untransfected. Cells were damaged by scraping and dysferlin 
detected with Hamlet-1 by western blot. CAPN2 shows calpain-2 expression and GAPDH 
indicates even loading. Asterisks indicate mini-dysferlinC72. Experiments performed by Natalie 
Woolger. Figure sourced from Redpath et al., 2014. 
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(hereafter referred to as dysferlin exon 40a) expression construct. Scrape damage of transfected 
HEK293 cells revealed that dysferlin isoform 1 was not cleaved to mini-dysferlinC72 following 
scrape injury (Figure 5.1A, DYSF). Dysferlin exon 40a is cleaved to mini-dysferlinC72 in a 
calcium-dependent manner (Figure 5.1B, +40a), confirming that exon 40a contains the calpain 
cleavage site in dysferlin responsible for mini-dysferlinC72 formation. 
Summary:  Exon 40a contains the calpain cleavage site responsible for mini-dysferlinC72 
formation. 
 Cleavage within the alternatively spliced exon 40a is consistent with mini-dysferlinC72 
formation. 
 The alternatively spliced exon 40a contains the highest-confidence predicted calpain 
cleavage site in dysferlin. 
 Dysferlin without exon 40a is not cleaved following scrape injury. 
 Dysferlin with exon 40a is cleaved following scrape injury, establishing exon 40a as 
the calpain cleavage site within dysferlin. 
Identifying the calpains responsible for dysferlin cleavage. 
As calpain-1 and -2 have previously been demonstrated to be indispensable for membrane 
repair (Mellgren et al., 2007), we hypothesised calpain-1 and -2 would cleave dysferlin 
following membrane injury. We sourced calpain small-subunit 1 (Capns1) knockout mouse 
embryonic fibroblasts (MEFs) from Professor Peter Greer at Queens University, Canada (Tan 
et al., 2006). Calpain-1 and calpain-2 exist as heterodimers with Capns1 and removal of Capsn1 
disrupts the stability of calpain-1 and -2, leading to no detectable calpain-1 and -2 activity 
within the MEFs (Tan et al., 2006) (Chapter 1.6). Capns1 knockout (Capns1 -/-) fibroblasts 
provide an effective calpain-1 and -2 knockout with which to study dysferlin cleavage. We 
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were also provided with Capns1 -/- MEFs that had Capns1 rescued by lentiviral transduction 
(Capns1 -/-R). Natalie Woolger demonstrated that Capns1 -/-R fibroblasts have increased levels 
of calpain-2 (Figure 5.1B, CAPN2) 
Natalie Woolger transfected wild type (WT), Capns1 -/- and Capns1 -/-R MEFs with our 
dysferlin constructs with and without exon 40a. Damage of the untransfected MEFs and the 
MEFs transfected with dysferlin without exon 40a resulted in no mini-dysferlinC72 formation. 
Only damage of wild-type MEFs transfected with dysferlin exon 40a resulted in mini-
dysferlinC72 formation (Figure 5.1B, WT, mini-dysferlinC72 denoted with asterisk). No mini-
dysferlinC72 formation was observed in Capns1 -/- MEFs transfected with dysferlin exon 40a, 
confirming that calpain-1 and -2 are responsible for cleavage of dysferlin to mini-dysferlinC72 
(Figure 5.1B, -/-). In the Capns1 -/-R rescued MEFs, we observed increased calpain-2 
expression and increased mini-dysferlinC72 formation, indicating that dysferlin cleavage is 
dependent on calpain expression levels (Figure 5.1B, -/-R, mini-dysferlinC72 denoted with 
asterisk). 
Summary: Calpains-1 and -2 cleave dysferlin in exon 40a. 
 Knockout of Capns1, resulting in no active calpain-1 and -2, abolishes dysferlin 
cleavage at exon 40a in scraped cells. 
 Lentiviral rescue of Capns1, resulting in increased calpain-2 expression, increases 
dysferlin cleavage at exon 40a. 
 Calpains-1 and -2 are the calpains responsible for cleaving dysferlin following 
membrane injury. 
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5.3 In vitro characterisation of the dose- time- and calcium-dependence of calpain 
cleavage of dysferlin 
Following the identification of the exon 40a calpain cleavage site and confirmation that the 
ubiquitous calpains cleave dysferlin in response to membrane injury, I sought to characterise 
in detail the calpain cleavage of dysferlin. 
Initially, I established an in vitro calpain cleavage assay based upon the assay performed by 
Mandic et al., (2002). In this assay, HEK293 cells were transfected with C-terminal epitope 
tagged dysferlin expression constructs +/- exon 40a. Dysferlin was immunoprecipitated on 
Protein-G-sepharose beads with Romeo-1 in strict calcium-free conditions including calpeptin 
to minimise calpain activity. The dysferlin-bound sepharose was split into equal aliquots, 
washed and re-suspended in calcium-containing buffer for the subsequent calpain cleavage. 
Purified calpain (purchased from Millipore) was then added to the dysferlin-bound sepharose 
beads to cleave dysferlin. 
The dose-dependent calpain cleavage of dysferlin. 
In my first in vitro cleavage experiments, I performed a titration to determine how much calpain 
was required to cleave dysferlin. Purified calpain-1 and calpain-2 was added in increasing 
amounts (based upon determined activity, termed active units or units) to immunoprecipitated 
dysferlin with or without exon 40a. 
 
Neither calpain-1 nor -2 were capable of cleaving dysferlin without exon 40a to mini-
dysferlinC72, confirming previous experiments presented in Chapter 5.2 (Figure 5.2A and C). 
Calpain-1 and -2 cleaved dysferlin containing exon 40a to mini-dysferlinC72 in a dose-
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dependent manner (Figure 5.2B and D, mini-dysferlinC72 indicated with black arrow). Calpain-
2 cleaved dysferlin exon 40a with two times higher efficiency than calpain-1, with no full-
Figure 5.2: Calpain-1 and calpain-2 cleave dysferlin containing exon 40a in vitro. HEK293 
cells were transfected with dysferlin without exon 40a (DYSF (-) 40a) or dysferlin with exon 
40a (DYSF (+) 40a). Transfected cells were lysed and dysferlin immunoprecipitated with 
Romeo-1 and protein-G-sepharose. Sepharose beads were washed and transferred into calpain 
cleavage buffer. Calpain was added and incubated at 30°C for 3 minutes, after which cleavage 
was quenched with SDS and DTT and heating to 94°C for 3 minutes. Dysferlin was detected 
by western blot with Hamlet-1. A- and B- Immunoprecipitated dysferlin cleavage with calpain-
1 at the indicated active units. C- and D- Immunoprecipitated dysferlin cleavage with calpain-
2 at the indicated active units. Figure sourced from Redpath et al., 2014. 
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length dysferlin present following incubation with 0.1 units of calpain-2 (Figure 5.2D), 
compared to 0.2 units of calpain-1 (Figure 5.2B). 
From the in vitro calpain cleavage assay, bands in addition to mini-dysferlinC72 were produced 
in a calpain-dependent manner. I calculated the molecular weight of the additional bands and 
Figure 5.3: Calpain cleavage produces addition products in dysferlin with and without 
exon 40a. The banding pattern of the calpain-cleavage assay performed in Figure 5.2 was 
analysed and the molecular weight of the bands present was calculated. Bands were compared 
to the table of predicted calpain cleavage sites (Table 5.1) and sites that correlate with the 
predicted molecular weight of the bands selected. Bands that match predicted calpain cleavage 
sites were annotated against dysferlin with and without exon 40a and indicated by number. 
Mini-dysferlinC72 maps only to dysferlin containing exon 40a (red arrow, red mDYSF72). 
Bands that do not correspond to a predicted calpain cleavage site are denoted by asterisks. 
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compared this to predicted calpain cleavage sites. Seven bands could be mapped to predicted 
calpain cleavage sites (Figure 5.3, denoted 1-7). Two bands (bands 3 and 4) are produced by 
putative calpain cleavage in dysferlin lacking exon 40a that are not produced in dysferlin with 
exon 40a. Compared to mini-dysferlinC72 these additional cleavage products are minor species. 
Additional bands that do not correlate with any predicted calpain cleavage sites are also 
observed (Figure 5.3, asterisks). 
Summary: Calpain cleavage of dysferlin is dose-dependent in vitro. 
 Calpain-1 and calpain-2 cleave dysferlin in a dose-dependent manner in vitro, with both 
cleaving dysferlin at similar efficiencies. 
 Neither calpain-1 nor calpain-2 cleave dysferlin to produce mini-dysferlinC72 without 
exon 40a in vitro. 
 At high concentrations of calpain-2, additional calpain cleavage products are observed, 
mapping to other predicted calpain cleavage sites within dysferlin. 
Time and calcium-dependence of calpain cleavage of dysferlin. 
As dysferlin is cleaved within 30 seconds in situ in scrape-damaged cells, I tested the timeframe 
of dysferlin cleavage in the in vitro cleavage assay. Dysferlin with or without exon 40a was 
incubated with limiting units of calpain-2 (0.05 units, below the level that gives complete 
cleavage of full-length dysferlin in Figure 5.2).  Once again, dysferlin without exon 40a was 
unable to be cleaved to mini-dysferlinC72 by calpain (Figure 5.4 DYSF (-) 40a). Dysferlin with 
exon 40a was cleaved to mini-dysferlinC72 within 20 seconds of calpain-2 addition (Figure 5.4, 
DYSF (+) 40a, mini-dysferlin, closed arrow). Incubation for longer time points does not 
increase mini-dysferlinC72 formation, indicating that with limited calpain present, maximal 
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cleavage occurs within 20 seconds (Figure 5.4). This result is consistent with the timeframe of 
mini-dysferlinC72 formation in damaged cells. 
My next aim was to elucidate calcium-dependence of calpains-1 and -2 in mini-dysferlinC72 
formation in vitro. Mini-dysferlinC72 requires ~200 μM extracellular calcium for formation in 
myotubes (Lek et al., 2013). I hoped that in vitro determination of the calcium-dependence of 
calpain-1 and -2 cleavage of dysferlin might shed light on the calpain responsible for dysferlin 
cleavage in vivo. 
Figure 5.4: Calpain cleavage of dysferlin is rapid in vitro. HEK293 cells were transfected 
with dysferlin with or without exon 40a. Transfected cells were lysed and dysferlin 
immunoprecipitated with Romeo-1 and protein-G-sepharose. Sepharose beads were washed 
and transferred into calpain cleavage buffer. 0.05 units of calpain-2 was added to the sepharose 
and incubated at 30°C for 20, 60, 180 or 600 seconds. Cleavage was quenched with addition of 
SDS and DTT and heating to 94°C for 3 minutes. Dysferlin was detected on western blot with 
Hamlet-1. Mini-dysferlinC72 is indicated with a black arrow. 
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Cleavage of dysferlin by calpain-1 occurred even in the absence of calcium in the cleavage 
buffer, and complete cleavage of full-length dysferlin occurred with 50 μM calcium (Figure 
5.5A and C). Dysferlin cleavage to mini-dysferlinC72 by calpain-2 required at least 400 μM 
calcium,   with  900  μM  calcium  required  for  complete  cleavage  of  full-length  dysferlin   
(Figure 5.5B and D). Mini-dysferlinC72 is a stable product: even with complete cleavage of full-
length dysferlin, mini-dysferlinC72 was not proteolysed further. In contrast the N-terminal 
counter-fragment appears to be further cleaved in a calpain dependent manner (Figure 5.5C 
and D, grey arrow). Mini-dysferlinC72 is a stable dysferlin cleavage product, while the N-
terminal cleavage product appears unstable in my in vitro cleavage assay. 
To dissect which calpain may be responsible for mini-dysferlinC72 formation in myotubes, I 
quantified calcium titrations performed using our scrape assay on primary human myotubes by 
Angela Lek and myself. For this quantification, ImageJ was used to count the pixels present in 
Figure 5.6: Quantification of the calcium requirement of mini-dysferlin formation. Mini-
dysferlinC72 production in five independent extracellular calcium titrations performed on 
scraped primary human myotubes was quantified using ImageJ. The pixel count for each 
calcium titration was normalised to 900 μM Ca2+ for each independent experiment. Error bars 
represent the 95% confidence interval. Experiments were performed by myself and Angela 
Lek. Figure sourced from Redpath et al., 2014. 
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the mini-dsyferlinC72 bands. Mini-dysferlinC72 formation at all calcium concentrations was 
compared to the levels at 900 μM calcium (which is set as 100% mini-dysferlinC72 formation). 
Quantification of five independent experiments (a representative titration performed by myself 
Figure 5.5: Calpain-1 requires 50 μM calcium for complete dysferlin cleavage, while 
calpain-2 requires 900 μM calcium for complete dysferlin cleavage. HEK293 cells were 
transfected with dysferlin containing exon 40a. Transfected cells were lysed and dysferlin 
immunoprecipitated with Romeo-1 and protein-G-sepharose. Sepharose beads were washed and 
transferred into calpain cleavage buffer containing the indicated concentration of calcium. 0.2 
active units of calpain-1 or -2 were added and incubated at 30°C for 3 minutes, after which 
cleavage was quenched. Dysferlin was detected on western blot with anti-Myc or Romeo-1. 
Calcium titration of calpain-1 cleavage detected with anti-myc (A) Romeo-1 (C). Calcium 
titration of calpain-2 cleavage detected with anti-myc (B) Romeo-1 (D). Mini-dysferlinC72: black 
arrow; N-terminal counter fragment: grey arrow. IgG heavy chain is indicated with an asterisk. 
Figure sourced from Redpath et al., 2014. 
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is presented in Figure 4.5A) revealed that 50% of mini-dysferlin formation occurred at ~250 
μM calcium (Figure 5.6).  
From in vitro analysis of mini-dysferlinC72 formation, I know that calpain-1 maximally cleaves 
dysferlin with 50 μM calcium (Figure 5A and C), and calpain-2 does not cleave dysferlin until 
400 μM calcium is present (Figure 5B and D). If calpain-1 was solely responsible for mini-
dysferlinC72 formation, I would expect maximal mini-dysferlinC72 formation at around 50 μM 
extracellular calcium in scraped myotubes; if calpain-2 was solely responsible I would not 
expect to observe mini-dysferlinC72 formation until around 400 μM calcium was present in 
scraped myotubes. These results suggest a combination of both calpain-1 and -2 activity 
cleaves dysferlin to mini-dysferlinC72 following scrape injury. 
Summary: Calpain-1 and -2 are both responsible for dysferlin cleavage. 
 Dysferlin is rapidly cleaved to mini-dysferlinC72 in vitro. 
 Calpain-1 completely cleaves full-length dysferlin with 50 μM calcium. 
 Calpain-2 completely cleaves full-length dysferlin with 900 μM calcium. 
 50% of mini-dysferlinC72 is formed with 250 μM calcium in scrape damaged myotubes. 
 Dysferlin cleavage in the cell is most likely due to a combination of both calpain-1 and 
calpain-2 activity. 
  
 
163 
 
5.4 Calpain and dysferlin recruitment to sites of membrane injury. 
In the study preceding this work, our group established the temporal recruitment of MG53 and 
dysferlin to sites of membrane injury (Lek et al., 2013). MG53 was observed at ballistics-
induced membrane lesions 2 seconds post-injury, preceding dysferlin recruitment, which 
occurred between 2 and 10 seconds post-injury (Lek et al., 2013). 
Our current hypothesis is that calpain-1 and/or calpain-2 regulate dysferlin-mediated 
membrane repair via cleavage of dysferlin to mini-dysferlinC72. Mini-dysferlinC72, recruits to 
sites of membrane injury where it can subsequently effect vesicle-dependent membrane repair. 
Calpain-1 and -2 interact with membrane phospholipids, and phospholipid interaction 
decreases the calcium requirement for calpain activation (Fernández-Montalván et al., 2006; 
Leloup et al., 2010). I investigated calpain-2 to determine if calpain-2 was enriched at sites of 
injury, and if enrichment was temporally consistent with dysferlin recruitment. 
I damaged primary human myotubes with our ballistics assay and investigated calpain 
recruitment at 2 seconds post injury (preceding dysferlin recruitment) and 10 seconds post 
injury (when dysferlin has recruited, (Lek et al., 2013)). Calpain-2 is observed at sites of 
membrane injury at 2 and 10 seconds post injury (Figure 5.7, upper two panels). Calpain-2 is 
readily observable at MG53-positive small holes and membrane ‘bruises’ (Figure 5.7, upper 
two panels), but appears lost from larger membrane perforations (Figure 5.7, lower panel).  To 
visualise calpain-2 at sites of injury, a very light permeabilisation (0.01% triton for 1 minute) 
was required. Further permeabilisation decreases visible calpain-2 in the cell. It is possible that 
triton extraction may remove calpain-2 from the membrane and cytosol around larger 
membrane lesions. 
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These results place calpain-2 at the right place at the right time to cleave dysferlin, releasing 
mini-dysferlinC72 to recruit to sites of membrane injury. 
Figure 5.7: Calpain-2 recruits to sites of membrane damage within 2 seconds post-injury. 
Primary human myotubes were damaged by ballistics assay and fixed 2 or 10 seconds post-
injury (as indicated) in cold, 3% PFA. Cells were permeabilised with 0.01% triton and stained 
with anti-calpain-2 (anti-rabbit488- green) and anti-MG53 (anti-mouse555- red). Scale bars 
represent 5 μM. Figure sourced from Redpath et al., 2014. 
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Work in our group has now determined that dysferlin can only be identified at sites of 
membrane injury with the C-terminal antibody Hamlet-1 (Lek et al., 2013), dysferlin is cleaved 
to mini-dysferlinC72 in response to plasma membrane injury and dysferlin cleavage is mediated 
by the calcium-dependent proteases, calpains.  
To determine if mini-dysferlinC72 is recruiting to sites of membrane injury in an endogenous 
system, we purchased a custom antibody derived to the sequence of exon 40a. For this 
antibody, anti-exon 40a reactive rabbit serum was used (unless otherwise indicated) and is 
termed anti-exon 40a from here. I damaged primary human myotubes with our ballistics assay 
Figure 5.8: Anti exon-40a detects dysferlin at sites of membrane injury. Primary human 
myotubes were damaged with our ballistics assay and fixed with 3% cold PFA 10 seconds post-
injury. Saponin-permeabilised cells were labelled with anti-exon 40a (anti-rabbit488- green) and 
anti-MG53 (anti-mouse555, red).  Scale bars represent 5 μM. 
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and used anti-exon 40a to immuno-label the cells. Anti-exon 40a detected robust enrichment 
of dysferlin at MG53 positive sites of injury, providing the first direct evidence for dysferlin 
containing exon 40a recruitment to sites of injury (Figure 5.8). 
To confirm that dysferlin exon 40a is present at sites of injury, I needed to confirm the 
specificity of the anti-exon 40a antibody. Anti-exon 40a does not recognize dysferlin lacking 
exon 40a by western blot (Figure 5.9A). Using exon 40a dysferlin cleaved by calpain-2, I 
demonstrated that anti-exon 40a can recognise mini-dysferlinC72 (Figure 5.9B), but does not 
appear to recognise the N-terminal counter fragment. 
Anti-exon 40a recognises dysferlin exon 40a transfected cells (Figure 5.10A upper panel), and 
recognition of dysferlin exon 40a in transfected cells is blocked by addition of the blocking 
Figure 5.9: Anti-exon 40a specifically recognises dysferlin containing exon 40a and mini-
dysferlinC72. A- HEK293 transfected with dysferlin with or without exon 40a were run on a 
western blot. Hamlet-1 or purified anti-40a reactive IgG were used to detect dysferlin. Anti-40a 
IgG recognises only exon 40a containing dysferlin. GAPDH indicates equal loading, and 
Hamlet-1 reprobe indicates dysferlin transfection. Experiment performed by Natalie Woolger. 
B- Immunopurified dysferlin exon 40a incubated with or without purified calpain was 
investigated by western blot with Romeo-1 (R1- left), Hamlet-1 (H1- middle) or anti-exon 40a 
(α-40a- right). Anti-exon 40a recognises full-length dysferlin and mini-dysferlinC72, but not the 
N-terminal counter-fragment. Figure sourced from Redpath et al., 2014. 
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peptide (Figure 5.10A, lower panel). Anti-exon 40a is specific for exon 40a containing 
dysferlin by both western blot (Figure 5.9A) and immunocytochemistry (Figure 5.10A). 
Figure 5.10: Anti-exon 40a specifically labels dysferlin containing exon 40a. A- Anti-exon 
40a was used to label HEK293 cells transfected with our dysferlin exon 40a-pIRES EGFP 
expression construct. Anti-exon 40a recognises dysferlin exon 40a transfected cells (upper 
panel). Addition of the blocking peptide abolishes recognition of GFP positive cells (middle 
panel). Transfected cells: white arrows. Scale bar represents 20 μM. B- Ballistics assay injured 
primary human myotubes were labelled with anti-exon 40a and MG53. Anti-exon 40a does not 
recognise MG53 positive sites of injury in damaged primary human myotubes with addition of 
the blocking peptide (indicated with white arrows, scale bar represents 5 μM).  
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Furthermore, anti-exon 40a does not recognise MG53 positive sites of membrane injury in 
primary human myotubes with addition of the blocking peptide (Figure 5.10B, sites of injury 
denoted by white arrows), indicating that anti-exon 40a staining at sites of injury is specific. 
Anti-exon 40a labelling at sites of injury indicates that exon 40a containing isoforms are 
present at membrane lesions. As this antibody recognises exon 40a-containing full-length 
dysferlin or mini-dysferlinC72 (Figure 5.9A), but not the N-terminal cleavage product, the 
staining pattern observed with this antibody fits with our hypothesis that mini-dysferlinC72 is 
the dysferlin species present at sites of membrane injury. Due to recognition of full-length 
dysferlin by anti-exon 40a, I cannot exclude the caveat that exon 40a-containing full-length 
dysferlin is present at sites of injury and the N-terminus of dysferlin is consistently masked 
from detection. Uncovering the exact dysferlin species at sites of membrane injury is of great 
interest to our group, and is the subject of ongoing research (detailed in Future Directions, 
Chapter 7). 
Summary: Exon 40a dysferlin recruits to sites of injury. 
 Calpain-2 is enriched at sites of injury temporally preceding dysferlin recruitment. 
 An antibody raised to exon 40a specifically recognises full-length exon 40a dysferlin 
and mini-dysferlinC72. 
 Anti-exon 40a recognises dysferlin at sites of membrane injury. 
 As anti-exon 40a recognises full-length dysferlin in addition to mini-dysferlinC72, I 
cannot exclude the possibility that full-length exon 40a containing dysferlin is present 
at sites of injury. 
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5.5 Expression and analysis of exon 40a in human and mouse tissues. 
We next investigated the expression of dysferlin exon 40a in human tissues. A study by 
Promano et al., (2009) revealed that dysferlin isoforms containing exon 40a are expressed in 
only 11% of human skeletal muscle transcripts, as determined by quantitative PCR. Exon 40a 
only being present in 11% of skeletal muscle transcripts surprised us. As we are hypothesising 
that mini-dysferlinC72 cleaved from dysferlin containing exon 40a is responsible for plasma 
membrane repair, we expected exon 40a would be in the majority of skeletal muscle transcripts. 
The expression of dysferlin exon 40a was characterised by Natalie Woolger in a human cDNA 
panel to confirm the results by Promano et al., (2009). Using a semi-quantitative PCR 
approach, dysferlin transcripts were amplified with primers to exon 39 and 41, which would 
amplify dysferlin with and without exon 40a. PCR was performed for 30, 35 and 40 cycles to 
allow an estimation of the relative abundance of exon 40a transcripts in eight human tissues. 
Surprisingly, dysferlin exon 40a was least abundant in human skeletal muscle, where it was 
present in 10-15% of transcripts (Figure 5.11A). In heart and brain, exon 40a was present in 
around 25% of transcripts, while all remaining tissues expressed exon 40a in at least 50% of 
transcripts (Figure 5.11A). 
We know that dysferlin can only be cleaved to mini-dysferlinC72 from exon 40a containing 
transcripts. I turned to mouse tissues to confirm that mini-dysferlinC72 can be formed in tissues 
with calpain addition. I immuno-purified the total pool of dysferlin from mouse tissues and 
added calpain-1 and -2 to cleave any exon 40a-dysferlin present. 
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Calpains cleave a proportion of full-length dysferlin to mini-dysferlinC72 in all tissues within 
10 seconds (Figure 5.11B, black arrow), confirming that exon 40a-dysferlin is translated and 
Figure 5.11: Exon 40a is expressed ubiquitously and mini-dysferlinC72 can be generated in 
all tissues. A- Dysferlin exons 40a was PCR amplified from a human tissue cDNA panel using 
primers flanking the exon. PCR amplification was performed for 35 and 40 cycles to derive a 
saturation control and transcript approximation. Ctrl: plasmid control +/- exon 40a. Experiment 
performed by Natalie Woolger. B- Mouse tissues were sectioned, lysed and endogenous 
dysferlin immunoprecipitated with Romeo and protein-G-sepharose. Dysferlin-bound 
sepharose beads were incubated with 0.2 units purified recombinant calpain-1 (C1) or calpain-
2 (C2) at 30°C for 10 or 300 seconds in the presence of 2 mM CaCl2. Dysferlin was detected 
by Western analysis with the C-terminal antibody, Hamlet-1. Mini-dysferlinC72 is indicated with 
black arrows, astrisks indicate additional cleavage products. 
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cleavable in all tissues. 
In vitro, calpain-1 appears to cleave dysferlin from tissues faster than calpain-2, with more 
mini-dysferlinC72 present in all tissues after 10 seconds of calpain-1 incubation compared to 
calpain-2 (Figure 5.11B, black arrow). At the time of undertaking this experiment the purified 
calpains were 6 months old, raising the possibility that calpain activity had diminished. In all 
tissues, the level of mini-dysferlinC72 formed after 300 seconds is similar between both calpain-
1 and calpain-2 (Figure 5.11B, black arrow). 
Additional calpain-dependent bands are observed after 300 seconds of calpain-1 incubation 
(Figure 5.11B, indicated with asterisks in skeletal muscle). These bands correlate with calpain-
cleavage products that I observed only in isoform 1 of dysferlin (lacking exon 40a, Bands 3 
and 4 in Figure 5.3). These products appear after mini-dysferlinC72, and are possibly a 
secondary proteolytic event of dysferlin lacking exon 40a (Figure 5.11B). As these bands are 
only observed following in vitro digestion of dysferlin without exon 40a, the additional 
cleavage products are likely the result of over-digestion by calpains that may not occur in a 
cell.   
Summary: Dysferlin exon 40a is ubiquitously expressed. 
 Exon 40a is expressed in eight human tissues examined. 
 Exon 40a expression is lowest in skeletal muscle. 
 Mini-dysferlinC72 can be generated from the total dysferlin pool in six mouse tissues. 
 Exon 40a dysferlin is translated and cleavable in all tissues. 
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5.6 Other ferlin family members are calpain substrates. 
Having identified dysferlin as a calpain substrate, I questioned if other members of the ferlin 
family were cleaved by calpains. The first step to determine if the other ferlins are calpain 
substrates was to perform in silico cleavage prediction. Multiple splice isoforms of otoferlin 
and myoferlin have been identified, and as calpain cleavage of dysferlin is conferred via 
alternative splicing, these were included in the analysis. For Fer1L5 and Fer1L6 only one 
validated isoform has been identified and published in UniPROT. 
Otoferlin is predicted to have many C-terminal calpain cleavage sites, with two notable clusters 
containing sites with predictions scores over 1 between amino acids 1302-1313 and 1379-1400 
(Table 5.2, red boxes). In myoferlin, the highest predicted cleavage sites scores lie within the 
alternatively spliced exon 38a (Table 5.3, red box), analogous to dysferlin exon 40a. Fer1L5 
does not contain any predicted sites over 1 in the C-terminal half of the protein (Table 5.4). In 
Fer1L6, a cluster of cleavage sites reminiscent of dysferlin exon 40a and myoferlin exon 38a 
lies between amino acids 1120 and 1128 (Table 5.5, red box). 
From the in silico prediction of ferlin calpain cleavage, I hypothesised that our otoferlin and 
Fer1L6 isoform 1 expression constructs would be cleaved in the predicted regions highlighted 
(Table 5.2 and 5.5, red boxes). I hypothesised that Fer1L5 would not be cleaved by the calpains 
(Table 5.3), and that our myoferlin isoform 1 expression construct would not be cleaved as it 
lacks exon 38a (Tables 5.4). 
To experimentally determine if calpain cleavage of the ferlin family occurs, I transfected our 
ferlin expression constructs into HEK293 cells, immunoprecipitated the ferlin and performed 
in vitro calpain cleavage. 
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Table 5.2: Continued on next page.  
         Otoferlin Isoform 1/5    Otoferlin Isoform 3      Otoferlin Isoform 2/4 
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Table 5.2: Prediction of calpain cleavage sites in otoferlin. GPS-CCD 1.0 (Liu et al., 
2011) was used to predict the potential calpain cleavage sites within otoferlin isoform 1 
(UniPROT ID: Q9HC10-1) and 5 (Q9HC10-5) and the short isoforms (Q9HC10-2, -3, -4). 
For cleavage prediction, the highest possible score cutoff was used (0.654). The left-hand 
column represents the predicted calpain cleavage sites in otoferlin isoforms 1 and 5, which 
do not differ, the middle column represents the predicted sites in isoform 3 and the right 
column represents the predicted sites in isoforms 2 and 4. 
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Table 5.3: Prediction of calpain cleavage sites in myoferlin. GPS-CCD 1.0 (Liu et al., 
2011) was used to predict the potential calpain cleavage sites within myoferlin isoform 1 
(UniPROT ID: Q9NZM1-1) and the verified alternatively spliced exons. For cleavage 
prediction, the highest possible score cutoff was used (0.654). The left-hand column 
represents the predicted calpain cleavage sites in myoferlin isoform 1, while the right hand 
column displays how alternative splicing modifies the predicted calpain cleavage sites. 
Myoferlin Isoform 1    Alternately Spliced Isoforms 
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Table 5.4: Prediction of calpain cleavage sites in Fer1L5. GPS-CCD 1.0 (Liu et al., 2011) 
was used to predict the potential calpain cleavage sites within Fer1L5 isoform 1 (UniPROT 
ID: AOAVI2-1). For cleavage prediction, the highest possible score cutoff was used 
(0.654).  
                       Fer1L5 Isoform 1 
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Table 5.5: Prediction of calpain cleavage sites in Fer1L6. GPS-CCD 1.0 (Liu et al., 2011) 
was used to predict the potential calpain cleavage sites within Fer1L6 isoform 1 (UniPROT 
ID: Q2WGJ9). For cleavage prediction, the highest possible score cutoff was used (0.654). 
The right hand column is a continuation of Fer1L6 isoform 1 cleavage prediction. 
Fer1L6 Isoform 1                        Fer1L6 Isoform 1 
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In vitro calpain cleavage revealed that all ferlins are digested by calpain-1 and each ferlin 
except Fer1L5 produces a C-terminal cleavage product (Figure 5.12). Dysferlin and otoferlin 
were cleaved within 2 seconds of calpain addition (Figure 5.12, DYSF, OTOF). Surprisingly, 
myoferlin was also cleaved after 2 seconds incubation with calpain, forming a similar-sized C-
terminal fragment to mini-dysferlinC72 (Figure 5.12, MYOF). Fer1L6 cleavage required longer 
incubation with calpain, displaying more robust mini-ferlin formation after 10 seconds (Figure 
5.12, Fer1L6).  
After 300 seconds of calpain incubation, all full-length ferlins are completely cleaved (Figure 
5.12). Despite complete cleavage of the full-length protein, the C-terminal cleavage mini-
products for dysferlin, myoferlin and Fer1L6 remained stable (Figure 5.12, DYSF, MYOF, 
Fer1L6, 300s). Unlike the other ferlins, the amount of mini-otoferlin diminishes after 300 
seconds of calpain incubation and further C-terminal cleavage products are produced (Figure 
Figure 5.12: The ferlin protein family members are cleaved by calpain in vitro. HEK293 
cells were transfected with dysferlin exon 40a (DYSF); otoferlin (OTOF); myoferlin (MYOF); 
Fer1L5 or Fer1L6. Transfected cells were lysed and ferlins immunoprecipitated with anti-myc 
and protein-G-sepharose. Sepharose beads were washed and transferred into calpain cleavage 
buffer. Calpain-1 was added and incubated at 30°C for 2, 10 or 300 seconds, after which 
cleavage was quenched with SDS and DTT and heating to 94°C for 3 minutes. Each ferlin was 
detected by western blot using anti-Flag or anti-myc (dysferlin). 
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5.12, OTOF, 300s) indicating that unlike other mini-ferlins, mini-otoferlin may not be a stable 
product. 
Probing for the N-terminal mini-ferlin counter fragments for dysferlin and myoferlin show that 
similar to their respective C-terminal products, the N-termini are stable after 300 seconds of 
calpain incubation with no reduction in the amount of N-terminal cleavage product observed 
(Figure 5.13, DYSF, MYOF). The initial otoferlin N-terminal cleavage product is cleaved 
further with increasing calpain incubation, indicating that similar to mini-otoferlin, the N-
terminal cleavage products are unstable (Figure 5.13, OTOF). 
Figure 5.13: Mini-ferlin N-terminal counter fragments are similarly stable to their C-
terminal counterparts. Calpain-cleaved ferlin proteins prepared previously were separated by 
SDS-PAGE and transferred onto PVDF membrane. The dysferlin N-terminus was detected with 
Romeo-1, the otoferlin N-terminus with anti-otoferlin C12 and the myoferlin N-terminus by 
Abcam anti-myoferlin. Figure sourced from Repath et al., 2014) 
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I calculated the molecular weight of each mini-ferlin by plotting the migration of the mini-
ferlin compared to migration of the molecular weight markers in the gel (using ExPASy 
Calculate MW/pI tool), and subtracted the molecular weight of the epitope tag. The predicted 
mini-ferlin molecular weight was compared to predicted calpain cleavage sites to determine 
the most likely cleavage site. 
The molecular weight of the initial mini-otoferlin product indicates cleavage occurs at amino 
acid 1154. The further cleavage of mini-otoferlin observed with 300 seconds of calpain 
Figure 5.14: Schematic calculated calpain cleavage sites in the ferlin protein family and 
the resulting C-terminal products. The molecular weight of each mini-ferlin was calculated 
and matched to a predicted calpain cleavage site of best fit. The position of each ferlin C2 
domain is displayed, revealing each mini-ferlin contains two C2 domains anchored by the 
transmembrane domain. Synaptotagmin-1 (vi) is included as a reference dual C2 domain 
containing protein. Schematic generated using DOG 1.0 (Ren et al., 2009). 
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incubation occurs within the predicted clusters between amino acids 1297-1313 and 1376-1400 
(Table 5.2, red boxes; Figure 5.14-ii). 
Surprisingly, myoferlin was cut in vitro by calpain in exon 38. A predicted site at amino acid 
1421 has a prediction score over 1, providing an attractive candidate for calpain cleavage 
(Table 5.3; Figure 5.14-iii). 
In Fer1L6, a cluster of predicted cleavage sites is present between amino acids 1120 and 1128 
which appears similar to dysferlin exon 40a and myoferlin exon 38a. The calculated molecular 
weight of mini-Fer1L6 indicates the cleavage of Fer1L6 occurs in this region (Figure 5.14-iv). 
For each mini-ferlin, two C2 domains and the transmembrane domain are present (Figure 5.14 
i-iv); a broadly similar structure to the synaptotagmin family (Figure 5.14, vi). Given the 
hypothesised role for dysferlin and otoferlin in vesicle fusion, and the compelling evidence for 
the synaptotagmins functioning in vesicle fusion, this similarity in structure seems remarkable.  
Ferlins can be cleaved in vitro, but what about in response to intracellular calcium elevation in 
a cell? To answer this question, I transfected HEK293 cells with each ferlin and scrape-
damaged the cells in the presence of extracellular calcium (which is sufficient to create mini-
dysferlinC72), or lysed them in the presence of calcium to activate calpains, or lysed them in the 
absence of calcium with EDTA and protease inhibitors to provide a negative control. 
Only dysferlin and otoferlin displayed calcium-dependent mini-ferlin formation (Figure 5.15, 
DYSF and OTOF). I investigated isoforms 1 (neuronal) and 5 (ubiquitous) of otoferlin. These 
two isoforms differ in their transmembrane domains, with isoform 1 targeted to the trans-Golgi 
network, and isoform 5 targeted to the trans-Golgi and plasma membrane at low levels (Chapter 
3). Both otoferlin isoforms are cleaved with similar efficiency in cells (Figure 5.15 OTOFIsoform1 
 
182 
 
and OTOFIsoform5), indicating that the cellular localisation of both isoforms exposes them to 
calpains following calcium influx through the plasma membrane. 
Interestingly, myoferlin and FerL6 do not display calcium-dependent mini-ferlin formation: 
the C-terminal myoferlin and Fer1L6 cleavage products are present even in minus calcium 
conditions (Figure 5.15 MYOF and Fer1L6 RIPA-Ca2+). The mini-myoferlin product observed 
in cells is of comparable molecular weight to the mini-myoferlin I observed in Figure 5.12. 
The mini-Fer1L6 product observed in cells is not similar in molecular weight to the mini-
Fer1L6 generated by in vitro calpain cleavage (Figure 5.12, Fer1L6; Figure 5.15, Fer1L6). It 
is possible that the observed myoferlin and Fer1L6 cleavage products in cells are not a result 
of calpain proteolysis, or for myoferlin is the result of constitutive proteolysis by the calpains. 
Figure 5.15: Dysferlin and otoferlin display calcium-dependent mini-ferlin formation, 
while myoferlin and Fer1L6 mini-ferlin production is calcium-independent. HEK293 
cells transfected with ferlin expression constructs were scraped (Scr) or lysed (RIPA +Ca2+) 
in the presence of calcium, or lysed without calcium with EDTA and protease inhibitors 
(RIPA –Ca2+). Dysferlin was detected by western blot with anti-myc, while the remaining 
ferlins were detected with anti-flag. Equal loading is indicated with Coomassie membrane 
staining. Arrowheads indicate mini-ferlin products correlating to calpain cleavage products 
produced in vitro. 
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The observed Fer1L6 fragments do appear to be a specific Fer1L6 product, as they are not 
present in other ferlins probed for with the same antibody (Figure 5.15).  
Summary: The ferlins are calpain substrates. 
 Dysferlin, otoferlin, myoferlin and Fer1L6 are cleaved by calpains in vitro. 
 Dysferlin and otoferlin cleavage is calcium-dependent in cells. 
 Myoferlin is constitutively cleaved in cells. 
 The Fer1L6 calpain cleavage product is not observed in transfected cells. 
 The mini-ferlins all contain 2 C2 domains and are anchored by the transmembrane 
domain, making them structurally similar to the synaptotagmins. 
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Chapter 6: Discussion 
In chapters 4 and 5 of my thesis, I established that dysferlin cleavage is a ubiquitous response 
to plasma membrane injury. Calpain cleaves dysferlin to mini-dysferlinC72 following 
membrane injury in all cell types I examined. Natalie Woolger refined the calpain cleavage site 
in dysferlin to the alternatively spliced exon 40a, and together we confirmed that the ubiquitous 
calpains-1 and -2 are responsible for dysferlin cleavage following membrane injury. Using an 
antibody raised to dysferlin exon 40a, I identified that exon 40a-containing dysferlin isoforms 
recruit to sites of membrane injury, consistent with our hypothesis that it is the cleaved C-
terminal fragment of dysferlin that is recruiting to sites of injury. Finally, I identified that 
otoferlin and myoferlin are also calpain substrates, releasing similar C-terminal fragments to 
dysferlin following calpain cleavage.  
There are three outstanding questions from this section of my project that I will discuss here: 
1. Does mini-dysferlinC72 recruit to sites of membrane injury and participate in membrane 
repair? 
2. Could mini-ferlins be synaptotagmin-like vesicle fusion modules? 
3. Why do the ferlins need to be cleaved? 
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6.1 Mini-dysferlinC72 is the likely dysferlin species responsible for plasma membrane 
repair. 
We hypothesise that mini-dysferlinC72 is the dysferlin species at sites of membrane injury, 
where it participates in vesicle-fusion, leading to plasma membrane repair. In support of this 
hypothesis, I have identified dysferlin at sites of injury with an antibody that is specific to exon 
40a. Anti-exon 40a recognises mini-dysferlinC72 as well as full-length dysferlin but not the N-
terminal counter-fragment. Together with Angela Lek’s data showing that three N-terminal 
antibodies with epitopes ranging from near C2A to C2DE fail to detect dysferlin at injury sites 
((Lek et al., 2013); Chapter 1.12), I think the evidence suggesting that mini-dysferlinC72 is the 
dysferlin species at sites of injury is compelling. 
However, one question remains: is mini-dysferlinC72 actually required for membrane 
repair? 
Fortuitously, the mouse model for mini-dysferlin has already been made. Krahn et al., (2010) 
identified a patient mini-dysferlin resulting from deletion of exons 2-40 of the dysferlin gene, 
which results in a protein product produced from a cryptic translation initiation site in intron 
40. The resulting dysferlin protein contains 11 amino acids encoded from intron 40 before 
splicing onto exon 41 (Figure 6.1: Additional 11 amino acids). From exon 41, this patient mini-
dysferlin is identical to mini-dysferlinC72 (Figure 6.1: Exon 41, (Krahn et al., 2010b)). 
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Expressing patient mini-dysferlin in dysferlin null mouse muscle fibres rescued the 
membrane repair defect these fibres otherwise display. Mini-dysferlin expressing fibres 
displayed a comparable level of dye uptake to wild-type fibres following laser injury (Krahn et 
al., 2010b). As patient mini-dysferlin and mini-dysferlinC72 are so strikingly similar, I think it 
is probable that mini-dysferlinC72 is responsible for dysferlin-dependent plasma membrane 
repair in vivo. 
Despite rescuing the membrane repair defect with mini-dysferlin expression, mini-dysferlin 
expressing dysferlin-deficient mice displayed no correction of dystrophic pathology (Krahn et 
al., 2010b). Acute membrane resealing is not the only function of dysferlin. Development 
of muscular dystrophy due to dysferlin deficiency results from more than an acute membrane 
repair defect. This finding is concordant with my results showing there are (at least) two forms 
of dysferlin: mini-dysferlinC72 (cleaved from exon 40a-dysferlin), and dysferlin that cannot be 
cleaved following membrane injury. It is clear that full-length dysferlin is indispensable for 
skeletal muscle maintenance, and is required in addition to mini-dysferlinC72 to maintain 
skeletal muscle integrity. 
Figure 6.1: Alignment of cleaved dysferlin exon 40a with patient mini-dysferlin. The 
predicted sequence for cleaved mini-dysferlinC72 and exon 41 was aligned with the patient 
mini-dysferlin sequence reported by Krahn et al. (2010) using the ClustalW multiple sequence 
alignment tool.  
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Mini-dysferlinC72 provides a link between calpains, vesicle fusion and membrane repair. 
My work provides a candidate for the missing link between calpains and vesicle fusion in 
membrane repair. To recap, Godell et al., (1997) demonstrated that calpain inhibition prevented 
resealing of transected squid and crayfish giant axons. When calpains were inhibited, vesicles 
accumulated at, but did not fuse with, the transection site and the axon did not repair, indicating 
that calpains are required for vesicle fusion in membrane repair (Godell et al., 1997). How 
calpains are required for vesicle fusion at sites of injury has remained unclear. 
Angela Lek provided evidence that mini-dysferlinC72 is a vesicle fusion module of dysferlin. 
With increasing calcium, dysferlin (which we presume to be mini-dysferlinC72) interdigitates 
with MG53 at sites of injury in a process that resembles vesicle fusion (Lek et al., 2013). As 
calpains are responsible for mini-dysferlinC72 formation, my work provides a mechanism as to 
how calpains may regulate vesicle fusion in membrane repair. Calpains cleave dysferlin, 
releasing mini-dysferlinC72 which may mediate vesicle fusion at sites of membrane injury. 
Without calpain activation (such as when calpains are inhibited or knocked out), mini-
dysferlinC72 will not be produced and vesicle fusion at sites of injury may not occur.  
I propose that dysferlin provides the intermediate between calpains and vesicle fusion at sites 
of membrane injury. 
Exon 40a expression appears to be tightly regulated in excitable tissues. 
One puzzling result of our lab’s collective discovery that exon 40a contains the calpain 
cleavage site in dysferlin is that exon 40a appears to be expressed lowest in the tissue that I 
think needs it the most: skeletal muscle. If mini-dysferlin (made from exon 40a) is responsible 
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for membrane repair, then why would skeletal muscle be the tissue that can make the least of 
it? I think there are three hypotheses regarding this result. 
Contrary to expectations, muscle-specific dysferlin over-expression has previously shown to 
be induce muscle wasting and atrophy in mice (Glover et al., 2010). Furthermore, as discussed 
above, mini-dysferlin over-expression does not correct the muscular dystrophy of dysferlin-
deficient mice (Krahn et al., 2010b). Too much full-length dysferlin, and perhaps too much 
mini-dysferlin is detrimental to muscle integrity. If formation of too much mini-dysferlin is 
detrimental or toxic to muscle, perhaps keeping levels of exon 40a low in muscle is a 
mechanism to prevent excess mini-dysferlin formation. 
Interestingly, exon 40a expression is lowest in the most excitable tissues we investigated: 
skeletal muscle, cardiac muscle and brain. Calcium influx through calcium-channels has been 
established to activate calpains-1 and -2 (Waters et al., 1997), therefore calpain activation and 
dysferlin cleavage is conceivable in excitable tissues. Promiscuous dysferlin cleavage 
following calcium channel activation may be detrimental to cell function, therefore in tissues 
that are highly excitable, levels of cleavable dysferlin are limited by reducing expression of 
exon 40a. 
My final hypothesis regarding the low level of exon 40a expression in skeletal muscle is that 
the mRNA level of exon 40a transcript may simply not correlate with the exon 40a containing 
protein level. Of note is the discrepancy noted between my observation that myoferlin is 
expressed abundantly at the mRNA level, and yet is observed only in two of seventeen tissues 
investigated by western blot by Turtoi et al, (2013). Recent RNA sequencing data also indicates 
myoferlin transcript is present ubiquitously (http://www.gtexportal.org/home/gene/MYOF), 
showing that for the ferlin most related to dysferlin the amount of transcript does not correlate 
to the amount of protein present. 
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While the above points are hypotheses, the fact that dysferlin over-expression causes muscle 
atrophy, mini-dysferlin does not rescue the muscular dystrophy phenotype of dysferlin 
deficient mice and exon 40a is expressed lowest in skeletal muscle indicates that caution is 
required in developing dysferlinopathy therapies that reply on the genetic replacement of 
dysferlin.  
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6.2 Mini-ferlins as synaptotagmin-like vesicle fusion modules. 
My project has demonstrated that dysferlin, myoferlin and otoferlin are calpain substrates and 
calpain cleavage releases similar C-terminal fragments from each ferlin. Type-I (dysferlin-like) 
and type-II (otoferlin-like) ferlins are hypothesised to have evolved from a single ancestral 
ferlin, detectable in limpets (Lek et al., 2010). As both type-I and type-II human ferlins are 
calpain substrates, I think that ferlin cleavage predates type-I and type-II ferlin evolution. 
Calpain cleavage of the ferlins is an evolutionarily conserved modification, which highlights 
the importance of calpain cleavage for ferlin function.  
The similarities between the mini-ferlins and the synaptotagmins are notable. Synaptotagmins 
are anchored by an N-terminal transmembrane domain and contain two cytosolic C2 domains. 
The mini-ferlins are anchored by a C-terminal transmembrane domain and also have two 
cytosolic C2 domains. Given the broad similarity in structure between the mini-ferlins and the 
synaptotagmin family, we couldn’t help but speculate that the mini-ferlins may be ancient, 
conserved, synaptotagmin-like vesicle fusion modules. I will use a comparison between 
synaptotagmin 1 and mini-dysferlinC72, mini-otoferlin and mini-myoferlin to examine the 
evidence for and against this hypothesis. 
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Could mini-ferlins be synaptotagmin-like modules? 
Structural similarities of synaptotagmin and ferlin C2 domains. 
Calcium-coordination by the C2 domain top loop regions provides the basis of synaptotagmin-
1 regulation of vesicle fusion. Alignment of ferlin C2E domains with synaptotagmin-1 C2B 
reveals that four of five calcium-binding aspartic acid residues are conserved between 
synaptotagmin-1 C2B and dysferlin and myoferlin C2E. The synaptotagmin-1 C2B aspartic 
acid not conserved with dysferlin and myoferlin C2E is a glutamic acid, which is also a 
glutamic acid in Drosophila melanogaster synaptotagmin-1 C2B (Lee et al., 2013a). All five 
calcium-binding residues are conserved between synaptotagmin-1 C2B and otoferlin C2E 
(Figure 6.2A, upper alignment, green). Four of five calcium-binding aspartic acid residues are 
conserved between synaptotagmin-1 C2A and the ferlin C2F domains (Figure 6.2, bottom, 
green). 
Dysferlin C2E and F bind calcium with similar affinity to synaptotagmin-1 (Syt-1 C2A: 119 
μM; C2B: 199 μM (Radhakrishnan et al., 2009); DYSF C2E: 186 μM: C2F: 124 μM (Abdullah 
et al., 2014)), suggesting that conservation of C2 domain calcium-binding residues imparts 
similar calcium-binding properties between the synaptotagmins and ferlins. 
Dysferlin and myoferlin C2F also possess the YVK motif present in both synaptotagmin-1 C2 
domains (Figure 6.2, yellow; (Thomas and Elferink, 1998)). Mutation of the YKV motif 
disrupts calcium-dependent syntaxin-1 and alpha-tubulin binding in synaptotagmin-1 (Honda 
et al., 2002; Thomas and Elferink, 1998). Conservation of this motif in dysferlin and myoferlin 
C2F could conceivably impart SNARE binding to the mini-ferlins. 
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C2B (Lee et al., 2012). All five calcium-binding residues are conserved between  jbfive five  
Figure 6.2: Alignment of mini-ferlin and synaptotagmin-1 C2 domains. A- ClustalW 
alignment of dysferlin, myoferlin and otoferlin C2E and F domains with synaptagmin-1 C2 
domains. B- Schematic of synaptotagmin-1 detailing functional domains (adapted from Lin et 
al., 2014). 
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A highly charged linker region is present between the transmembrane domain and C2A of 
synaptotagmin-1 (Figure 6.2B, Linker). Mini-otoferlin is around 10 kDa larger than mini-
dysferlin and myoferlin due to inclusion of a highly charged region between the calpain 
cleavage site (amino acid 1164) and C2E. The otoferlin charged region contains poly-K and 
poly-D regions, similar to the linker between the transmembrane domain and C2A of 
synaptotagmin-1 (Figure 6.2B, Linker). In synaptotagmin-1, this linker region is an 
electrostatic clamp, retaining the transmembrane-domain anchored vesicle in close proximity 
to the C2A domain (Lin et al., 2014). In mini-otoferlin, the charged region is at the N-terminus 
and does not reside between the transmembrane domain and C2F, and as such may not be 
functionally analogous to the charged linker in synaptotagmin-1. If the lysine residues in the 
mini-otoferlin charged region impart constitutive vesicle binding, the rest of the linker region 
may act as an electrostatic clamp, holding the vesicle in proximity to mini-otoferlin C2E. If the 
above case is true, the otoferlin charged linker may be functionally analogous to the 
synaptotagmin-1 charged linker, however this is highly speculative. 
Structural differences between synaptotagmin and ferlin C2 domains. 
A major structural difference between synaptotagmins and ferlins is the linker size between C2 
domains. All synaptotagmins share a highly conserved 9 amino acid linker between C2 
domains (Liu et al., 2014). The specific size of the linker between C2 domains facilitates 
synaptotagmin membrane penetration, with an increase in this linker size diminishing calcium-
dependent membrane insertion, the degree of which correlated with decreased evoked 
neurotransmitter release in cultured neurons. Furthermore, increasing the rigidity of the linker 
(via increasing proline content) or flexibility of the linker (via increasing glycine content) 
diminishes calcium-dependent membrane insertion of synaptotagmin-1, highlighting the tight 
control the synaptotagmin-1 C2 domain linker exerts on C2A and C2B cooperativity. 
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Increasing the C2 domain linker size does not abolish the ability of synaptotagmin-1 to 
stimulate vesicle fusion in vitro, and all synaptotagmin-1 linker mutations were capable of 
rescuing the evoked neurotransmitter release defect in synaptotagmin-1 knockout neurons to 
some degree. The size and composition of the synaptotagmin-1 linker is important for 
synaptotagmin-1 C2 domain function (Liu et al., 2014). 
The smallest linker region between ferlin C2 domains is between C2B and C2C (64 amino 
acids for dysferlin), and the linker region between dysferlin C2E and F is 150 amino acids. The 
in vitro calcium binding affinity for C2B and C2C of dysferlin does not change with the 
presence or absence of the linker region, indicating that the ferlin C2 domains are unlikely to 
display cooperative calcium binding (Abdullah et al., 2014). An increase in the synaptotagmin-
1 C2 domain linker size holds the C2 domains apart, diminishes calcium-dependent membrane 
insertion, and a correlative decrease in evoked neurotransmitter release in cultured neurons is 
observed. The precise length and structure of the C2 domain linker is therefore important for 
C2 domain cooperation and synatptogmin-1 function (Liu et al., 2014).While synaptotagmin-
1 C2 domains display cooperative calcium binding, synaptotagmin-IV C2 domains do not, 
therefore cooperative calcium binding is not required for synaptotagmin-mediated vesicle 
fusion (Johnson et al., 2010). Without structural studies it is impossible to know if the 
difference in ferlin and synaptotagmin C2 domain linker sizes leads to functional differences 
between the proteins, however the C2 domain linkers provide a region where mini-ferlins and 
synaptotagmins may differ functionally, via differences in how C2 domains cooperate. 
Synaptotagmin C2 domains also contain a poly-K (KKKK) motif (Figure 6.2A and B-KKKK, 
blue; (Thomas and Elferink, 1998)). The poly-K motif on C2B is proposed to interact with 
negatively charged phospholipids at the plasma membrane in a calcium-independent manner 
(Lin et al., 2014; Thomas and Elferink, 1998) (Figure 6.2B KKKK, PIP2). No mini-ferlin C2 
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domains contain this poly-K motif, which may mean that mini-ferlins do not associate with 
membranes in the absence of calcium.  
Summary: Mini-ferlins share structural similarities with synaptotagmin-1. 
 Four out of five calcium-binding residues are conserved between synaptotagmin-1 and 
mini-ferlin C2 domains. 
 Dysferlin C2E and C2F bind calcium with similar affinity to synaptotagmin-1 C2 
domains. 
 YKV, a putative SNARE interaction motif in synaptotagmins, is present in dysferlin 
and myoferlin C2F. 
 Mini-ferlin C2 domains do not contain the synaptotagmin poly-K lipid interaction 
motif. 
 Otoferlin contains a highly charged region similar to the sypatotamgin-1 linker region 
between the transmembrane domain and C2A. 
 The C2 domain linkers in the ferlins are large, suggesting that ferlin C2 domains may 
not display the same cooperativity that the small synaptotagmin C2 domain linkers 
allow. 
Evidence for ferlin C2 domains as mediators of vesicle fusion. 
Lipid ordering experiments by Marty et al. (2013) and microscopy data from Angel Lek (Lek 
et al., 2013) supports a role for dysferlin acting as a vesicle fusion-stimulating molecule. 
Dysferlin C2 domains are able to insert into lipid bilayers and order lipid membranes in a 
calcium-dependent manner (Marty et al., 2013). Ordering of lipid bilayers is a proposed 
precursor to vesicle fusion (Marty et al., 2013). Super-resolution data from Angela Lek’s Ph.D. 
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revealed that the C-terminus of dysferlin (most likely mini-dysferlinC72) interdigitates with 
MG53 at the plasma membrane in a calcium-dependent manner in a process resembling vesicle 
fusion (Lek et al., 2013).  
Otoferlin C2 domains are capable of ordering lipid bilayers (Marty et al., 2013). All otoferlin 
C2 domains excepting C2A stimulate calcium-dependent liposome aggregation and calcium-
dependent, SNARE-mediated vesicle fusion in vitro (Johnson and Chapman, 2010). An 
otoferlin construct consisting of C2D, E and F and the associated linker regions stimulates 
fusion of vesicles containing V- and t-SNAREs to each other in a calcium-dependent manner 
(Johnson and Chapman, 2010). In a comparable assay, synaptotagmin-1 C2A and B stimulate 
calcium-dependent fusion of vesicles containing V- and t-SNAREs to each other (Stein et al., 
2007). While the interaction between otoferlin and neuronal SNAREs appears irrelevant for 
inner hair cell function (Chapter 1.5, (Nouvian et al., 2011)), these results do indicate otoferlin 
may be a SNARE interacting protein like the synaptotagmins. In vitro stimulation of SNARE 
mediated vesicle fusion by otoferlin C2E and C2F is consistent with mini-otoferlin (and also 
full-length otoferlin) being a mediator of vesicle fusion in a similar manner to synaptotagmin-
1. No SNARE interactions or SNARE mediated vesicle fusion has been described for dysferlin 
or myoferlin. 
Synaptotagmin interaction with SNAREs is a proposed mechanism in which the 
synaptotagmins mediate vesicle fusion (Stein et al., 2007). Synaptotagmins are capable of 
interacting with SNAREs and stimulating calcium-dependent vesicle fusion and aggregation 
in vitro, supportive of a role as a mediator of vesicle fusion in vivo (Stein et al., 2007). The 
similarity of otoferlin stimulation of vesicle fusion and aggregation in vitro supports a role for 
mini-otoferlin as a synaptotagmin-like vesicle fusion module. 
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Summary: Mini-ferlins are potential mediators of vesicle fusion. 
 Dysferlin and otoferlin are capable of ordering lipid bilayers. 
 Mini-dysferlinC72 interdigitates with MG53 at the plasma membrane in a manner 
resembling vesicle fusion. 
 Otoferlin C2DEF can stimulate calcium-dependent, SNARE mediated vesicle 
aggregation and fusion. 
The mini-ferlins display the hallmarks of vesicle-fusion modules. 
The similarities of mini-ferlins to synaptotagmin-1 indicate to me that the mini-ferlins are 
capable of acting as vesicle fusion modules. In vitro, the C-terminal C2 domains of otoferlin 
stimulate vesicle fusion in a manner similar to synaptotagmin-1, and mini-dysferlinC72 appears 
to be involved in vesicle fusion at sites of injury.  
Structurally, mini-ferlin C2 domains are similar to synaptotagmin-1 C2 domains, with 
conserved calcium-binding residues, SNARE interaction motifs (dysferlin and myoferlin) and 
potential electrostatic clamps for positioning vesicles (otoferlin). Structural differences indicate 
that unlike synaptotagmin-1, mini-ferlin C2 domains will not constitutively bind lipid 
membranes (due to the lack of poly-K motif) and will not display cooperative calcium binding 
due to the size of their linker regions. However, C2 domain cooperation or presence of the 
poly-K motif are not requisite for vesicle fusion to occur (Johnson et al., 2010; Lin et al., 2014; 
Liu et al., 2014; Xue et al., 2008). 
On the balance of evidence, I think that despite the structural differences between 
synaptotagmins and mini-ferlins, the mini-ferlins are most likely vesicle fusion modules, 
released from the full-length ferlin by calpains in response to specific calcium signals. For 
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dysferlin, we know the signal: increased intracellular calcium from membrane damage. 
Determining what leads to otoferlin and myoferlin cleavage and the vesicle fusion event the 
mini-ferlins are involved in is the most interesting future research direction stemming from my 
project. 
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6.3. Why are the ferlins cleaved? 
Ferlin cleavage releases putative vesicle fusion modules from the full-length protein. Why not 
have the mini-ferlin produced by a separate transcript? Or why not produce the mini-ferlin from 
a separate gene, as the synaptotagmins are? Clearly releasing the mini-ferlin specifically when 
calpains are activated is important for mini-ferlin function. I have two potential explanations 
as to why the ferlins may need to be cleaved: cleavage speeds up the function the full-length 
ferlin otherwise fulfils, or cleavage releases the mini-ferlin from negative regulation of the N-
terminus. For both examples, I will focus on dysferlin and mini-dysferlinC72. 
Mini-ferlin diffusion is theoretically faster than diffusion of full-length ferlins. 
Small molecules move faster than large ones. Mini-dysferlinC72, at 72 kDa, is around one 
quarter of the size of full-length dysferlin, at 239 kDa (with exon 40a present). In soleus and 
extensor digitorum longus mouse muscle fibres, haemoglobin (64.5 kDa) diffuses 
approximately three times quicker that catalase (247.5 kDa) following microinjection into the 
fibre (Papadopoulos et al., 2000). Therefore it could be expected that mini-ferlins will diffuse 
around 3 times quicker than a full-length ferlin. 
Globular diameter of a protein plays a much larger role in determining protein diffusion than 
molecular weight (Papadopoulos et al., 2000). Catalase (diameter= 10 nm) and ferritin 
(diameter= 12 nm) diffuse in water or dilute buffer at a rate proportional to their diameter 
(ferritin diffuse 1.2 time slower than catalase, Figure 6.3A; (Papadopoulos et al., 2000)). In 
soleus muscle however, diffusion is no longer proportional to diameter and the 2 nm ( or 1.2 
times) diameter increase of ferritin leads to a 5 times diffusion speed decrease compared to 
catalase ((Papadopoulos et al., 2000); Figure 6.3A).  
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Dysferlin C2A is approximately 3 nm in diameter (Fuson et al., 2014). Assuming the dysferlin 
C2 domains lie as ‘beads on a string’, full-length dysferlin would have a minimum globular 
diameter of around 21 nm (3 nm for each of the 7 C2 domains, Figure 6.3B). Cleavage to mini-
dysferlinC72, which contains only 2 C2 domains would give a hypothetical diameter of 6 nm 
(or 2/7th that of full-length dysferlin, Figure 6.3B). A potential diameter decrease of 15 nm 
would increase recruitment speed by many fold, given the impact of the 2 nm diameter increase 
between catalase and ferritin. Ferlin cleavage could be a mechanism to allow the ferlins to play 
their everyday function, but at a much more rapid pace, providing the diffusion dynamics of a 
membrane-anchored protein are comparable to the cytoplasmic proteins analysed by 
Papadopoulos et al., (2000). Importantly, dysferlin (or any ferlin) may exhibit more secondary 
Figure 6.3: Schematic of the effect of protein diameter on diffusion speed. A- The diffusion 
of catalase and ferritin is proportional to protein diameter in water, but not in soleus muscle 
(Data sourced from Papadopoulos et al., 2000. Catalase structure: Jawahar Swaminathan, 
http://www.ebi.ac.uk/pdbe/entry-images/7cat_cbc600.png. Ferritin structure: (Grant and 
Donaldson, 2009). B- Depiction of the potential diameter of full-length dysferlin and mini-
dysferlinC72. 
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or tertiary protein structure than just within the C2 domains. If dysferlin folds back upon itself, 
dimerises or the C2 domain linkers form any secondary structure, this would alter the globular 
diameter of dysferlin and therefore dysferlin diffusion speed. Until the more of the secondary 
structure of dysferlin is known any hypotheses regarding its diffusion are purely speculative.  
The dysferlin N-terminus may negatively regulate recruitment. 
Another possibility is that dysferlin cleavage could allow recruitment to occur if the N-terminus 
negatively regulates the C-terminus in a manner that prevents mini-dysferlinC72 recruitment to 
sites of injury.  
The C2A and C2B domains of dysferlin interact with alpha tubulin in a calcium-independent 
manner (Azakir et al., 2010). The N-terminus of dysferlin may be constitutively associated 
with microtubules. I think the N-terminal interaction with alpha-tubulin may ‘hold back’ 
dysferlin from recruiting to sites of membrane injury. Cleavage of mini-dysferlinC72 from the 
N-terminus would release this brake on dysferlin, releasing mini-dysferlinC72 from 
microtubules to recruit to sites of injury, while the N-terminus remains associated with alpha-
tubulin, distal to injury sites.  
The above scenario is speculative, but does provide an example of how the N-terminus of 
dysferlin may negatively regulate mini-dysferlinC72 recruitment. Interaction partners of the 
dysferlin N-terminus other than alpha-tubulin may affect the negative regulation in vivo, 
however other plausible candidates are yet to be identified. Negative regulation of the C-
terminal mini-ferlin by the N-terminus could be conceptually extended to otoferlin and 
myoferlin. 
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Other considerations of otoferlin and myoferlin cleavage. 
Mini-otoferlin was completely degraded with increasing calpain incubation in vitro, in 
comparison to mini-dysferlinC72 and mini-myoferlin, which were stable with increasing calpain 
incubation. It is possible that mini-otoferlin is a short-lived module that fulfils its function and 
is then rapidly degraded by the calpains. However, in my cell-scrape assay, mini-otoferlin 
persisted at least as long as mini-dysferlinC72 (at least for the 30 seconds between scraping and 
quenching the cell pellet with EDTA). Determining the half-life of the mini-ferlins in situ may 
help inform us regarding their function. Is mini-dysferlinC72 long lived, regulating vesicle 
fusion at sites of injury for a matter of minutes? And is mini-otoferlin short lived, rapidly 
stimulating vesicle fusion and then quickly removed by the calpains? 
Myoferlin appeared constitutively cleaved in my cell scrape assay, even in cells lysed in the 
absence of calcium. This raises the possibility that another enzyme may be cleaving myoferlin. 
While my in vitro cleavage clearly shows calpains can cleave myoferlin, the presence of mini-
myoferlin in the absence of calcium indicates either calpains are always cleaving a proportion 
of myoferlin, or a calcium-independent protease is cleaving myoferlin. Calpain cleavage 
prediction indicated the strongest candidate cleavage sites are in the alternatively spliced exon 
38a. I was surprised to see myoferlin cleavage in our expression construct lacking exon 38a. It 
is possible that calpains do cleave myoferlin, and so do other enzymes. Ann-Katrin Piper is 
currently investigating the role of exon 38a in myoferlin cleavage, and determining why 
myoferlin appears to be constitutively cleaved. 
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Chapter 7: Future Directions 
Confirming the recruitment of mini-dysferlinC72 at sites of membrane injury. 
For the following section, A/P Sandra Cooper and Dr. Frances Lemckert have conceived of 
the experiments, the project is underway and is being performed by Dr. Frances Lemckert. 
Calpains-1 and -2 cleave dysferlin specifically in exon 40a in response to plasma membrane 
injury. Angela Lek previously demonstrated that dysferlin is only identifiable at sites of injury 
with the C-terminal Hamlet-1 antibody, and not with three more N-terminal antibodies (Lek et 
al., 2013). I extended this finding, showing that an antibody specifically raised to exon 40a, the 
calpain cleavage site in dysferlin that releases mini-dysferlinC72, recognises dysferlin at injury 
sites. The collective evidence that it is mini-dysferlinC72 at sites of injury is strong, but not 
unambiguous. The evidence provided by Krahn et al., (2010a) (in which a naturally occurring 
mini-dysferlin similar to mini-dysferlinC72 rescues the membrane repair defect in dysferlin 
deficient mice) strongly suggests that mini-dysferlinC72 is responsible for dysferlin-dependent 
muscle membrane repair. However, the 11 amino acid difference between the patient mini-
dysferlin used in the Krahn transgenic mouse model and our native mini-dysferlinC72 means 
that it is not certain that mini-dysferlinC72 is responsible for dysferlin-dependent membrane 
repair. 
To address the recruitment of mini-dysferlinC72 to sites of injury and its functional role in 
membrane repair, Dr. Frances Lemckert is generating an exon 40a knockout mouse using 
CRISPR/Cas9. CRISPR/Cas9 efficiently induces targeted double-stranded DNA breaks, which 
results in non-homologous end joining in a proportion of DNA repair events (Ran et al., 2013). 
Non-homologous end joining can disrupt the reading frame of the transcript, leading to 
effective knockout of the transcript (Ran et al., 2013). Exon 40a is being knocked out (exon 
 
204 
 
40a -/-) using CRISPR/Cas9 to induce a double-stranded DNA break and induce non-
homologous end joining to prevent exon 40a transcription.  
Ballistics injury of either myotubes or muscle fibres isolated from the exon 40a -/- mice should 
provide definitive evidence that it is indeed mini-dysferlinC72 at sites of injury. I would expect 
to observe no dysferlin recruitment in the exon 40a -/- mouse at membrane lesions that are 
MG53 positive (MG53 is our positive marker of sites of membrane injury). In wild-type mouse 
myotubes or fibres, I would expect to see dysferlin recruitment with Hamlet-1, but not any N-
terminal dysferlin antibodies. Together, I think observing no dysferlin recruitment in myotubes 
without exon 40a, and only C-terminal dysferlin recruitment in mice with exon 40a will be 
sufficient evidence to say with confidence that it is mini-dysferlinC72 at sites of membrane 
injury. 
The exon 40a -/- mouse will also enable us to directly determine if dysferlin cleavage is 
required for membrane repair. Comparing FM143 (or a comparable dye) uptake following laser 
injury of wild-type, exon 40a -/- and dysferlin-null mouse muscle fibres would tell us if exon 
40a is required for membrane repair, and by extension, that mini-dysferlinC72 is responsible for 
muscle membrane repair. Furthermore, we can damage other tissues, or primary cell lines 
isolated from other tissues (isolating primary fibroblasts, myoblasts, cardiomyocytes, 
astrocytes, microglia and oligodendrocytes are within our group’s expertise).  As the exon 40a 
-/- mouse model will be a global exon 40a knockout, it would inform us if exon 40a, and by 
extension mini-dysferlinC72, is required for plasma membrane throughout the body. 
As the Krahn et al., (2010), patient mini-dysferlin over-expressing mouse develops a dystrophy 
despite being membrane repair competent, it would be interesting to determine if exon 40a 
knockout leads to a progressive muscular dystrophy in the mice. Comparison of the dystrophy 
progression between exon 40a -/- and dysferlin null mice could inform us as to the relative 
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contribution of the membrane repair defect in dysferlinopathy, compared to other potential 
functions of dysferlin in extension to, or beyond plasma membrane repair. 
Determining the cargo and interacting partners of the ferlins. 
I have established that the type-I ferlins, dysferlin and myoferlin, are present throughout the 
secretory pathway, the plasma membrane and late endosomes. Type-II ferlins, otoferlin and 
Fer1L6, are present throughout the secretory pathway, plasma membrane and recycling 
compartments within the cell, primarily within sub-compartments of the trans-Golgi network. 
Type-I ferlins traffic to the plasma membrane and may exert their function there or in the late 
endosomes/endo-lysosomal pathway. Type-II ferlins traffic to the plasma membrane, 
following which they may function in recycling pathways in the cell. 
Having identified the location and endocytic trafficking pathways of the ferlins, the next step 
is to determine what each ferlin is interacting with or trafficking. Initially, studies should be 
performed in cell lines expressing the ferlin endogenously. Cell lines expressing dysferlin 
(myoblasts/myotubes) and myoferlin (breast cancer lines such as MDA-MB-231) have been 
identified. For otoferlin, a screen of neural cell lines would have to be undertaken to identify 
lines expressing otoferlin endogenously. Fer1L6 is highly expressed in human stomach, lung, 
kidney, heart and male and female reproductive tissues (as annotated on the Human Protein 
Atlas). Cell lines originating from this range of tissues would be screened to find a line 
expressing endogenous Fer1L6. Fer1L6 appears to be downregulated in cancerous tissues (as 
annotated on the Human Protein Atlas), therefore cell lines originating from cancerous tissues 
may need to be avoided. 
Upon identification of appropriate cell lines, each ferlin can be knocked out using 
CRISPR/Cas9. CRISPR/Cas9 can be targeted to induce a double-stranded DNA break in exon 
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1 (or the exon containing the initiating ATG of each ferlin). Insertions or deletions induced by 
non-homologous end joining in exon 1 should lead to an out-of-frame mRNA transcript, which 
as it is in exon 1 should lead to a premature stop codon and effective knockout of the ferlin. 
Following ferlin knockout, using either a range of antibody arrays or a whole proteome 
investigation by mass spectrometry, each ferlin knockout proteome could be compared to the 
wild-type cell line. Differences in protein expression identified by proteome studies would 
ideally identify candidates for the proteins each ferlin may interact with or traffic, providing 
avenues of future investigation to determine the vesicle fusion events each ferlin may regulate.  
For a more refined approach, each endogenous ferlin could be tagged using CRISPR/Cas9. 
Using CRISPR/Cas9, a double stranded break would be induced in the final exon of each ferlin. 
Instead of relying on non-homologous end joining, a DNA template would be used to allow 
homology directed repair to occur (Ran et al., 2013). A homology-directed repair DNA 
template consisting of the final exon of the ferlin with a DDK/Flag epitope tag immediately 
prior to the stop codon could be used to add an epitope tag to the endogenous ferlin. The tagged 
endogenous ferlin could then be immunoprecipitated with an anti-Flag antibody and any 
proteins bound to the ferlin identified by mass spectrometry. 
Investigating mini-ferlin cleavage. 
One of the more interesting findings of my thesis was that the ferlins are cleaved by the 
calpains, releasing synaptotagmin-like C-terminal fragments. We hypothesise that these mini-
ferlins are vesicle fusion modules. We know when dysferlin is cleaved: following membrane 
injury. We have yet to identify the situations in which otoferlin and myoferlin are cleaved, or 
refine the sub-cellular localisation and trafficking of any mini-ferlins. 
Determining when otoferlin and myoferlin are cleaved. 
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Using an excitable neuronal (otoferlin) cell line would be the best starting point for 
investigating when otoferlin is cleaved. As otoferlin appears to play a role in vesicle exocytosis 
(Roux et al., 2006) and recycling (Pangrsic et al., 2010) following membrane depolarisation in 
inner hair cells, I would expect mini-otoferlin to be formed following the calcium influx and 
subsequent calpain activation following plasma membrane depolarisation. I hypothesise that 
depolarising an endogenous otoferlin-expressing excitable cell line would lead to mini-
otoferlin production (or otoferlin cleavage to generate mini-otoferlin). Treating cells with 
calcium-channel blockers prior to depolarisation should prevent otoferlin cleavage, identifying 
otoferlin cleavage as a specific response to calcium channel activation. Alternatively, we could 
investigate otoferlin cleavage following depolarisation in cultured inner hair cells. While this 
would provide more physiologically relevant results, isolation of inner hair cells is currently 
outside of our group’s expertise. This could be readily performed in collaboration with a group 
that focuses on inner hair cell function however. 
Myoferlin cleavage appeared constitutive in our cell scrape assay. Constitutive cleavage could 
either be due to continuous cleavage by active calpains, or due to cleavage by another enzyme. 
As part of her Ph.D project, Ann-Katrin Piper is currently investigating the cleavage of 
myoferlin. Her project is focussing on whether calpains are the sole proteases responsible for 
myoferlin cleavage, refining the cleavage site in myoferlin and determining why myoferlin is 
cleaved constitutively. Dysferlin cleavage occurs only in an alternatively spliced isoform (exon 
40a containing isoforms) and only in response to plasma membrane repair. Myoferlin cleavage 
does not require an alternatively spliced isoform and occurs continuously. Comparing the 
cellular situations and signals that lead to the very different cleavage of these otherwise highly 
similar proteins will help us determine more about the functions of them both. 
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Defining the precise cleavage site of mini-ferlins. 
We do not yet know the exact cleavage site for the mini-ferlins. Dysferlin is cleaved specifically 
in exon 40a, while I have determined the most likely theoretical cleavage sites of otoferlin and 
myoferlin. Sequencing the N-terminus of the mini-ferlin could refine the cleavage site to within 
a few amino acids, however as calpains are documented to often cleave proteins to within a 
region of approximately 5 amino acids (Sorimachi and Ono, 2012), the sequence determined 
for the mini-ferlin N-terminus may vary. To determine the region the ferlin is cleaved in (that 
is, the 5-10 amino acid stretch), it could be of utility to engineer calpain-resistant ferlin 
constructs in the future. Single amino acid mutation has been utilised successfully to abolish 
calpain cleavage of talin previously (Franco et al., 2004). 
For dysferlin mutation of amino acids to abolish the cleavage site is not strictly required: nature 
has provided us with an un-cleavable dysferlin already in any isoform not containing exon 40a. 
For otoferlin and myoferlin, we could use calpain GPS-CCD, the calpain cleavage prediction 
programme we utilise, to perform in silico single amino acid mutations of ferlin calpain 
cleavage sites. Once the best potential mutation to abolish the cleavage site has been identified, 
this could be engineered into ferlin expression constructs for validation with our in vitro 
cleavage assay and cellular assays (such as our scrape damage assay with dysferlin). Preventing 
myoferlin or otoferlin cleavage by mutating the cleavage site could be useful when we have 
identified functions of the mini-ferlins, and could assay the effect preventing ferlin cleavage 
has. Crucially, determining when calpains cleave myoferlin and otoferlin, and the function of 
the mini-ferlin should be undertaken prior to mutating ferlin cleavage sites. 
 
 
209 
 
Comparing the trafficking of mini-ferlins to their full-length counterparts. 
As we now know where full-length dysferlin, myoferlin, otoferlin and Fer1L6 traffic within 
the cell, and the site at which each is cleaved by calpains (from my in vitro cleavage assays) 
we can ask a simple but very interesting question: does cleavage alter ferlin trafficking? We 
are currently generating mini-ferlin expression constructs for each ferlin. Once these constructs 
have been validated, we can compare each full-length ferlin to the ‘mini’ counterpart, 
investigating sub-cellular localisation and endocytic trafficking to determine if mini-ferlins 
have comparable sub-cellular localisation and endocytic trafficking to full-length ferlins. 
Furthermore, once we have identified interacting partners or cargo of the full-length ferlins, we 
can perform comparative mass-spectrometry between full-length and mini-ferlins to 
investigate whether mini-ferlins interact with or traffic the same cargo as full-length ferlins. 
Comparison of the cargo of endogenous full-length and mini-ferlins would be the most relevant 
to determine. As there is currently limited availability of antibodies to both the N- and C-
termini of every ferlin, the use of tagged endogenous ferlin would be ideal. If generation of C-
terminally tagged endogenous ferlins is successful, then N-terminal tags could also be added 
to the endogenous ferlin using CRISPR/Cas9 and homology-directed repair. The endogenous 
full length and mini-ferlin could then be immunoprecipitated, bound proteins identified by 
mass spectrometry and any differences in identified binding partners confirmed by other 
methods (such as co-immunoprecipitation and co-localisation studies). Irrespective of the 
success of tagging the endogenous ferlin, comparison of binding partners or cargo of epitope-
tagged full-length and mini-ferlin expression constructs would allow us to investigate the 
proteomes of all mini-ferlins. I think it would be very interesting, and exciting, if ferlin cleavage 
leads to a difference in where the ferlin traffics, or what proteins the ferlin may be binding to. 
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Investigating the role of mini-ferlins in vesicle fusion. 
Investigating the role of the mini-ferlins in vesicle fusion is a longer-term goal. I would like to 
compare the mini-ferlins to their full-length counterparts in in vitro vesicle fusion assays such 
as those used by Johnson and Chapman (2010). I hypothesise that each ferlin would be capable 
of stimulating calcium-dependent vesicle fusion in vitro, and that the mini-ferlins would 
stimulate vesicle fusion at a faster rate than the full-length ferlin. 
As the SNARE complex is the minimal protein set required for vesicle fusion, SNAREs are 
required for in vitro vesicle fusion assays (Kobayashi and Fukuda, 2013). While otoferlin may 
interact with neuronal SNAREs in the brain (Johnson and Chapman, 2010; Ramakrishnan et 
al., 2014; Ramakrishnan, 2009), to date no SNARE complex has been identified that plays a 
convincing role in plasma membrane repair (dysferlin) or inner hair cell exocytosis (otoferlin). 
Before we can determine if mini-ferlins stimulate vesicle fusion, and do so at a quicker speed 
than full-length ferlins, we must first identify the SNAREs relevant to each ferlin. Determining 
what proteins the mini-ferlins interact with (as above), and then showing they co-localise in an 
endogenous expression system would hopefully identify plausible candidate SNAREs for each 
ferlin. Once candidate SNAREs have been identified, we can perform in vitro vesicle fusion 
assays and confirm that the ferlins are indeed vesicle fusion proteins, and that mini-ferlins 
perform this vesicle fusion role at a greater rate compared to the full-length counterpart. 
Concluding comments. 
My thesis has identified where the ferlins are in the cell, the endocytic trafficking of each ferlin, 
and that the ferlins are calpain substrates. My thesis is primarily hypothesis generating: now 
we know where the ferlins are and where their endocytosis takes them, we can begin to 
speculate as to what cargo they may traffic and what proteins they may interact with. Now we 
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know that the ferlins are cleaved by calpains and what the cleaved mini-ferlins look like, we 
can hypothesise that they may be ancient, conserved vesicle fusion modules, (perhaps) lending 
greater weight to the roles these mini-ferlins execute. 
My work has established new research projects in our group. Ongoing and future work includes 
investigating myoferlin cleavage in detail and refining the trafficking pathways of each ferlin. 
I think the experiments I have proposed above regarding the ferlins and mini-ferlins can 
provide direction for a cohesive future project. Firstly, we can compare and contrast where the 
mini-ferlins are in the cell using established cell biology techniques. Secondly, we can identify 
binding partners and cargo of the ferlins (ideally from endogenous expression systems), with a 
focus on vesicle fusion machinery. Third, we would confirm that any novel binding partners 
of the ferlins not only physically interact (with co-immuno-precipitation), but that they are 
present in the same cells/tissues, and co-localise in the cells or tissues. Finally, if vesicle fusion 
machinery is identified that interacts and co-localises with each, or any, ferlin, we can perform 
in vitro vesicle fusion assays, establishing the ferlins and mini-ferlins as bona-fide vesicle 
fusion mediating molecules. 
Finally, it is my hope that the work of my Ph.D. will prove beneficial to the ferlin field as a 
whole. I hope that groups researching the ferlins can take my novel findings, such as the 
identification of the ferlins as calpain substrates, and apply them to their own assays, cell lines 
and ferlin models. I look forward to us, as a field, discovering what the ferlins do in the hope 
that we may understand the diseases they are involved in in greater detail, to ultimately lead to 
informed therapeutic strategies for pathologies relating to each ferlin. 
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Appendix 1: Secondary antibody controls. 
Figure A1: Secondary antibodies used in this study are specific. HEK293 cells were 
transfected with Fer1L6MycFlag. Coverslips were fixed, permeabilised and incubated with rabbit 
or mouse anti-Myc for 1.5 hours at room temperature. Following washing, coverslips were then 
incubated with the indicated secondary antibodies and mounted. Anti-mouse488 displays some 
non-specific binding to cells incubated with rabbit anti-Myc and anti-rabbit594, however this 
binding is present throughout the cell and not to regions specifically recognised by rabbit anti-
Myc and anti-rabbit647. 
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Appendix 2: Author statements regarding Redpath et al., 2016 (Chapter 3). 
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Appendix 3: Author statements regarding Redpath et al., 2014 (Chapter 4). 
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Appendix 4: Supplementary videos related to Chapter 3. 
In the paper presented in Chapter 3.1, there are two supplementary movies (Supplementary 
Movies 1 and 2) that were not able to be integrated into the main text of my thesis. They are 
presented on the following pages. 
A.	  
C.	   D.	  
B.
Movie S1: 3D reconstructions of intracellular ferlin staining. A- HEK293s transfected with 
dysferlinMycHis were co-labeled with anti-Myc (red) and LAMP1 (green). Dysferlin endosomes are large at up to 
1 micron in diameter with a clearly observable lumen. However, on dysferlin-positive, LAMP1-positive 
endosomes, dysferlin appears to be on the outer lysosomal membrane, in a similar plane to LAMP1. B- 
HEK293s transfected with myoferlinMycFlag were co-labeled with anti-Myc (red) and LAMP1 (green). Myoferlin 
endosomes are large at up to 1 micron in diameter with a clearly observable lumen. On myoferlin-positive, 
LAMP1-positive endosomes, myoferlin appears to be on the outer lysosomal membrane, in a similar plane to 
LAMP1. C- HEK293s transfected with ubiquitous otoferlinMycFlag were co-labeled with anti-Myc (red) and 
TGOLN2 (green). Otoferlin appears to be in the same trans-Golgi structure as TGOLN2, but in a specific, 
adjacent microdomain. D- HEK293s transfected with Fer1L6MycFlag were co-labeled with anti-Myc (red) and 
TGOLN2 (green). Fer1L6 is present as two sheets above and below each other, with a distinct space 
in-between. TGOLN2 intercalates with Fer1L6 in the sheets, as well as being present between the Fer1L6 
sheets. Each red dash represents 1 µM. Reconstructions made using FIJI  and FIJI 3D viewer. Double-click 
images to play movie. 
A.	   B.	  
C.	   D.	  
Movie S2: 3D reconstructions of ferlin endosomal trafficking. C2C12 myoblasts were transfected with 
dysferlinMycHis (A) or myoferlinMycFlag (B). Anti-myc was added to C2C12 myoblasts in replacement 
media for 30 minutes at 37°C. Cells were washed with pH 2.2 glycine to remove surface anti-Myc, 
permeabilised and co-labeled for LAMP1 (green) and endocytosed anti-Myc detected (red). A- A 
proportion of dysferlin-positive endosomes co-localises with LAMP1. Dysferlin is observed within the lumen of 
the LAMP1-positive lysosome and occasionally within the membrane on the lysosome. B- Similar to dysferlin, 
myoferlin is observed within the lumen of the LAMP1-positive lysosome and occasionally within the 
membrane on the lysosome. HEK293s were transfected with ubiquitous otoferlinMycFlag (c) or Fer1L6MycFlag (B). 
Anti-Flag (otoferlin) or anti-Myc (Fer1L6) was added to HEK293s in replacement media for 30 minutes at 37°C. 
Following acid wash, fixation and permeabilisation, endocytosed anti-Myc/Flag (red) was detected and 
cells co-labelled for anti-TGOLN2 (green). C- Otoferlin endocytoses to the trans-Golgi network in a 
compartment adjacent to, yet distinct from TGOLN2. D- Fer1L6 endocytoses to a peri-nuclear compartment 
in two sheets above and below each other, with TGOLN2 intercalated between the Fer1L6 sheets. Each dash 
represents 1 µM. Reconstructions made using FIJI and FIJI 3D viewer. Double-click images to play movie. 
